{
  "914396e4-9f4f-4964-88b0-cb13bd93c255_PathologyAgent": [
    {
      "type": "human",
      "data": {
        "content": "{'context': '{\\n  \"patient_id\": \"MDT2024001\",\\n  \"demographics\": {\\n    \"age\": 62,\\n    \"gender\": \"F\",\\n    \"ethnicity\": \"Caucasian\",\\n    \"occupation\": \"Retired Teacher\",\\n    \"smoking_status\": \"Former smoker, quit 10 years ago\"\\n  },\\n  \"pathology_results\": {\\n    \"bronchoscopy_biopsy\": {\\n      \"date\": \"2024-02-15\",\\n      \"specimen\": \"Right upper lobe mass biopsy\",\\n      \"microscopic\": \"Malignant cells consistent with adenocarcinoma\",\\n      \"immunohistochemistry\": {\\n        \"TTF-1\": \"Positive\",\\n        \"CK7\": \"Positive\",\\n        \"CK20\": \"Negative\",\\n        \"PD-L1\": \"80% expression\"\\n      },\\n      \"molecular\": {\\n        \"EGFR\": \"Wild type\",\\n        \"ALK\": \"No rearrangement\",\\n        \"ROS1\": \"No rearrangement\",\\n        \"KRAS\": \"G12C mutation detected\"\\n      },\\n      \"diagnosis\": \"Lung adenocarcinoma, KRAS G12C mutated, PD-L1 80%\"\\n    }\\n  },\\n  \"current_condition\": {\\n    \"primary_complaint\": \"Persistent cough with occasional blood-tinged sputum\",\\n    \"onset\": \"2024-01-15\",\\n    \"severity\": \"Moderate to severe\",\\n    \"associated_symptoms\": [\\n      \"Unintentional weight loss (5kg in 3 months)\",\\n      \"Fatigue\",\\n      \"Decreased appetite\",\\n      \"Night sweats\"\\n    ],\\n    \"physical_exam\": {\\n      \"vital_signs\": {\\n        \"temperature\": \"37.2\\\\u00c2\\\\u00b0C\",\\n        \"blood_pressure\": \"132/82\",\\n        \"heart_rate\": \"88\",\\n        \"respiratory_rate\": \"20\",\\n        \"oxygen_saturation\": \"95% on room air\"\\n      },\\n      \"chest\": \"Decreased breath sounds in right upper lobe\",\\n      \"lymph_nodes\": \"Right supraclavicular lymphadenopathy\",\\n      \"weight\": \"68 kg\",\\n      \"height\": \"165 cm\"\\n    }\\n  },\\n  \"ehr_context\": {\\n    \"summary\": \"62-year-old female with history of smoking\",\\n    \"key_history_points\": [\\n      \"Former smoker\",\\n      \"Type 2 Diabetes\"\\n    ],\\n    \"current_presentation\": {\\n      \"main_symptoms\": [\\n        \"Persistent cough\",\\n        \"Weight loss\"\\n      ]\\n    }\\n  },\\n  \"imaging_context\": {\\n    \"summary\": \"Stage IIIA lung adenocarcinoma\",\\n    \"disease_extent\": {\\n      \"primary_tumor\": \"3.8 cm RUL mass\",\\n      \"nodal_status\": \"Multiple hilar and mediastinal nodes\"\\n    },\\n    \"staging\": {\\n      \"clinical_stage\": \"cT2aN2M0, Stage IIIA\"\\n    }\\n  }\\n}', 'task': \"Analyze the patient's pathological and molecular findings. Provide a structured interpretation including histological classification, molecular profile, biomarker status, and therapeutic implications.\"}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "human",
        "name": null,
        "id": null,
        "example": false
      }
    },
    {
      "type": "ai",
      "data": {
        "content": "{'summary': '**Pathology Analysis Report - Patient ID: MDT2024001**', 'histology': '**  A thorough review of the slides by an experienced pathologist is crucial to determine the grade and differentiation of the adenocarcinoma. This will refine prognostication and treatment planning.', 'molecular_profile': {'key_mutations': '**8. Biomarker Status:**', 'immunotherapy_markers': '**  Pembrolizumab, nivolumab, or other PD-1/PD-L1 inhibitors are strong candidates for either monotherapy or combination therapy.', 'other_markers': {'EGFR': '** Wild type – This excludes the use of EGFR tyrosine kinase inhibitors (TKIs) as a targeted therapy option.', 'ALK': '** No rearrangement – This excludes ALK inhibitors as a targeted therapy option.', 'ROS1': '** No rearrangement – This excludes ROS1 inhibitors as a targeted therapy option.', 'KRAS': '**  Sotorasib or adagrasib are the preferred first-line targeted therapies.'}}, 'therapeutic_implications': ['*10. Recommendations for Additional Testing:**']}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "ai",
        "name": null,
        "id": null,
        "example": false,
        "tool_calls": [],
        "invalid_tool_calls": [],
        "usage_metadata": null
      }
    }
  ],
  "08c6e9a5-120c-47d2-9f1e-3b708eb8ea05_PathologyAgent": [
    {
      "type": "human",
      "data": {
        "content": "{'context': '{\\n  \"patient_id\": \"test-patient-001\",\\n  \"demographics\": {\\n    \"age\": 65,\\n    \"gender\": \"Male\"\\n  },\\n  \"pathology_results\": {\\n    \"blood_work\": \"Elevated troponin (0.5 ng/mL). Normal CBC.\",\\n    \"cardiac_enzymes\": \"CK-MB slightly elevated at 12 ng/mL.\"\\n  },\\n  \"current_condition\": {\\n    \"description\": \"Presenting with chest pain and shortness of breath\",\\n    \"duration\": \"3 days\",\\n    \"severity\": \"moderate\"\\n  },\\n  \"ehr_context\": {\\n    \"summary\": \"This analysis is based on limited information.  The absence of data on smoking status, family history, current medications, and detailed social history limits a complete assessment.  A full clinical examination and further investigations are crucial to determine the definitive diagnosis and appropriate treatment plan.  This report should not be considered a substitute for a comprehensive medical evaluation by a qualified healthcare professional.\",\\n    \"details\": {\\n      \"summary\": \"This analysis is based on limited information.  The absence of data on smoking status, family history, current medications, and detailed social history limits a complete assessment.  A full clinical examination and further investigations are crucial to determine the definitive diagnosis and appropriate treatment plan.  This report should not be considered a substitute for a comprehensive medical evaluation by a qualified healthcare professional.\",\\n      \"key_history_points\": [],\\n      \"current_presentation\": {\\n        \"main_symptoms\": [],\\n        \"performance_status\": \"\",\\n        \"comorbidity_impact\": \"**  Optimal management of hypertension and T2DM is essential for overall patient well-being and to reduce the risk of complications.\"\\n      },\\n      \"risk_factors\": [],\\n      \"clinical_implications\": [],\\n      \"raw_output\": \"**EHR Analysis Agent Report - Patient ID: test-patient-001**\\\\n\\\\n**1. Key History Points:**\\\\n\\\\n* **Demographics:** 65-year-old male.  Age is a significant risk factor for cardiovascular disease.\\\\n* **Medical History:**  10-year history of hypertension and 5-year history of Type 2 Diabetes Mellitus (T2DM). Both are major risk factors for cardiovascular events.  Poorly controlled T2DM, as evidenced by HbA1c of 7.2%, further increases risk.\\\\n* **Current Condition:**  Onset of moderate chest pain and shortness of breath 3 days prior to presentation. This acute symptom presentation warrants immediate investigation.  The combination of chest pain and shortness of breath raises strong suspicion for cardiac ischemia or other life-threatening conditions.\\\\n\\\\n**2. Current Clinical Status:**\\\\n\\\\n* **Presenting Complaint:** Acute onset of moderate chest pain and shortness of breath.  This requires urgent evaluation to rule out acute coronary syndrome (ACS), pulmonary embolism (PE), or other critical conditions.\\\\n* **Laboratory Findings:**  Elevated HbA1c (7.2%) indicates poorly controlled T2DM. Elevated LDL cholesterol (140 mg/dL) signifies hyperlipidemia, another significant cardiovascular risk factor.\\\\n* **Comorbidities:** Hypertension and T2DM significantly increase the risk of cardiovascular complications.  The interaction of these conditions necessitates careful consideration of treatment options.\\\\n\\\\n**3. Relevant Risk Factors:**\\\\n\\\\n* **Age:** Advanced age increases the likelihood of cardiovascular disease and reduced physiological reserve.\\\\n* **Hypertension:**  A major risk factor for coronary artery disease (CAD), stroke, and heart failure.\\\\n* **Type 2 Diabetes Mellitus:**  Increases the risk of CAD, stroke, peripheral artery disease, and nephropathy.  Poor glycemic control exacerbates these risks.\\\\n* **Hyperlipidemia:**  Contributes significantly to atherosclerosis and the development of CAD.\\\\n* **Smoking Status:**  Information not provided.  Smoking is a crucial risk factor that needs to be ascertained.\\\\n* **Family History:** Information not provided.  Family history of cardiovascular disease would further increase risk assessment.\\\\n\\\\n**4. Performance Status Assessment:**\\\\n\\\\nWithout a formal ECOG (Eastern Cooperative Oncology Group) performance status assessment or a similar functional assessment, a precise evaluation is limited. However, based on the acute presentation of chest pain and shortness of breath, it is reasonable to assume a significantly reduced performance status, potentially ECOG 2-4, until further evaluation clarifies the severity and underlying cause of symptoms.  The patient\\'s ability to perform activities of daily living is likely compromised.\\\\n\\\\n**5. Clinical Implications:**\\\\n\\\\nThe patient\\'s presentation necessitates immediate and comprehensive investigation.  The high likelihood of a critical cardiovascular event demands urgent action.  Initial investigations should include:\\\\n\\\\n* **Electrocardiogram (ECG):** To assess for evidence of myocardial ischemia or arrhythmias.\\\\n* **Cardiac biomarkers (troponin, CK-MB):** To rule out myocardial infarction (MI).\\\\n* **Chest X-ray:** To evaluate for pulmonary pathology, such as pneumonia or pulmonary edema.\\\\n* **D-dimer:** To assess the risk of pulmonary embolism.\\\\n* **Further investigations may be necessary depending on initial findings** (e.g., echocardiogram, coronary angiography, computed tomography pulmonary angiography).\\\\n\\\\n**Treatment Planning Considerations:**\\\\n\\\\nTreatment will depend heavily on the results of the above investigations.  However, given the comorbidities, careful consideration must be given to:\\\\n\\\\n* **Potential drug interactions:**  Multiple medications will likely be required to manage the acute condition and the underlying comorbidities.  Careful attention to potential drug interactions is crucial.\\\\n* **Comorbidity management:**  Optimal management of hypertension and T2DM is essential for overall patient well-being and to reduce the risk of complications.\\\\n* **Patient preferences and shared decision-making:**  Treatment decisions should always involve the patient and consider their individual preferences and values.\\\\n\\\\n\\\\n**Limitations and Uncertainties:**\\\\n\\\\nThis analysis is based on limited information.  The absence of data on smoking status, family history, current medications, and detailed social history limits a complete assessment.  A full clinical examination and further investigations are crucial to determine the definitive diagnosis and appropriate treatment plan.  This report should not be considered a substitute for a comprehensive medical evaluation by a qualified healthcare professional.\"\\n    }\\n  },\\n  \"imaging_context\": {\\n    \"summary\": \"**Imaging Analysis Agent Report - Patient ID: test-patient-001**\",\\n    \"details\": {\\n      \"summary\": \"**Imaging Analysis Agent Report - Patient ID: test-patient-001**\",\\n      \"disease_extent\": {\\n        \"primary_tumor\": \"Details not specified\",\\n        \"nodal_status\": \"\",\\n        \"metastatic_status\": \"\"\\n      },\\n      \"staging\": {\\n        \"clinical_stage\": \"\",\\n        \"key_findings\": [\\n          \"Imaging findings analyzed\"\\n        ]\\n      },\\n      \"treatment_implications\": []\\n    }\\n  }\\n}', 'task': \"Analyze the patient's pathological and molecular findings. Provide a structured interpretation including histological classification, molecular profile, biomarker status, and therapeutic implications.\"}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "human",
        "name": null,
        "id": null,
        "example": false
      }
    },
    {
      "type": "ai",
      "data": {
        "content": "{'summary': '**Pathology Analysis Agent Report - Patient ID: test-patient-001**', 'histology': '**', 'molecular_profile': {'key_mutations': 'Key mutations not specified', 'immunotherapy_markers': '', 'other_markers': {}}, 'therapeutic_implications': [\"The elevated cardiac biomarkers strongly suggest the need for urgent investigation to rule out acute myocardial infarction or other forms of acute coronary syndrome.  Immediate management should focus on stabilizing the patient's condition and conducting the following:\", '**Electrocardiogram (ECG):** To assess for ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI).', '**Further cardiac enzyme monitoring:** Serial measurements of troponin and CK-MB are crucial to assess the extent and evolution of myocardial damage.', '**Chest X-ray:** To evaluate for pulmonary edema or other pulmonary pathology.', '**Echocardiogram:** To assess cardiac function and identify potential structural abnormalities.', '**Coronary angiography:**  If ECG and echocardiogram findings are suggestive of significant coronary artery disease, coronary angiography is essential to visualize the coronary arteries and determine the need for revascularization procedures (percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG)).', '*7. Recommendations for Additional Testing:**', 'Given the incomplete data and the suspicion of cardiovascular disease, the following additional tests are strongly recommended:', '**Complete blood count (CBC):** Although initially reported as normal, repeat CBC is recommended to monitor for any changes.', '**Comprehensive metabolic panel (CMP):** To assess renal function, electrolyte balance, and glucose control.', '**Lipid profile:** To assess cholesterol levels and risk factors for atherosclerosis.', '**Cardiac MRI:**  To assess myocardial viability, scar tissue, and the extent of myocardial damage.', '**Assessment of risk factors:** Detailed information regarding smoking status, family history of cardiovascular disease, current medications, and social history is essential for a complete risk stratification.', '*8. Limitations and Uncertainties:**', 'This analysis is based on limited laboratory data and lacks crucial clinical information (e.g., detailed history, physical examination findings, imaging results).  The absence of tissue-based pathological analysis significantly limits the ability to provide a definitive diagnosis and tailored treatment plan.  This report should be considered preliminary and must be integrated with a comprehensive clinical evaluation to formulate an appropriate management strategy.  The information provided should not be used as the sole basis for clinical decision-making.', '*9.  Pathological Diagnosis (Provisional):**', \"Based on the limited data, a provisional diagnosis of possible acute coronary syndrome (ACS) is suggested.  Further investigations are absolutely necessary to confirm or refute this diagnosis and to identify the specific cause of the patient's symptoms.\"]}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "ai",
        "name": null,
        "id": null,
        "example": false,
        "tool_calls": [],
        "invalid_tool_calls": [],
        "usage_metadata": null
      }
    }
  ],
  "991390b7-e3e8-4f36-ad6f-eda915d264e4_PathologyAgent": [
    {
      "type": "human",
      "data": {
        "content": "{'context': '{\\n  \"patient_id\": \"MDT2024001\",\\n  \"demographics\": {\\n    \"age\": 62,\\n    \"gender\": \"F\",\\n    \"ethnicity\": \"Caucasian\",\\n    \"occupation\": \"Retired Teacher\",\\n    \"smoking_status\": \"Former smoker, quit 10 years ago\"\\n  },\\n  \"pathology_results\": {\\n    \"bronchoscopy_biopsy\": {\\n      \"date\": \"2024-02-15\",\\n      \"specimen\": \"Right upper lobe mass biopsy\",\\n      \"microscopic\": \"Malignant cells consistent with adenocarcinoma\",\\n      \"immunohistochemistry\": {\\n        \"TTF-1\": \"Positive\",\\n        \"CK7\": \"Positive\",\\n        \"CK20\": \"Negative\",\\n        \"PD-L1\": \"80% expression\"\\n      },\\n      \"molecular\": {\\n        \"EGFR\": \"Wild type\",\\n        \"ALK\": \"No rearrangement\",\\n        \"ROS1\": \"No rearrangement\",\\n        \"KRAS\": \"G12C mutation detected\"\\n      },\\n      \"diagnosis\": \"Lung adenocarcinoma, KRAS G12C mutated, PD-L1 80%\"\\n    }\\n  },\\n  \"current_condition\": {\\n    \"primary_complaint\": \"Persistent cough with occasional blood-tinged sputum\",\\n    \"onset\": \"2024-01-15\",\\n    \"severity\": \"Moderate to severe\",\\n    \"associated_symptoms\": [\\n      \"Unintentional weight loss (5kg in 3 months)\",\\n      \"Fatigue\",\\n      \"Decreased appetite\",\\n      \"Night sweats\"\\n    ],\\n    \"physical_exam\": {\\n      \"vital_signs\": {\\n        \"temperature\": \"37.2\\\\u00b0C\",\\n        \"blood_pressure\": \"132/82\",\\n        \"heart_rate\": \"88\",\\n        \"respiratory_rate\": \"20\",\\n        \"oxygen_saturation\": \"95% on room air\"\\n      },\\n      \"chest\": \"Decreased breath sounds in right upper lobe\",\\n      \"lymph_nodes\": \"Right supraclavicular lymphadenopathy\",\\n      \"weight\": \"68 kg\",\\n      \"height\": \"165 cm\"\\n    }\\n  },\\n  \"ehr_context\": {\\n    \"summary\": \"Based on the presented information, a preliminary assessment suggests a Karnofsky Performance Status (KPS) score of 60-70%. This is an educated guess based on the reported fatigue, weight loss, and moderate to severe cough.  A more precise assessment requires a detailed functional assessment evaluating activities of daily living (ADLs).  The ECOG performance status would likely be 2.\",\\n    \"details\": {\\n      \"summary\": \"Based on the presented information, a preliminary assessment suggests a Karnofsky Performance Status (KPS) score of 60-70%. This is an educated guess based on the reported fatigue, weight loss, and moderate to severe cough.  A more precise assessment requires a detailed functional assessment evaluating activities of daily living (ADLs).  The ECOG performance status would likely be 2.\",\\n      \"key_history_points\": [],\\n      \"current_presentation\": {\\n        \"main_symptoms\": [],\\n        \"performance_status\": \"**  This patient requires urgent further investigation to confirm the diagnosis and stage the potential lung cancer. A multidisciplinary team (MDT) approach involving pulmonology, oncology, radiology, pathology, and potentially thoracic surgery is essential for optimal patient care.  The comorbidities need to be carefully managed throughout the treatment process.  Regular monitoring of performance status is crucial for adapting the treatment plan as needed.\",\\n        \"comorbidity_impact\": \"**  The patient\\'s Type 2 Diabetes and hypertension will necessitate careful monitoring and adjustments to medications during and after cancer treatment.  The osteoarthritis may influence pain management strategies.  Close collaboration with endocrinology and cardiology will be crucial.\"\\n      },\\n      \"risk_factors\": [],\\n      \"clinical_implications\": [],\\n      \"raw_output\": \"**EHR Analysis Agent Report: Patient ID MDT2024001**\\\\n\\\\n**1. Key History Points:**\\\\n\\\\n* **Chronological Progression of Symptoms:** The patient, a 62-year-old Caucasian female, presents with a persistent cough (onset January 15, 2024) initially described as moderate to severe, progressing to include blood-tinged sputum.  Significant associated symptoms include unintentional weight loss (5kg in 3 months), fatigue, decreased appetite, and night sweats \\\\u2013 all highly suggestive of malignancy.\\\\n\\\\n* **Medical History:**  The patient has a history of well-controlled Type 2 Diabetes (since 2015), well-controlled hypertension (since 2016), and osteoarthritis (since 2018).  These comorbidities will influence treatment choices and require careful monitoring.  Her former smoking status (quit 10 years ago) remains a significant risk factor.\\\\n\\\\n* **Social and Functional Factors:**  The patient is retired, suggesting potential availability for treatment but also potentially increased vulnerability due to reduced social support and physical activity.  Further social history is required to confirm this.\\\\n\\\\n**2. Current Clinical Status:**\\\\n\\\\n* **Primary Complaint:** Persistent cough with hemoptysis.\\\\n* **Physical Exam:** Significant findings include decreased breath sounds in the right upper lobe and right supraclavicular lymphadenopathy \\\\u2013 highly suspicious for lung cancer.  Vital signs are relatively stable, although the slightly elevated blood pressure warrants monitoring.\\\\n* **Laboratory Results:**  The complete blood count (CBC) shows normal hemoglobin, white blood cell count, and platelets, which is not definitive but doesn\\'t immediately suggest severe anemia or infection.  Liver function tests (LFTs) are mildly elevated (ALT 28 U/L, AST 32 U/L), which may be related to the underlying condition or medications, necessitating further investigation.  Albumin is within the normal range.  Renal function is normal (creatinine 0.9 mg/dL).\\\\n\\\\n**3. Relevant Risk Factors:**\\\\n\\\\n* **Age:** 62 years old (increased risk for lung cancer).\\\\n* **Gender:** Female (although lung cancer is more common in males, it\\'s still a significant risk).\\\\n* **Smoking History:** Former smoker (significant risk factor, even after cessation).\\\\n* **Symptoms:**  Classic presentation suggestive of lung cancer: cough, hemoptysis, weight loss, fatigue, anorexia, night sweats.\\\\n* **Physical Exam:** Right supraclavicular lymphadenopathy is a serious warning sign.\\\\n\\\\n\\\\n**4. Performance Status Assessment:**\\\\n\\\\nBased on the presented information, a preliminary assessment suggests a Karnofsky Performance Status (KPS) score of 60-70%. This is an educated guess based on the reported fatigue, weight loss, and moderate to severe cough.  A more precise assessment requires a detailed functional assessment evaluating activities of daily living (ADLs).  The ECOG performance status would likely be 2.\\\\n\\\\n\\\\n**5. Clinical Implications and Treatment Planning:**\\\\n\\\\nThe clinical presentation strongly suggests the possibility of lung cancer.  The right supraclavicular lymphadenopathy points towards advanced disease potentially involving mediastinal lymph nodes.  Further investigations are urgently required:\\\\n\\\\n* **Imaging:** High-resolution computed tomography (HRCT) of the chest is essential to confirm the presence of a lung mass, assess its size, location, and relationship to surrounding structures, and evaluate for mediastinal lymph node involvement.  A PET-CT scan would be beneficial for staging.\\\\n* **Bronchoscopy:**  To obtain tissue samples for histopathological examination (biopsy) and cytology.  This is crucial for definitive diagnosis and determining the type and subtype of lung cancer.\\\\n* **Thoracic Surgery Consultation:**  For potential biopsy and/or surgical intervention depending on the findings.\\\\n* **Oncology Consultation:** To discuss treatment options based on the staging and histological findings, which may include chemotherapy, targeted therapy, immunotherapy, or radiation therapy, or a combination.\\\\n\\\\n**Comorbidities\\' Impact on Treatment:**  The patient\\'s Type 2 Diabetes and hypertension will necessitate careful monitoring and adjustments to medications during and after cancer treatment.  The osteoarthritis may influence pain management strategies.  Close collaboration with endocrinology and cardiology will be crucial.\\\\n\\\\n**Medication Interactions:**  A thorough review of all current medications (Metformin, Lisinopril, PRN NSAIDs) is necessary to assess potential interactions with any planned cancer therapies.\\\\n\\\\n**Limitations and Uncertainties:** The diagnosis remains presumptive pending further investigations.  The severity of the lung cancer and its impact on prognosis cannot be definitively determined without further diagnostic testing and staging.\\\\n\\\\n\\\\n**Conclusion:**  This patient requires urgent further investigation to confirm the diagnosis and stage the potential lung cancer. A multidisciplinary team (MDT) approach involving pulmonology, oncology, radiology, pathology, and potentially thoracic surgery is essential for optimal patient care.  The comorbidities need to be carefully managed throughout the treatment process.  Regular monitoring of performance status is crucial for adapting the treatment plan as needed.\"\\n    }\\n  },\\n  \"imaging_context\": {\\n    \"summary\": \"**Imaging Analysis Report: Patient ID MDT2024001**\",\\n    \"details\": {\\n      \"summary\": \"**Imaging Analysis Report: Patient ID MDT2024001**\",\\n      \"disease_extent\": {\\n        \"primary_tumor\": \"**  If there is uncertainty about the extent of the primary tumor or the involvement of smaller lymph nodes.\",\\n        \"nodal_status\": \"** These are crucial for accurate staging of mediastinal lymph nodes.  This is necessary to confirm the N-stage and refine the overall staging.\",\\n        \"metastatic_status\": \"\"\\n      },\\n      \"staging\": {\\n        \"clinical_stage\": \"\",\\n        \"key_findings\": [\\n          \"* **Chest X-ray (2024-02-01):** Demonstrates a 3.5 cm mass in the right upper lobe with associated hilar lymphadenopathy.  The finding is highly suggestive of a primary lung malignancy.  The limited resolution prevents precise characterization of the lesion.\",\\n          \"* **CT Chest (2024-02-05):**  Confirms a 3.8 x 3.2 cm spiculated mass in the right upper lobe.  Multiple enlarged right hilar and mediastinal lymph nodes are present.  No evidence of distant metastases is identified. Mild emphysematous changes are noted in the upper lobes.  The spiculated margins of the mass are concerning for malignancy.\",\\n          \"* **PET-CT (2024-02-12):**  Shows a right upper lobe mass with a maximum standardized uptake value (SUVmax) of 12.4, indicating high metabolic activity consistent with malignancy.  FDG-avid right hilar and mediastinal lymph nodes are present, with a maximum SUVmax of 8.2, further supporting the diagnosis of lymph node involvement.  No evidence of distant metastatic disease is detected.\",\\n          \"* **Primary Lesion:** 3.8 x 3.2 cm (CT Chest)\",\\n          \"* **SUVmax of Primary Lesion:** 12.4 (PET-CT)\",\\n          \"Based on the imaging findings, the patient presents with a large primary lung mass in the right upper lobe with involvement of regional lymph nodes (hilar and mediastinal).  There is no evidence of distant metastases.  This imaging profile is most consistent with **Stage IIIA Non-Small Cell Lung Cancer (NSCLC)** according to the 8th edition TNM staging system.  However, this is a preliminary assessment pending histopathological confirmation of the diagnosis and precise nodal staging which requires tissue sampling and potentially mediastinoscopy or endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA).\",\\n          \"The primary lesion is located in the right upper lobe, close to the hilum and major vessels. The extent of lymph node involvement needs further clarification through invasive procedures to determine the exact N category. The close proximity of the tumor to major vessels could influence surgical resectability. The mild emphysema might impact surgical planning and post-operative recovery.\"\\n        ]\\n      },\\n      \"treatment_implications\": []\\n    }\\n  }\\n}', 'task': \"Analyze the patient's pathological and molecular findings. Provide a structured interpretation including histological classification, molecular profile, biomarker status, and therapeutic implications.\"}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "human",
        "name": null,
        "id": null,
        "example": false
      }
    },
    {
      "type": "ai",
      "data": {
        "content": "{'summary': '**', 'histology': '**', 'molecular_profile': {'key_mutations': '**4. Biomarker Status:**', 'immunotherapy_markers': '', 'other_markers': {'KRAS': '**  Sotorasib and adagrasib are FDA-approved targeted therapies specifically designed to inhibit KRAS G12C mutant proteins.  These should be considered as first-line treatment options given the strong molecular driver.'}}, 'therapeutic_implications': ['The provided data does not specify the grade or differentiation of the adenocarcinoma.  Further histopathological review of the biopsy specimen, including assessment of nuclear pleomorphism, mitotic rate, and architectural features, is necessary to determine the grade and level of differentiation. This information is crucial for prognosis and treatment planning.', 'Molecular testing reveals a *KRAS* G12C mutation.  *EGFR*, *ALK*, and *ROS1* are wild type (no rearrangements detected).  The presence of a *KRAS* G12C mutation is a significant finding, as it identifies a targetable oncogenic driver.', 'PD-L1 expression is 80%, indicating a high likelihood of response to immunotherapy.  This is a significant positive biomarker for treatment selection.', '**5. Therapeutic Targets and Implications:**', '* **KRAS G12C Inhibitors:**  Sotorasib and adagrasib are FDA-approved targeted therapies specifically designed to inhibit KRAS G12C mutant proteins.  These should be considered as first-line treatment options given the strong molecular driver.', '* **Immunotherapy:**  Given the high PD-L1 expression (80%), immunotherapy with a PD-1 or PD-L1 inhibitor (e.g., pembrolizumab, nivolumab, atezolizumab) could be highly effective either as monotherapy or in combination with a KRAS G12C inhibitor.  The high PD-L1 expression supports the use of immunotherapy, even in the context of a *KRAS* mutation.  Combination therapy may offer synergistic effects.', '* **Chemotherapy:**  While targeted therapy and immunotherapy are preferred given the molecular profile, chemotherapy might be considered in specific circumstances, such as in cases of resistance to targeted therapy.', '* **Comprehensive genomic profiling:**  Consideration of broader next-generation sequencing (NGS) panels to screen for other potential actionable mutations beyond the *KRAS* G12C mutation.  This can identify additional therapeutic targets if the initial treatment fails.', \"* **Assessment of performance status:**  A formal assessment of the patient's Karnofsky Performance Status (KPS) and Eastern Cooperative Oncology Group (ECOG) performance status is essential for tailoring treatment decisions and managing treatment-related toxicities.\", 'This patient presents with a lung adenocarcinoma with a *KRAS* G12C mutation and high PD-L1 expression.  This molecular profile suggests a favorable prognosis and opens up several effective treatment options, primarily KRAS G12C inhibitors and immunotherapy, potentially used in combination.  However, a complete histopathological evaluation and further staging are crucial to refine the treatment plan and provide accurate prognostic information.  The MDT should carefully consider all findings and the patient’s overall health to develop a personalized treatment strategy.  Regular monitoring of response to therapy and potential toxicities is essential.']}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "ai",
        "name": null,
        "id": null,
        "example": false,
        "tool_calls": [],
        "invalid_tool_calls": [],
        "usage_metadata": null
      }
    }
  ],
  "da2c3429-47dd-4ab4-9e33-9446bb29bfe6_PathologyAgent": [
    {
      "type": "human",
      "data": {
        "content": "{'context': '{\\n  \"patient_id\": \"MDT2024001\",\\n  \"demographics\": {\\n    \"age\": 62,\\n    \"gender\": \"F\",\\n    \"ethnicity\": \"Caucasian\",\\n    \"occupation\": \"Retired Teacher\",\\n    \"smoking_status\": \"Former smoker, quit 10 years ago\"\\n  },\\n  \"pathology_results\": {\\n    \"bronchoscopy_biopsy\": {\\n      \"date\": \"2024-02-15\",\\n      \"specimen\": \"Right upper lobe mass biopsy\",\\n      \"microscopic\": \"Malignant cells consistent with adenocarcinoma\",\\n      \"immunohistochemistry\": {\\n        \"TTF-1\": \"Positive\",\\n        \"CK7\": \"Positive\",\\n        \"CK20\": \"Negative\",\\n        \"PD-L1\": \"80% expression\"\\n      },\\n      \"molecular\": {\\n        \"EGFR\": \"Wild type\",\\n        \"ALK\": \"No rearrangement\",\\n        \"ROS1\": \"No rearrangement\",\\n        \"KRAS\": \"G12C mutation detected\"\\n      },\\n      \"diagnosis\": \"Lung adenocarcinoma, KRAS G12C mutated, PD-L1 80%\"\\n    }\\n  },\\n  \"current_condition\": {\\n    \"primary_complaint\": \"Persistent cough with occasional blood-tinged sputum\",\\n    \"onset\": \"2024-01-15\",\\n    \"severity\": \"Moderate to severe\",\\n    \"associated_symptoms\": [\\n      \"Unintentional weight loss (5kg in 3 months)\",\\n      \"Fatigue\",\\n      \"Decreased appetite\",\\n      \"Night sweats\"\\n    ],\\n    \"physical_exam\": {\\n      \"vital_signs\": {\\n        \"temperature\": \"37.2\\\\u00b0C\",\\n        \"blood_pressure\": \"132/82\",\\n        \"heart_rate\": \"88\",\\n        \"respiratory_rate\": \"20\",\\n        \"oxygen_saturation\": \"95% on room air\"\\n      },\\n      \"chest\": \"Decreased breath sounds in right upper lobe\",\\n      \"lymph_nodes\": \"Right supraclavicular lymphadenopathy\",\\n      \"weight\": \"68 kg\",\\n      \"height\": \"165 cm\"\\n    }\\n  },\\n  \"ehr_context\": {\\n    \"summary\": \"** The current information is incomplete.  A comprehensive evaluation including the above-mentioned investigations is required for a definitive diagnosis and appropriate treatment plan.  This analysis is based solely on the provided data and does not replace a thorough clinical examination and assessment by a qualified medical professional.  The albumin level warrants further investigation to rule out other causes such as malnutrition or liver disease.\",\\n    \"details\": {\\n      \"summary\": \"** The current information is incomplete.  A comprehensive evaluation including the above-mentioned investigations is required for a definitive diagnosis and appropriate treatment plan.  This analysis is based solely on the provided data and does not replace a thorough clinical examination and assessment by a qualified medical professional.  The albumin level warrants further investigation to rule out other causes such as malnutrition or liver disease.\",\\n      \"key_history_points\": [],\\n      \"current_presentation\": {\\n        \"main_symptoms\": [],\\n        \"performance_status\": \"**  Treatment options will depend heavily on the diagnosis and staging of the cancer.  This might range from surgery, chemotherapy, radiation therapy, targeted therapy, or a combination thereof.  The MDT approach is crucial for optimal treatment planning, taking into account the patient\\'s age, comorbidities, performance status, and preferences.\",\\n        \"comorbidity_impact\": \"**  The patient\\'s comorbidities need to be carefully managed during any subsequent treatment.  Close monitoring of blood glucose and blood pressure is essential.  The choice of cancer treatment will need to account for potential drug interactions and the impact on the patient\\'s overall health.\"\\n      },\\n      \"risk_factors\": [],\\n      \"clinical_implications\": [],\\n      \"raw_output\": \"**EHR Analysis Agent Report: Patient MDT2024001**\\\\n\\\\n**1. Key History Points:**\\\\n\\\\n* **Chronological Progression of Symptoms:** The patient, a 62-year-old Caucasian female, presents with a persistent cough (onset January 15th, 2024) initially described as moderate to severe, progressing to include blood-tinged sputum.  This is accompanied by significant unintentional weight loss (5kg in 3 months), fatigue, decreased appetite, and night sweats \\\\u2013 all highly suggestive of a serious underlying condition, potentially malignancy.\\\\n\\\\n* **Comorbidities:** The patient has well-controlled Type 2 Diabetes (HbA1c 6.8%), well-controlled hypertension (average BP 128/78), and osteoarthritis affecting her knees and hands.  These comorbidities will need careful consideration during treatment planning due to potential drug interactions and impact on tolerability.\\\\n\\\\n* **Social and Functional Factors:**  The patient is a retired teacher, suggesting a previously active lifestyle.  Her current symptoms significantly impact her functional status, likely limiting her activities of daily living.  Further social history is needed to assess support systems.\\\\n\\\\n* **Risk Factors:**  Former smoker (quit 10 years ago) increases the risk of lung cancer.  Age and female gender are also relevant risk factors.\\\\n\\\\n**2. Current Clinical Status:**\\\\n\\\\n* **Primary Complaint:** Persistent cough with hemoptysis.\\\\n* **Physical Examination:**  Significant findings include decreased breath sounds in the right upper lobe and right supraclavicular lymphadenopathy \\\\u2013 strongly suggestive of a possible lung malignancy.\\\\n* **Laboratory Results:**  Complete blood count shows normal hemoglobin, WBC, and platelets.  Basic metabolic panel reveals normal creatinine, mildly elevated AST and ALT (potentially related to comorbidities or medication), and a slightly low albumin (3.8 g/dL, warrants further investigation).  These lab results are not conclusive but do not exclude malignancy.\\\\n\\\\n**3. Relevant Risk Factors:**\\\\n\\\\n* **Age:** 62 years (increased risk for lung cancer)\\\\n* **Smoking History:** Former smoker (increased risk for lung cancer)\\\\n* **Symptoms:** Hemoptysis, weight loss, fatigue, night sweats, and lymphadenopathy (highly suggestive of malignancy)\\\\n* **Physical Exam:** Decreased breath sounds and lymphadenopathy further support suspicion of lung cancer.\\\\n\\\\n**4. Performance Status Assessment:**\\\\n\\\\nBased on the presented information, a preliminary assessment would place the patient at an ECOG performance status of 2-3.  This is based on her significant fatigue, weight loss, and the impact of her symptoms on her daily activities. A more precise assessment requires a more detailed functional assessment.\\\\n\\\\n**5. Clinical Implications:**\\\\n\\\\nThe constellation of symptoms, physical examination findings, and risk factors strongly suggests the possibility of lung cancer.  Further investigation is urgently required:\\\\n\\\\n* **Imaging:**  High-resolution computed tomography (HRCT) of the chest is essential to visualize the lung parenchyma, delineate the extent of any lesion, and assess for mediastinal lymphadenopathy.  Further imaging may be indicated depending on the HRCT findings.\\\\n* **Biopsy:**  Tissue biopsy (bronchoscopy with endobronchial ultrasound-guided transbronchial needle aspiration or percutaneous biopsy) is crucial for definitive diagnosis and histological characterization of the lesion (if identified on imaging).\\\\n* **Further Investigations:**  Depending on the biopsy results, further investigations might include a PET scan to assess for distant metastases, and potentially other tests depending on the specific diagnosis and stage.\\\\n\\\\n**Comorbidity Management:**  The patient\\'s comorbidities need to be carefully managed during any subsequent treatment.  Close monitoring of blood glucose and blood pressure is essential.  The choice of cancer treatment will need to account for potential drug interactions and the impact on the patient\\'s overall health.\\\\n\\\\n**Treatment Planning:**  Treatment options will depend heavily on the diagnosis and staging of the cancer.  This might range from surgery, chemotherapy, radiation therapy, targeted therapy, or a combination thereof.  The MDT approach is crucial for optimal treatment planning, taking into account the patient\\'s age, comorbidities, performance status, and preferences.\\\\n\\\\n**Limitations and Uncertainties:** The current information is incomplete.  A comprehensive evaluation including the above-mentioned investigations is required for a definitive diagnosis and appropriate treatment plan.  This analysis is based solely on the provided data and does not replace a thorough clinical examination and assessment by a qualified medical professional.  The albumin level warrants further investigation to rule out other causes such as malnutrition or liver disease.\\\\n\\\\n\\\\n**Conclusion:**  This patient requires urgent specialist referral to a pulmonologist and oncologist for further evaluation and management.  A multidisciplinary team approach is essential for optimal patient care.\"\\n    }\\n  },\\n  \"imaging_context\": {\\n    \"summary\": \"**Imaging Analysis Report: Patient MDT2024001**\",\\n    \"details\": {\\n      \"summary\": \"**Imaging Analysis Report: Patient MDT2024001**\",\\n      \"disease_extent\": {\\n        \"primary_tumor\": \"** While a CT chest has been performed, a dedicated high-resolution CT is recommended to better assess the precise extent of the primary tumor and its relationship to adjacent structures (chest wall, vessels, mediastinum). This will better define the T stage.\",\\n        \"nodal_status\": \"**  These procedures are essential for obtaining tissue samples for definitive diagnosis, histological subtyping, and molecular testing (including EGFR, ALK, ROS1, etc.) to guide targeted therapy options.  EBUS/EUS will also allow for a more precise assessment of mediastinal lymph node involvement.\",\\n        \"metastatic_status\": \"** M0 (no distant metastasis).  Both CT and PET-CT scans show no evidence of distant metastases.\"\\n      },\\n      \"staging\": {\\n        \"clinical_stage\": \"\",\\n        \"key_findings\": [\\n          \"* **Chest X-ray (2024-02-01):** Demonstrates a 3.5 cm mass in the right upper lobe with associated hilar lymphadenopathy.  The findings are highly suggestive of a primary lung malignancy.  The resolution is limited, hindering precise characterization.\",\\n          \"* **CT Chest (2024-02-05):**  Reveals a 3.8 x 3.2 cm spiculated mass in the right upper lobe, consistent with a lung malignancy.  Multiple enlarged right hilar and mediastinal lymph nodes are present. No evidence of distant metastases is identified.  Mild emphysematous changes are noted in the upper lobes.\",\\n          \"* **PET-CT (2024-02-12):** Confirms the presence of a right upper lobe mass with a maximum standardized uptake value (SUVmax) of 12.4, indicative of high metabolic activity consistent with malignancy.  FDG-avid right hilar and mediastinal lymph nodes are present, with a maximum SUVmax of 8.2.  No evidence of distant metastatic disease is detected.\",\\n          \"* **Primary Lesion:** 3.8 x 3.2 cm (CT Chest).\",\\n          \"The primary lesion is located in the right upper lobe, with involvement of ipsilateral hilar and mediastinal lymph nodes. The location and size of the tumor, along with lymph node involvement, have significant implications for surgical resectability and treatment planning.  The mild emphysema may affect surgical options.\"\\n        ]\\n      },\\n      \"treatment_implications\": []\\n    }\\n  }\\n}', 'task': \"Analyze the patient's pathological and molecular findings. Provide a structured interpretation including histological classification, molecular profile, biomarker status, and therapeutic implications.\"}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "human",
        "name": null,
        "id": null,
        "example": false
      }
    },
    {
      "type": "ai",
      "data": {
        "content": "{'summary': '## Pathology Analysis Agent Report: Patient MDT2024001', 'histology': '**', 'molecular_profile': {'key_mutations': '** While *KRAS* G12C is the primary driver mutation, additional molecular profiling might be considered for comprehensive characterization of the tumor, particularly if the response to targeted therapy is not optimal.  This could include next-generation sequencing (NGS) panels.', 'immunotherapy_markers': \"**  Given the high PD-L1 expression (80%), immunotherapy with a PD-1 or PD-L1 inhibitor (e.g., pembrolizumab, nivolumab) may be considered as a single agent or in combination with chemotherapy or targeted therapy.  The efficacy of immunotherapy in *KRAS*-mutated lung cancer is less established than in other subtypes, but the high PD-L1 expression warrants consideration.  However, the choice will depend on the patient's overall health and response to other therapies.\", 'other_markers': {'KRAS': '**  Sotorasib and adagrasib are FDA-approved targeted therapies specifically for *KRAS* G12C-mutated non-small cell lung cancer (NSCLC).  These agents should be considered as a primary treatment option.'}}, 'therapeutic_implications': ['The provided data does not specify the grade and differentiation of the adenocarcinoma.  Further histopathological review of the biopsy specimen, including assessment of nuclear pleomorphism, mitotic rate, and architectural features, is necessary to determine the grade and assess the degree of differentiation. This information is crucial for prognosis and treatment planning.', '* **KRAS G12C:**  The presence of this mutation identifies a specific therapeutic target.', '**5. Therapeutic Targets:**', 'The identified *KRAS* G12C mutation and high PD-L1 expression provide clear therapeutic targets.', '* **KRAS G12C inhibitors:**  Sotorasib and adagrasib are FDA-approved targeted therapies specifically for *KRAS* G12C-mutated non-small cell lung cancer (NSCLC).  These agents should be considered as a primary treatment option.', \"* **PD-1/PD-L1 inhibitors:**  Given the high PD-L1 expression (80%), immunotherapy with a PD-1 or PD-L1 inhibitor (e.g., pembrolizumab, nivolumab) may be considered as a single agent or in combination with chemotherapy or targeted therapy.  The efficacy of immunotherapy in *KRAS*-mutated lung cancer is less established than in other subtypes, but the high PD-L1 expression warrants consideration.  However, the choice will depend on the patient's overall health and response to other therapies.\", '* **Comprehensive staging workup:**  This is crucial to determine the extent of disease and guide treatment decisions. This should include:', '* **Further molecular testing:** While *KRAS* G12C is the primary driver mutation, additional molecular profiling might be considered for comprehensive characterization of the tumor, particularly if the response to targeted therapy is not optimal.  This could include next-generation sequencing (NGS) panels.', 'This analysis is based on limited data. The grade and differentiation of the adenocarcinoma are yet to be determined.  The optimal treatment strategy will depend on the results of the comprehensive staging workup and multidisciplinary team discussion.  The effectiveness of immunotherapy in KRAS-mutated lung cancer with high PD-L1 expression warrants close monitoring.', \"The treatment plan should be individualized based on the patient's overall health, performance status, comorbidities (including diabetes and hypertension), preferences, and shared decision-making within the MDT.  The potential side effects of the various treatment options need to be discussed with the patient.\", 'This report serves as a preliminary assessment.  A comprehensive MDT discussion including surgical oncology, medical oncology, radiation oncology, and thoracic surgery is essential to develop a personalized and optimal treatment plan for Patient MDT2024001.']}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "ai",
        "name": null,
        "id": null,
        "example": false,
        "tool_calls": [],
        "invalid_tool_calls": [],
        "usage_metadata": null
      }
    }
  ],
  "7b7a2677-8758-4551-9b1e-019ee8402748_PathologyAgent": [
    {
      "type": "human",
      "data": {
        "content": "{'context': '{\\n  \"patient_id\": \"MDT2024001\",\\n  \"demographics\": {\\n    \"age\": 62,\\n    \"gender\": \"F\",\\n    \"ethnicity\": \"Caucasian\",\\n    \"occupation\": \"Retired Teacher\",\\n    \"smoking_status\": \"Former smoker, quit 10 years ago\"\\n  },\\n  \"pathology_results\": {\\n    \"bronchoscopy_biopsy\": {\\n      \"date\": \"2024-02-15\",\\n      \"specimen\": \"Right upper lobe mass biopsy\",\\n      \"microscopic\": \"Malignant cells consistent with adenocarcinoma\",\\n      \"immunohistochemistry\": {\\n        \"TTF-1\": \"Positive\",\\n        \"CK7\": \"Positive\",\\n        \"CK20\": \"Negative\",\\n        \"PD-L1\": \"80% expression\"\\n      },\\n      \"molecular\": {\\n        \"EGFR\": \"Wild type\",\\n        \"ALK\": \"No rearrangement\",\\n        \"ROS1\": \"No rearrangement\",\\n        \"KRAS\": \"G12C mutation detected\"\\n      },\\n      \"diagnosis\": \"Lung adenocarcinoma, KRAS G12C mutated, PD-L1 80%\"\\n    }\\n  },\\n  \"current_condition\": {\\n    \"primary_complaint\": \"Persistent cough with occasional blood-tinged sputum\",\\n    \"onset\": \"2024-01-15\",\\n    \"severity\": \"Moderate to severe\",\\n    \"associated_symptoms\": [\\n      \"Unintentional weight loss (5kg in 3 months)\",\\n      \"Fatigue\",\\n      \"Decreased appetite\",\\n      \"Night sweats\"\\n    ],\\n    \"physical_exam\": {\\n      \"vital_signs\": {\\n        \"temperature\": \"37.2\\\\u00b0C\",\\n        \"blood_pressure\": \"132/82\",\\n        \"heart_rate\": \"88\",\\n        \"respiratory_rate\": \"20\",\\n        \"oxygen_saturation\": \"95% on room air\"\\n      },\\n      \"chest\": \"Decreased breath sounds in right upper lobe\",\\n      \"lymph_nodes\": \"Right supraclavicular lymphadenopathy\",\\n      \"weight\": \"68 kg\",\\n      \"height\": \"165 cm\"\\n    }\\n  },\\n  \"ehr_context\": {\\n    \"summary\": \"The analysis is based on the information provided. Further investigations are necessary to confirm the diagnosis and determine the appropriate treatment strategy.  The mild elevation in LFTs requires further exploration to determine the etiology.  A detailed psychosocial assessment is recommended to fully understand the patient\\'s support systems and functional capacity.\",\\n    \"details\": {\\n      \"summary\": \"The analysis is based on the information provided. Further investigations are necessary to confirm the diagnosis and determine the appropriate treatment strategy.  The mild elevation in LFTs requires further exploration to determine the etiology.  A detailed psychosocial assessment is recommended to fully understand the patient\\'s support systems and functional capacity.\",\\n      \"key_history_points\": [],\\n      \"current_presentation\": {\\n        \"main_symptoms\": [],\\n        \"performance_status\": \"\",\\n        \"comorbidity_impact\": \"** The patient has well-controlled Type 2 Diabetes Mellitus (T2DM) and hypertension, managed with Metformin and Lisinopril respectively.  She also has osteoarthritis affecting her knees and hands. These comorbidities will need to be considered when selecting and managing treatment.  The relatively good control of her T2DM and hypertension is positive.\"\\n      },\\n      \"risk_factors\": [],\\n      \"clinical_implications\": [],\\n      \"raw_output\": \"**EHR Analysis Agent Report: Patient MDT2024001**\\\\n\\\\n**1. Key History Points:**\\\\n\\\\n* **Chronological Progression of Symptoms:** The patient, a 62-year-old Caucasian female, presented with a persistent cough (onset 2024-01-15) initially, progressing to include blood-tinged sputum, unintentional weight loss (5kg in 3 months), fatigue, decreased appetite, and night sweats.  This constellation of symptoms warrants serious investigation, particularly given the timeline.\\\\n\\\\n* **Comorbidities:** The patient has well-controlled Type 2 Diabetes Mellitus (T2DM) and hypertension, managed with Metformin and Lisinopril respectively.  She also has osteoarthritis affecting her knees and hands. These comorbidities will need to be considered when selecting and managing treatment.  The relatively good control of her T2DM and hypertension is positive.\\\\n\\\\n* **Social and Functional Factors:** The patient is a retired teacher, suggesting a potentially reduced social support network compared to an employed individual.  However, her retirement status doesn\\'t automatically imply significant functional limitation. Further assessment is needed to understand her current level of independence and support systems.\\\\n\\\\n* **Risk Factors:**  Former smoker (quit 10 years ago) increases the risk of lung cancer.  Age (62) also places her within a higher risk group for various malignancies. The combination of cough, hemoptysis, weight loss, and lymphadenopathy are highly suggestive of a serious underlying condition, most likely malignancy.\\\\n\\\\n**2. Current Clinical Status:**\\\\n\\\\n* **Primary Complaint:** Persistent cough with occasional hemoptysis.\\\\n* **Physical Exam:**  Suggestive of a right upper lobe lung pathology; decreased breath sounds in the right upper lobe and right supraclavicular lymphadenopathy are highly concerning.\\\\n* **Laboratory Results:**  The complete blood count (CBC) shows normal hemoglobin, white blood cell count, and platelets, which don\\'t immediately suggest significant anemia or infection. Liver function tests (LFTs) are mildly elevated (ALT 28 U/L, AST 32 U/L), which could be due to various factors including underlying malignancy or medication effects. Further investigation is required.  The albumin level is within the normal range.\\\\n\\\\n\\\\n**3. Relevant Risk Factors:**\\\\n\\\\n* **Age:** 62 years old (increased risk for various cancers).\\\\n* **Smoking History:** Former smoker (increased risk of lung cancer and other respiratory diseases).\\\\n* **Symptom Constellation:**  Cough, hemoptysis, weight loss, fatigue, decreased appetite, night sweats, and lymphadenopathy \\\\u2013 highly suggestive of malignancy (likely lung cancer).\\\\n\\\\n**4. Performance Status Assessment:**\\\\n\\\\nBased on the presented information, a preliminary assessment suggests a performance status (PS) of either 1 or 2 according to the Eastern Cooperative Oncology Group (ECOG) scale.  A PS of 1 indicates that the patient is ambulatory and capable of all self-care but with some limitations in physical activity. A PS of 2 indicates that the patient is ambulatory and capable of only limited self-care.  A more thorough assessment is needed to definitively determine her PS. This assessment will significantly influence treatment choices.\\\\n\\\\n**5. Clinical Implications:**\\\\n\\\\nThe clinical presentation strongly suggests the need for urgent further investigation to rule out or confirm a malignancy, most likely lung cancer.  The following investigations are warranted:\\\\n\\\\n* **Chest X-ray:** To visualize the suspected right upper lobe pathology.\\\\n* **Computed Tomography (CT) scan of the chest:**  To further delineate the extent of the lung lesion and assess for mediastinal lymphadenopathy.\\\\n* **Bronchoscopy with bronchoalveolar lavage (BAL) and biopsy:**  To obtain tissue samples for definitive histopathological diagnosis.  This is crucial for determining the type and stage of cancer.\\\\n* **Positron Emission Tomography (PET) scan:** To assess for distant metastasis.\\\\n\\\\n**Treatment Planning Considerations:**\\\\n\\\\nTreatment planning will depend heavily on the histological diagnosis, staging, and performance status.  The comorbidities (T2DM and hypertension) will require careful consideration when selecting chemotherapy regimens to minimize potential drug interactions and adverse effects.  The osteoarthritis will also need to be factored into treatment decisions, particularly concerning the use of NSAIDs which may interact with other medications or exacerbate her existing condition.  Patient preference and shared decision-making are crucial elements in treatment planning.\\\\n\\\\n**Limitations and Uncertainties:**\\\\n\\\\nThe analysis is based on the information provided. Further investigations are necessary to confirm the diagnosis and determine the appropriate treatment strategy.  The mild elevation in LFTs requires further exploration to determine the etiology.  A detailed psychosocial assessment is recommended to fully understand the patient\\'s support systems and functional capacity.\\\\n\\\\n\\\\n**Conclusion:**\\\\n\\\\nThis patient presents with a highly concerning clinical picture suggestive of lung cancer. Urgent further investigation and multidisciplinary team (MDT) discussion are crucial for timely diagnosis and treatment planning, taking into consideration her comorbidities and performance status.  This approach ensures patient-centered care and optimal outcomes.\"\\n    }\\n  },\\n  \"imaging_context\": {\\n    \"summary\": \"**Imaging Analysis Report: Patient MDT2024001**\",\\n    \"details\": {\\n      \"summary\": \"**Imaging Analysis Report: Patient MDT2024001**\",\\n      \"disease_extent\": {\\n        \"primary_tumor\": \"** 3.8 x 3.2 cm (CT Chest).\",\\n        \"nodal_status\": \"**  To obtain tissue samples for histopathological diagnosis and definitive lymph node staging.  This is essential for accurate subtyping of NSCLC (adenocarcinoma, squamous cell carcinoma, etc.) and informing treatment decisions.  EBUS-TBNA is generally preferred for mediastinal lymph node sampling to minimize invasiveness.\",\\n        \"metastatic_status\": \"** M0 (no distant metastases).\"\\n      },\\n      \"staging\": {\\n        \"clinical_stage\": \"\",\\n        \"key_findings\": [\\n          \"* **Chest X-ray (2024-02-01):** Demonstrates a 3.5 cm mass in the right upper lobe with associated hilar lymphadenopathy.  The findings are highly suggestive of a primary lung malignancy.  Resolution is limited, precluding precise characterization.\",\\n          \"* **CT Chest (2024-02-05):** Confirms a 3.8 x 3.2 cm spiculated mass in the right upper lobe, consistent with malignancy.  Multiple enlarged right hilar and mediastinal lymph nodes are present. No evidence of distant metastases is identified. Mild emphysematous changes are noted in the upper lobes.\",\\n          \"* **PET-CT (2024-02-12):**  Shows a right upper lobe mass with an SUVmax of 12.4, indicating high metabolic activity consistent with malignancy. FDG-avid right hilar and mediastinal lymph nodes are present (SUVmax 8.2). No evidence of distant metastatic disease is observed.\",\\n          \"* **Primary lesion:** 3.8 x 3.2 cm (CT Chest).\",\\n          \"The primary lesion is located in the right upper lobe, close to the hilum.  The involvement of hilar and mediastinal lymph nodes indicates locoregional spread. The relationship of the tumor to major vessels and bronchi cannot be fully assessed from the provided imaging alone and requires further detailed analysis by a thoracic surgeon if surgical resection is considered. The mild emphysema may impact surgical planning.\"\\n        ]\\n      },\\n      \"treatment_implications\": []\\n    }\\n  }\\n}', 'task': \"Analyze the patient's pathological and molecular findings. Provide a structured interpretation including histological classification, molecular profile, biomarker status, and therapeutic implications.\"}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "human",
        "name": null,
        "id": null,
        "example": false
      }
    },
    {
      "type": "ai",
      "data": {
        "content": "{'summary': '**Pathology Analysis Agent Report: Patient MDT2024001**', 'histology': '**', 'molecular_profile': {'key_mutations': '**Pathological Diagnosis:**', 'immunotherapy_markers': '** This patient has a *KRAS* G12C-mutated lung adenocarcinoma with high PD-L1 expression, indicating several promising therapeutic options.  However, comprehensive staging and further pathological assessment are crucial before initiating treatment. A multidisciplinary team (MDT) meeting with oncologists, surgeons, radiologists, and other relevant specialists is strongly recommended to develop a personalized treatment plan.', 'other_markers': {}}, 'therapeutic_implications': ['The provided data does not specify the grade or differentiation of the adenocarcinoma.  Further pathological assessment of the biopsy specimen, including a detailed review by a pathologist experienced in lung cancer grading (e.g., using the WHO classification system), is necessary to determine the grade and differentiation. This information is crucial for prognostication and treatment planning.', 'Molecular testing reveals a *KRAS* G12C mutation.  *EGFR*, *ALK*, and *ROS1* are all wild-type (no rearrangements detected). The presence of a *KRAS* G12C mutation is a significant finding, as it indicates a targetable mutation with specific therapeutic implications.', 'PD-L1 expression is 80%. This high level of PD-L1 expression suggests that the patient may benefit from immunotherapy, specifically PD-1/PD-L1 inhibitors.  Further assessment of the PD-L1 expression using a standardized assay (e.g., the FDA-approved companion diagnostic test) is recommended to confirm the result and guide treatment decisions.', '**5. Therapeutic Targets:**', \"The *KRAS* G12C mutation is a key therapeutic target.  Sotorasib and adagrasib are FDA-approved therapies specifically targeting this mutation.  The high PD-L1 expression (80%) also suggests that immunotherapy with a PD-1 or PD-L1 inhibitor could be beneficial, either as monotherapy or in combination with a KRAS G12C inhibitor.  The choice of treatment will depend on several factors including the patient's overall health, performance status, and presence of any other comorbidities.\", '* Targeted therapy with a KRAS G12C inhibitor (sotorasib or adagrasib) is indicated.', '* Immunotherapy with a PD-1/PD-L1 inhibitor is a strong consideration, either as monotherapy or in combination with a KRAS G12C inhibitor.  This decision will be based on the confirmed PD-L1 expression level and other clinical factors.', \"* Further assessment of the patient's performance status and comorbidities is crucial for selecting the most appropriate treatment regimen.\", '1. **Confirmation of PD-L1 expression:**  Repeat PD-L1 IHC using a standardized, FDA-approved assay to ensure accurate quantification and guide immunotherapy decisions.', '2. **Grading and Differentiation:**  Detailed review of the biopsy specimen by an expert lung pathologist to determine the grade and differentiation of the adenocarcinoma. This is essential for accurate prognostication and treatment planning.', '3. **Comprehensive Staging:**  Further imaging (CT chest with contrast, PET-CT scan), and potentially EBUS-TBNA or mediastinoscopy, to accurately stage the disease (determine the extent of local and regional spread) before treatment commences.  This includes assessment of mediastinal lymph node involvement.', '4. **Molecular testing on additional samples:**  If sufficient tissue is available, consider additional molecular testing for other potential targetable mutations, even though *KRAS* G12C is already identified.', '5. **Further blood tests:** Complete blood count with differential, comprehensive metabolic panel, including liver function tests (LFTs) and coagulation studies to assess overall health and identify any potential contraindications to treatment.  The mildly elevated LFTs should be investigated further.', '**Overall:** This patient has a *KRAS* G12C-mutated lung adenocarcinoma with high PD-L1 expression, indicating several promising therapeutic options.  However, comprehensive staging and further pathological assessment are crucial before initiating treatment. A multidisciplinary team (MDT) meeting with oncologists, surgeons, radiologists, and other relevant specialists is strongly recommended to develop a personalized treatment plan.']}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "ai",
        "name": null,
        "id": null,
        "example": false,
        "tool_calls": [],
        "invalid_tool_calls": [],
        "usage_metadata": null
      }
    }
  ],
  "e594fda1-7c91-45c2-9394-fc7360d58e04_PathologyAgent": [
    {
      "type": "human",
      "data": {
        "content": "{'context': '{\\n  \"patient_id\": \"MDT2024001\",\\n  \"demographics\": {\\n    \"age\": 62,\\n    \"gender\": \"F\",\\n    \"ethnicity\": \"Caucasian\",\\n    \"occupation\": \"Retired Teacher\",\\n    \"smoking_status\": \"Former smoker, quit 10 years ago\"\\n  },\\n  \"pathology_results\": {\\n    \"bronchoscopy_biopsy\": {\\n      \"date\": \"2024-02-15\",\\n      \"specimen\": \"Right upper lobe mass biopsy\",\\n      \"microscopic\": \"Malignant cells consistent with adenocarcinoma\",\\n      \"immunohistochemistry\": {\\n        \"TTF-1\": \"Positive\",\\n        \"CK7\": \"Positive\",\\n        \"CK20\": \"Negative\",\\n        \"PD-L1\": \"80% expression\"\\n      },\\n      \"molecular\": {\\n        \"EGFR\": \"Wild type\",\\n        \"ALK\": \"No rearrangement\",\\n        \"ROS1\": \"No rearrangement\",\\n        \"KRAS\": \"G12C mutation detected\"\\n      },\\n      \"diagnosis\": \"Lung adenocarcinoma, KRAS G12C mutated, PD-L1 80%\"\\n    }\\n  },\\n  \"current_condition\": {\\n    \"primary_complaint\": \"Persistent cough with occasional blood-tinged sputum\",\\n    \"onset\": \"2024-01-15\",\\n    \"severity\": \"Moderate to severe\",\\n    \"associated_symptoms\": [\\n      \"Unintentional weight loss (5kg in 3 months)\",\\n      \"Fatigue\",\\n      \"Decreased appetite\",\\n      \"Night sweats\"\\n    ],\\n    \"physical_exam\": {\\n      \"vital_signs\": {\\n        \"temperature\": \"37.2\\\\u00b0C\",\\n        \"blood_pressure\": \"132/82\",\\n        \"heart_rate\": \"88\",\\n        \"respiratory_rate\": \"20\",\\n        \"oxygen_saturation\": \"95% on room air\"\\n      },\\n      \"chest\": \"Decreased breath sounds in right upper lobe\",\\n      \"lymph_nodes\": \"Right supraclavicular lymphadenopathy\",\\n      \"weight\": \"68 kg\",\\n      \"height\": \"165 cm\"\\n    }\\n  },\\n  \"ehr_context\": {\\n    \"summary\": \"Based on the presented information, a preliminary assessment suggests a performance status of ECOG 2-3.  The patient is experiencing significant symptoms (fatigue, weight loss, cough) impacting her daily activities.  Further assessment using a validated performance status scale (e.g., ECOG, Karnofsky) is necessary for a definitive assessment.\",\\n    \"details\": {\\n      \"summary\": \"Based on the presented information, a preliminary assessment suggests a performance status of ECOG 2-3.  The patient is experiencing significant symptoms (fatigue, weight loss, cough) impacting her daily activities.  Further assessment using a validated performance status scale (e.g., ECOG, Karnofsky) is necessary for a definitive assessment.\",\\n      \"key_history_points\": [],\\n      \"current_presentation\": {\\n        \"main_symptoms\": [],\\n        \"performance_status\": \"\",\\n        \"comorbidity_impact\": \"** The patient has well-controlled Type 2 Diabetes Mellitus (diagnosed 2015), well-controlled hypertension (diagnosed 2016), and osteoarthritis (diagnosed 2018). These comorbidities will need careful consideration during treatment planning due to potential drug interactions and impact on overall tolerance.\"\\n      },\\n      \"risk_factors\": [],\\n      \"clinical_implications\": [],\\n      \"raw_output\": \"## EHR Analysis Agent Report: Patient MDT2024001\\\\n\\\\n**1. Key History Points:**\\\\n\\\\n* **Chronological Progression of Symptoms:** The patient, a 62-year-old Caucasian female, presents with a persistent cough (onset January 15th, 2024) initially characterized as moderate to severe, now complicated by occasional blood-tinged sputum.  This is accompanied by significant unintentional weight loss (5kg in 3 months), fatigue, decreased appetite, and night sweats \\\\u2013 all highly suggestive of a serious underlying condition, potentially malignancy.\\\\n\\\\n* **Comorbidities:** The patient has well-controlled Type 2 Diabetes Mellitus (diagnosed 2015), well-controlled hypertension (diagnosed 2016), and osteoarthritis (diagnosed 2018). These comorbidities will need careful consideration during treatment planning due to potential drug interactions and impact on overall tolerance.\\\\n\\\\n* **Social and Functional Factors:** The patient is a retired teacher, suggesting a potentially stable social support network but also potential limitations in physical activity due to osteoarthritis.  Her retirement status may impact her ability to tolerate intensive treatment regimens.\\\\n\\\\n* **Risk Factors:**  Former smoker (quit 10 years ago) increases the risk of lung cancer.  Age (62) also places her within a high-risk age group for various malignancies.  The combination of weight loss, cough, hemoptysis, and lymphadenopathy significantly increases suspicion for lung cancer.\\\\n\\\\n**2. Current Clinical Status:**\\\\n\\\\n* **Primary Complaint:** Persistent cough with hemoptysis.\\\\n* **Physical Exam:**  Significant findings include decreased breath sounds in the right upper lobe, right supraclavicular lymphadenopathy, and unintentional weight loss. These findings strongly suggest a possible right upper lobe lung mass.\\\\n* **Laboratory Results:**  While the complete blood count (CBC) shows no overt anemia (hemoglobin 12.8 g/dL), the liver function tests (LFTs) show mildly elevated AST (32 U/L) and ALT (28 U/L), which warrants further investigation.  Albumin levels are within the normal range.  Creatinine is normal.\\\\n\\\\n**3. Relevant Risk Factors:**\\\\n\\\\n* **Age:** 62 years old (increased risk for various cancers)\\\\n* **Smoking History:** Former smoker (increased risk of lung cancer)\\\\n* **Weight Loss:** Significant unintentional weight loss (5kg in 3 months) \\\\u2013 a major red flag for malignancy.\\\\n* **Hemoptysis:** Presence of blood in sputum.\\\\n* **Lymphadenopathy:** Right supraclavicular lymphadenopathy \\\\u2013 suggestive of metastatic disease.\\\\n* **Fatigue, Anorexia, Night Sweats:**  Constitutional symptoms highly suggestive of malignancy.\\\\n\\\\n**4. Performance Status Assessment:**\\\\n\\\\nBased on the presented information, a preliminary assessment suggests a performance status of ECOG 2-3.  The patient is experiencing significant symptoms (fatigue, weight loss, cough) impacting her daily activities.  Further assessment using a validated performance status scale (e.g., ECOG, Karnofsky) is necessary for a definitive assessment.\\\\n\\\\n**5. Clinical Implications:**\\\\n\\\\nThe clinical presentation strongly suggests the possibility of lung cancer.  The right upper lobe findings, lymphadenopathy, and constitutional symptoms warrant urgent further investigation.\\\\n\\\\n**Further Investigations:**\\\\n\\\\n* **Chest X-ray:** To confirm the presence and extent of the suspected lung lesion.\\\\n* **Computed Tomography (CT) Scan of the Chest and Abdomen/Pelvis:** To further characterize the lung lesion, assess for mediastinal involvement, and evaluate for distant metastases.\\\\n* **Bronchoscopy with Bronchoalveolar Lavage (BAL) and Biopsy:**  To obtain tissue for definitive pathological diagnosis.\\\\n* **Positron Emission Tomography (PET) Scan:** To assess for distant metastases and to stage the disease.\\\\n* **Further Blood Tests:**  Tumor markers (CEA, CYFRA 21-1) may be considered.\\\\n\\\\n\\\\n**Treatment Planning:**\\\\n\\\\nTreatment planning will depend heavily on the pathological diagnosis, staging, and the patient\\'s performance status.  Options may include surgery, chemotherapy, radiation therapy, targeted therapy, or a combination thereof.  Management of comorbidities (diabetes, hypertension, osteoarthritis) will be crucial throughout the treatment process.  Close monitoring of medication interactions will be essential.  A multidisciplinary team (MDT) approach involving pulmonologists, oncologists, radiologists, pathologists, and potentially other specialists is crucial for optimal patient care.\\\\n\\\\n**Limitations and Uncertainties:**\\\\n\\\\nThis analysis is based on limited information.  A definitive diagnosis and treatment plan require further investigations as outlined above.  The severity of comorbidities and their impact on treatment tolerance remain to be fully assessed.\\\\n\\\\n**Patient-Centered Care:**\\\\n\\\\nThroughout the diagnostic and treatment process, patient preferences, values, and goals must be considered and integrated into the care plan.  Open communication and shared decision-making are essential to ensure optimal patient-centered care.\"\\n    }\\n  },\\n  \"imaging_context\": {\\n    \"summary\": \"## Imaging Analysis Report: Patient MDT2024001\",\\n    \"details\": {\\n      \"summary\": \"## Imaging Analysis Report: Patient MDT2024001\",\\n      \"disease_extent\": {\\n        \"primary_tumor\": \"** 3.8 x 3.2 cm (CT Chest)\",\\n        \"nodal_status\": \"** This is highly recommended to obtain tissue samples for definitive diagnosis and to further characterize the mediastinal lymph node involvement.  This will allow for precise staging and surgical planning.\",\\n        \"metastatic_status\": \"**  Given the physical exam findings, further evaluation of the supraclavicular lymphadenopathy with ultrasound or CT is warranted to assess for potential metastatic spread.\"\\n      },\\n      \"staging\": {\\n        \"clinical_stage\": \"\",\\n        \"key_findings\": [\\n          \"* **Chest X-ray (2024-02-01):** Demonstrates a 3.5 cm mass in the right upper lobe with associated hilar lymphadenopathy.  The impression of a highly suspicious primary lung malignancy is consistent with subsequent imaging.\",\\n          \"* **CT Chest (2024-02-05):** Confirms a 3.8 x 3.2 cm spiculated mass in the right upper lobe, consistent with malignancy.  Multiple enlarged right hilar and mediastinal lymph nodes are identified. No evidence of distant metastases is seen. Mild emphysematous changes are noted in the upper lobes.\",\\n          \"* **PET-CT (2024-02-12):**  Shows an SUVmax of 12.4 in the right upper lobe mass, confirming its high metabolic activity.  FDG-avid right hilar and mediastinal lymph nodes are present (SUVmax 8.2), indicating likely metastatic involvement. No evidence of distant metastatic disease is detected.\",\\n          \"* **Primary lesion:** 3.8 x 3.2 cm (CT Chest)\",\\n          \"Based on the imaging findings, the patient presents with a right upper lobe lung mass with significant mediastinal lymph node involvement and no evidence of distant metastases.  This strongly suggests a Stage IIIA non-small cell lung cancer (NSCLC) according to the 8th edition TNM staging system.  Further clarification regarding precise nodal involvement (N2 vs N3) may require further imaging or pathological assessment.  The exact T-stage (T1-T4) will require pathological confirmation following biopsy. However, based on the size of the lesion, a T2-T3 classification is likely.  Therefore, a preliminary staging assessment is **Stage IIIA (T2-3 N2 M0)**, acknowledging the possibility of refinement upon histopathological analysis.\",\\n          \"The primary lesion is located in the right upper lobe, close to the hilum, with direct involvement of regional hilar and mediastinal lymph nodes.  The proximity of the tumor to the hilum and the extent of nodal involvement are crucial factors in treatment planning, particularly regarding surgical resectability. The mild emphysema may impact surgical approach and post-operative recovery.  The presence of right supraclavicular lymphadenopathy on physical exam warrants correlation with imaging findings.  It is possible that this is a result of the primary disease, but other possibilities need to be considered.\"\\n        ]\\n      },\\n      \"treatment_implications\": []\\n    }\\n  }\\n}', 'task': \"Analyze the patient's pathological and molecular findings. Provide a structured interpretation including histological classification, molecular profile, biomarker status, and therapeutic implications.\"}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "human",
        "name": null,
        "id": null,
        "example": false
      }
    },
    {
      "type": "ai",
      "data": {
        "content": "{'summary': '**Pathology Analysis Agent Report: Patient MDT2024001**', 'histology': '**', 'molecular_profile': {'key_mutations': '**4. Biomarker Status:**', 'immunotherapy_markers': '**  Consideration should be given to a combination of a KRAS G12C inhibitor (sotorasib or adagrasib) and a PD-1/PD-L1 inhibitor.  The high PD-L1 expression strongly supports the inclusion of immunotherapy.', 'other_markers': {}}, 'therapeutic_implications': ['The provided data does not specify the grade or differentiation of the adenocarcinoma.  This information is crucial for prognosis and treatment planning and should be obtained from the full pathology report.  Further analysis of the biopsy specimen, including assessment of nuclear atypia, mitotic rate, and architectural features, is necessary to determine the grade.', 'Molecular testing reveals a *KRAS* G12C mutation.  This is a significant finding, as it identifies a targetable oncogenic driver mutation.  The absence of EGFR, ALK, and ROS1 rearrangements excludes the use of tyrosine kinase inhibitors (TKIs) targeting these pathways.', '* **PD-L1:**  High PD-L1 expression (80%) is observed. This indicates a potential response to immunotherapy, specifically PD-1/PD-L1 inhibitors.  The high expression level suggests a greater likelihood of benefit from immunotherapy compared to lower expression levels.', '**5. Therapeutic Targets:**', 'Given the molecular and biomarker profile, the primary therapeutic target is the *KRAS* G12C mutation.  Sotorasib and adagrasib are FDA-approved targeted therapies specifically designed to inhibit KRAS G12C.  The high PD-L1 expression suggests that a combination therapy incorporating a PD-1/PD-L1 inhibitor (e.g., pembrolizumab, nivolumab) alongside a KRAS G12C inhibitor may be highly beneficial.', '* **First-line therapy:**  Consideration should be given to a combination of a KRAS G12C inhibitor (sotorasib or adagrasib) and a PD-1/PD-L1 inhibitor.  The high PD-L1 expression strongly supports the inclusion of immunotherapy.', '* **Alternative strategies:** If the patient is ineligible for or does not tolerate the combination therapy, monotherapy with either a KRAS G12C inhibitor or a PD-1/PD-L1 inhibitor could be considered, although the combination approach is generally preferred given the data.', '* **Close monitoring:**  Close monitoring for treatment response and toxicity is essential.  Regular imaging and clinical assessments are needed to track disease progression and the effects of therapy.', '1. **Complete pathology report:**  Obtain the full pathology report to determine the grade and differentiation of the adenocarcinoma.  This will refine the prognosis and inform treatment decisions.', '2. **Comprehensive genomic profiling:** While KRAS G12C is identified, a more comprehensive genomic profile may reveal other targetable mutations or biomarkers that could influence treatment decisions.', '4. **Further staging investigations:**  While imaging suggests Stage IIIA, definitive staging requires complete pathological assessment of lymph node involvement.  This is crucial for treatment planning (surgery vs. non-surgical options).', '**Disclaimer:** This analysis is based on the provided data and represents a preliminary assessment.  A complete and definitive treatment plan requires a comprehensive review of all clinical information, radiological findings, and the complete pathology report within a multidisciplinary team setting.  The recommendations herein should be considered in consultation with the patient and her treating oncologist.']}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "ai",
        "name": null,
        "id": null,
        "example": false,
        "tool_calls": [],
        "invalid_tool_calls": [],
        "usage_metadata": null
      }
    }
  ],
  "9bb0c567-a29c-4d59-97c5-98d55b7cdb1f_PathologyAgent": [
    {
      "type": "human",
      "data": {
        "content": "{'context': '{\\n  \"patient_id\": \"MDT2024001\",\\n  \"demographics\": {\\n    \"age\": 62,\\n    \"gender\": \"F\",\\n    \"ethnicity\": \"Caucasian\",\\n    \"occupation\": \"Retired Teacher\",\\n    \"smoking_status\": \"Former smoker, quit 10 years ago\"\\n  },\\n  \"pathology_results\": {\\n    \"bronchoscopy_biopsy\": {\\n      \"date\": \"2024-02-15\",\\n      \"specimen\": \"Right upper lobe mass biopsy\",\\n      \"microscopic\": \"Malignant cells consistent with adenocarcinoma\",\\n      \"immunohistochemistry\": {\\n        \"TTF-1\": \"Positive\",\\n        \"CK7\": \"Positive\",\\n        \"CK20\": \"Negative\",\\n        \"PD-L1\": \"80% expression\"\\n      },\\n      \"molecular\": {\\n        \"EGFR\": \"Wild type\",\\n        \"ALK\": \"No rearrangement\",\\n        \"ROS1\": \"No rearrangement\",\\n        \"KRAS\": \"G12C mutation detected\"\\n      },\\n      \"diagnosis\": \"Lung adenocarcinoma, KRAS G12C mutated, PD-L1 80%\"\\n    }\\n  },\\n  \"current_condition\": {\\n    \"primary_complaint\": \"Persistent cough with occasional blood-tinged sputum\",\\n    \"onset\": \"2024-01-15\",\\n    \"severity\": \"Moderate to severe\",\\n    \"associated_symptoms\": [\\n      \"Unintentional weight loss (5kg in 3 months)\",\\n      \"Fatigue\",\\n      \"Decreased appetite\",\\n      \"Night sweats\"\\n    ],\\n    \"physical_exam\": {\\n      \"vital_signs\": {\\n        \"temperature\": \"37.2\\\\u00b0C\",\\n        \"blood_pressure\": \"132/82\",\\n        \"heart_rate\": \"88\",\\n        \"respiratory_rate\": \"20\",\\n        \"oxygen_saturation\": \"95% on room air\"\\n      },\\n      \"chest\": \"Decreased breath sounds in right upper lobe\",\\n      \"lymph_nodes\": \"Right supraclavicular lymphadenopathy\",\\n      \"weight\": \"68 kg\",\\n      \"height\": \"165 cm\"\\n    }\\n  },\\n  \"ehr_context\": {\\n    \"summary\": \"This analysis is based on the provided information.  A complete assessment requires a thorough physical examination, additional investigations (as outlined above), and potentially further history taking, including family history of cancer.  The absence of family history information limits the risk stratification.  The exact stage and histology of any potential malignancy are unknown at this time.  The patient\\'s performance status requires formal assessment.\",\\n    \"details\": {\\n      \"summary\": \"This analysis is based on the provided information.  A complete assessment requires a thorough physical examination, additional investigations (as outlined above), and potentially further history taking, including family history of cancer.  The absence of family history information limits the risk stratification.  The exact stage and histology of any potential malignancy are unknown at this time.  The patient\\'s performance status requires formal assessment.\",\\n      \"key_history_points\": [],\\n      \"current_presentation\": {\\n        \"main_symptoms\": [],\\n        \"performance_status\": \"**  Treatment will depend on the stage and histology of the cancer.  Options might include surgery, chemotherapy, radiotherapy, targeted therapy, or a combination. The patient\\'s comorbidities (T2DM, hypertension, osteoarthritis) will influence treatment selection and require close monitoring for potential adverse effects and interactions.  The patient\\'s performance status will also be a major factor in determining treatment intensity and feasibility.  Multidisciplinary team (MDT) discussion involving oncologists, pulmonologists, radiologists, and pathologists is crucial for optimal management.\",\\n        \"comorbidity_impact\": \"** The patient has well-controlled Type 2 Diabetes Mellitus (T2DM) and Hypertension, managed with Metformin and Lisinopril respectively.  She also has Osteoarthritis affecting her knees and hands. These comorbidities will need careful consideration during treatment planning due to potential drug interactions and impact on overall tolerance.  Her good glycemic control (HbA1c 6.8%) is positive.\"\\n      },\\n      \"risk_factors\": [],\\n      \"clinical_implications\": [],\\n      \"raw_output\": \"**EHR Analysis Agent Report: Patient MDT2024001**\\\\n\\\\n**1. Key History Points:**\\\\n\\\\n* **Chronological Progression of Symptoms:** The patient, a 62-year-old Caucasian female, presents with a concerning symptom constellation starting January 15th, 2024.  The primary complaint is a persistent cough with occasional hemoptysis (blood-tinged sputum), accompanied by significant unintentional weight loss (5kg in 3 months), fatigue, decreased appetite, and night sweats. This symptom cluster strongly suggests a possible malignancy, particularly lung cancer.\\\\n\\\\n* **Comorbidities:** The patient has well-controlled Type 2 Diabetes Mellitus (T2DM) and Hypertension, managed with Metformin and Lisinopril respectively.  She also has Osteoarthritis affecting her knees and hands. These comorbidities will need careful consideration during treatment planning due to potential drug interactions and impact on overall tolerance.  Her good glycemic control (HbA1c 6.8%) is positive.\\\\n\\\\n* **Social and Functional Factors:**  The patient is a retired teacher, suggesting a potentially stable social support system, but also a potential reduction in physical activity compared to her previous occupation.  Her functional status needs further assessment to determine her capacity to tolerate treatment.\\\\n\\\\n* **Risk Factors:**  The patient\\'s former smoking history (quit 10 years ago) is a significant risk factor for lung cancer.  Age (62) also increases the risk.\\\\n\\\\n**2. Current Clinical Status:**\\\\n\\\\n* **Symptoms:**  The persistent cough with hemoptysis, significant weight loss, fatigue, decreased appetite, and night sweats are highly suggestive of a serious underlying condition, most likely lung cancer.\\\\n\\\\n* **Physical Examination:**  Decreased breath sounds in the right upper lobe and right supraclavicular lymphadenopathy strongly support the suspicion of lung malignancy.  Vital signs are relatively stable, although slightly elevated blood pressure (132/82) should be monitored.\\\\n\\\\n* **Laboratory Results:**  The complete blood count (CBC) shows normal hemoglobin, white blood cell count, and platelets, which does not rule out malignancy but doesn\\'t suggest a severe anemia or infection.  Liver function tests (ALT and AST) are mildly elevated, which warrants further investigation and could be related to the underlying condition or medications.  Albumin is within the normal range.  Creatinine is normal.\\\\n\\\\n**3. Relevant Risk Factors:**\\\\n\\\\n* **Smoking history:** Former smoker (quit 10 years ago) \\\\u2013 significant risk factor for lung cancer.\\\\n* **Age:** 62 years \\\\u2013 increased risk for various malignancies.\\\\n* **Family history:**  (Not provided, but crucial information missing for complete risk assessment)\\\\n\\\\n\\\\n**4. Performance Status Assessment:**\\\\n\\\\nA full performance status assessment (e.g., ECOG or Karnofsky) is needed to determine the patient\\'s ability to tolerate various treatment regimens.  Based on the reported symptoms (significant fatigue, weight loss), a preliminary assessment suggests a potentially compromised performance status. This needs formal evaluation.\\\\n\\\\n\\\\n**5. Clinical Implications:**\\\\n\\\\n* **Differential Diagnosis:** The most likely diagnosis is lung cancer. Other possibilities, though less likely given the presentation, include tuberculosis, lung infection, and other granulomatous diseases.  Further investigation is crucial.\\\\n\\\\n* **Investigations:**  Urgent chest imaging (CT scan of the chest with contrast) is essential to confirm the diagnosis and stage the disease.  Bronchoscopy with biopsy is likely necessary for tissue diagnosis and cytology.  Further investigations may include PET scan depending on the initial imaging findings.\\\\n\\\\n* **Treatment Planning:**  Treatment will depend on the stage and histology of the cancer.  Options might include surgery, chemotherapy, radiotherapy, targeted therapy, or a combination. The patient\\'s comorbidities (T2DM, hypertension, osteoarthritis) will influence treatment selection and require close monitoring for potential adverse effects and interactions.  The patient\\'s performance status will also be a major factor in determining treatment intensity and feasibility.  Multidisciplinary team (MDT) discussion involving oncologists, pulmonologists, radiologists, and pathologists is crucial for optimal management.\\\\n\\\\n* **Medication Considerations:**  Careful monitoring of the patient\\'s current medications (Metformin, Lisinopril, PRN NSAIDs) is necessary, particularly for potential drug interactions with cancer therapies.\\\\n\\\\n\\\\n**Limitations and Uncertainties:**\\\\n\\\\nThis analysis is based on the provided information.  A complete assessment requires a thorough physical examination, additional investigations (as outlined above), and potentially further history taking, including family history of cancer.  The absence of family history information limits the risk stratification.  The exact stage and histology of any potential malignancy are unknown at this time.  The patient\\'s performance status requires formal assessment.\\\\n\\\\n\\\\n**Conclusion:**\\\\n\\\\nThis patient requires urgent further investigation to confirm the suspected diagnosis and stage the disease.  A multidisciplinary team approach is essential for optimal management, taking into account her comorbidities and performance status to ensure patient-centered care.\"\\n    }\\n  },\\n  \"imaging_context\": {\\n    \"summary\": \"**Imaging Analysis Report: Patient MDT2024001**\",\\n    \"details\": {\\n      \"summary\": \"**Imaging Analysis Report: Patient MDT2024001**\",\\n      \"disease_extent\": {\\n        \"primary_tumor\": \"** 12.4 (PET-CT)\",\\n        \"nodal_status\": \"** N2 (ipsilateral mediastinal lymph node involvement).  The presence of enlarged hilar and mediastinal lymph nodes confirmed on CT and PET-CT indicates N2 disease.\",\\n        \"metastatic_status\": \"** M0 (no evidence of distant metastases on CT and PET-CT).\"\\n      },\\n      \"staging\": {\\n        \"clinical_stage\": \"\",\\n        \"key_findings\": [\\n          \"* **Chest X-ray (2024-02-01):** Demonstrates a 3.5 cm mass in the right upper lobe with associated hilar lymphadenopathy.  The findings are highly suggestive of a primary lung malignancy.  The resolution is limited, preventing precise characterization of the mass.\",\\n          \"* **CT Chest (2024-02-05):**  Confirms a 3.8 x 3.2 cm spiculated mass in the right upper lobe.  Multiple enlarged right hilar and mediastinal lymph nodes are present.  No evidence of distant metastases is identified. Mild emphysematous changes are noted in the upper lobes. The spiculated nature of the mass is concerning for malignancy.\",\\n          \"* **PET-CT (2024-02-12):**  Shows a right upper lobe mass with an SUVmax of 12.4, indicating high metabolic activity consistent with malignancy.  FDG-avid right hilar and mediastinal lymph nodes are present, with an SUVmax of 8.2, further supporting the diagnosis of lymph node involvement.  No evidence of distant metastatic disease is detected.\",\\n          \"* **Primary lesion:** 3.8 x 3.2 cm (CT Chest)\",\\n          \"* **SUVmax of primary lesion:** 12.4 (PET-CT)\",\\n          \"* **T:** T3 ( > 7cm or invades chest wall, diaphragm, mediastinum)  or possibly T4 (invasion of mediastinum or other structures) based on the size and location of the mass and the involvement of the hilar lymph nodes.  Precise T-staging requires further assessment with bronchoscopy and potentially surgical exploration.\",\\n          \"The mass is located in the right upper lobe, close to the hilum and in proximity to mediastinal structures.  The involvement of hilar and mediastinal lymph nodes suggests potential local invasion. The relationship of the tumor to major vessels and bronchi needs further delineation.  This proximity to critical structures will influence surgical resectability.\"\\n        ]\\n      },\\n      \"treatment_implications\": []\\n    }\\n  }\\n}', 'task': \"Analyze the patient's pathological and molecular findings. Provide a structured interpretation including histological classification, molecular profile, biomarker status, and therapeutic implications.\"}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "human",
        "name": null,
        "id": null,
        "example": false
      }
    },
    {
      "type": "ai",
      "data": {
        "content": "{'summary': '**', 'histology': '**', 'molecular_profile': {'key_mutations': '**4. Biomarker Status:**', 'immunotherapy_markers': '** The high PD-L1 expression suggests that immunotherapy with a PD-1/PD-L1 inhibitor (e.g., pembrolizumab, nivolumab) could be a highly effective treatment option, either as monotherapy or in combination with other agents.', 'other_markers': {'ALK': '** No rearrangement.', 'ROS1': '** No rearrangement.'}}, 'therapeutic_implications': ['*10. Recommendations for Additional Testing:**', '**Complete histopathological assessment:**  Detailed review of the biopsy specimen to determine the grade and differentiation of the adenocarcinoma using established grading systems.', '**Comprehensive staging:**  Further imaging including CT and PET-CT scans are needed to fully assess the extent of the disease and determine a precise TNM stage.  This will involve evaluating the relationship of the tumor to critical structures and assessing for distant metastases.', \"**Performance status assessment:**  Formal assessment of the patient's performance status (e.g., ECOG or Karnofsky) is essential to guide treatment decisions.\", \"**Further clinical assessment:**  A thorough review of the patient's medical history, including family history of cancer, is needed for comprehensive risk stratification.  This is critical to determine underlying risk factors and guide treatment decisions.\", '*Disclaimer:** This report is based solely on the provided data and is for informational purposes only.  It does not constitute a formal medical diagnosis or treatment plan.  A complete clinical evaluation by a qualified medical professional is necessary for accurate diagnosis and appropriate management of the patient.']}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "ai",
        "name": null,
        "id": null,
        "example": false,
        "tool_calls": [],
        "invalid_tool_calls": [],
        "usage_metadata": null
      }
    }
  ],
  "0279bebc-10df-4927-a301-eab91d18c3bd_PathologyAgent": [
    {
      "type": "human",
      "data": {
        "content": "{'context': '{\\n  \"patient_id\": \"MDT2024001\",\\n  \"demographics\": {\\n    \"age\": 62,\\n    \"gender\": \"F\",\\n    \"ethnicity\": \"Caucasian\",\\n    \"occupation\": \"Retired Teacher\",\\n    \"smoking_status\": \"Former smoker, quit 10 years ago\"\\n  },\\n  \"pathology_results\": {\\n    \"bronchoscopy_biopsy\": {\\n      \"date\": \"2024-02-15\",\\n      \"specimen\": \"Right upper lobe mass biopsy\",\\n      \"microscopic\": \"Malignant cells consistent with adenocarcinoma\",\\n      \"immunohistochemistry\": {\\n        \"TTF-1\": \"Positive\",\\n        \"CK7\": \"Positive\",\\n        \"CK20\": \"Negative\",\\n        \"PD-L1\": \"80% expression\"\\n      },\\n      \"molecular\": {\\n        \"EGFR\": \"Wild type\",\\n        \"ALK\": \"No rearrangement\",\\n        \"ROS1\": \"No rearrangement\",\\n        \"KRAS\": \"G12C mutation detected\"\\n      },\\n      \"diagnosis\": \"Lung adenocarcinoma, KRAS G12C mutated, PD-L1 80%\"\\n    }\\n  },\\n  \"current_condition\": {\\n    \"primary_complaint\": \"Persistent cough with occasional blood-tinged sputum\",\\n    \"onset\": \"2024-01-15\",\\n    \"severity\": \"Moderate to severe\",\\n    \"associated_symptoms\": [\\n      \"Unintentional weight loss (5kg in 3 months)\",\\n      \"Fatigue\",\\n      \"Decreased appetite\",\\n      \"Night sweats\"\\n    ],\\n    \"physical_exam\": {\\n      \"vital_signs\": {\\n        \"temperature\": \"37.2\\\\u00b0C\",\\n        \"blood_pressure\": \"132/82\",\\n        \"heart_rate\": \"88\",\\n        \"respiratory_rate\": \"20\",\\n        \"oxygen_saturation\": \"95% on room air\"\\n      },\\n      \"chest\": \"Decreased breath sounds in right upper lobe\",\\n      \"lymph_nodes\": \"Right supraclavicular lymphadenopathy\",\\n      \"weight\": \"68 kg\",\\n      \"height\": \"165 cm\"\\n    }\\n  },\\n  \"ehr_context\": {\\n    \"summary\": \"** The current information is limited.  A definitive diagnosis cannot be made without further investigations.  The severity of the patient\\'s comorbidities and their impact on treatment tolerance needs further assessment.\",\\n    \"details\": {\\n      \"summary\": \"** The current information is limited.  A definitive diagnosis cannot be made without further investigations.  The severity of the patient\\'s comorbidities and their impact on treatment tolerance needs further assessment.\",\\n      \"key_history_points\": [],\\n      \"current_presentation\": {\\n        \"main_symptoms\": [],\\n        \"performance_status\": \"\",\\n        \"comorbidity_impact\": \"**  Treatment options will depend heavily on the results of the imaging and biopsy, including the stage and histological subtype of the cancer.  Treatment may involve surgery, chemotherapy, radiation therapy, targeted therapy, or a combination thereof.  The patient\\'s comorbidities (T2DM and hypertension) need careful consideration in treatment selection and management to minimize potential complications.  Her current medications will need to be reviewed for potential interactions with anticancer agents.  A multidisciplinary team (MDT) approach involving oncologists, pulmonologists, radiologists, pathologists, and potentially other specialists (e.g., endocrinologist for diabetes management) is essential for optimal management.\"\\n      },\\n      \"risk_factors\": [],\\n      \"clinical_implications\": [],\\n      \"raw_output\": \"**EHR Analysis Agent Report - Patient ID: MDT2024001**\\\\n\\\\n**1. Key History Points:**\\\\n\\\\n* **Chronological Progression of Symptoms:** The patient, a 62-year-old Caucasian female, presents with a persistent cough, occasionally producing blood-tinged sputum, starting on 2024-01-15.  This is accompanied by significant unintentional weight loss (5kg in 3 months), fatigue, decreased appetite, and night sweats \\\\u2013 all highly suggestive of a serious underlying illness, possibly malignancy.  The worsening cough and hemoptysis are particularly concerning.\\\\n\\\\n* **Medical History:**  The patient has a history of well-controlled Type 2 Diabetes Mellitus (T2DM), well-controlled hypertension, and osteoarthritis.  These comorbidities will need careful consideration during treatment planning due to potential drug interactions and increased risk of complications.  Her history of smoking, though she quit 10 years ago, remains a significant risk factor.\\\\n\\\\n* **Current Medications:** Metformin, Lisinopril, and PRN NSAIDs.  These medications need to be considered in the context of potential new treatments, particularly given the potential need for cytotoxic chemotherapy which can have interactions with these drugs.\\\\n\\\\n**2. Current Clinical Status:**\\\\n\\\\n* **Presenting Complaint:** Persistent cough with hemoptysis, significant weight loss, fatigue, decreased appetite, and night sweats.\\\\n\\\\n* **Physical Examination:**  The physical exam reveals concerning findings: decreased breath sounds in the right upper lobe, and right supraclavicular lymphadenopathy, strongly suggesting a possible lung malignancy.  Vital signs are relatively stable, although the slightly elevated blood pressure warrants monitoring.\\\\n\\\\n* **Laboratory Results:**  The complete blood count (CBC) is unremarkable, showing no significant anemia, leukocytosis, or thrombocytopenia.  Liver function tests (LFTs) are mildly elevated (ALT 28 U/L, AST 32 U/L), which could be related to the underlying condition or medications, but are not significantly alarming in isolation.  Albumin levels are within the normal range.  Renal function, as indicated by creatinine, is normal.\\\\n\\\\n\\\\n**3. Relevant Risk Factors:**\\\\n\\\\n* **Age:** 62 years old, placing her in a higher risk category for various cancers.\\\\n* **Gender:** Female (lung cancer incidence is lower in females but this is a significant symptom presentation).\\\\n* **Smoking History:** Former smoker (although quit 10 years ago, past smoking significantly increases lung cancer risk).\\\\n* **Weight Loss:** Significant unintentional weight loss is a major red flag for malignancy.\\\\n* **Symptoms:**  The combination of cough, hemoptysis, weight loss, fatigue, and night sweats is highly suggestive of lung cancer.\\\\n* **Physical Exam:** Decreased breath sounds and lymphadenopathy further support the suspicion of lung cancer.\\\\n\\\\n**4. Performance Status Assessment:**\\\\n\\\\nBased on the information provided, a preliminary assessment of performance status using the Eastern Cooperative Oncology Group (ECOG) scale would likely be between 2 and 3. The patient is experiencing significant fatigue, weight loss, and decreased appetite, impacting her daily activities. A more precise assessment requires a more detailed functional assessment.\\\\n\\\\n**5. Clinical Implications:**\\\\n\\\\nThe clinical picture strongly suggests the possibility of lung cancer.  Further investigations are urgently required, including:\\\\n\\\\n* **Imaging:**  High-resolution computed tomography (HRCT) of the chest is crucial to visualize the lung lesions and assess their extent, including lymph node involvement.  A CT scan of the abdomen and pelvis may also be necessary to rule out distant metastases.\\\\n* **Biopsy:**  A tissue biopsy (e.g., bronchoscopy with transbronchial needle aspiration or percutaneous needle biopsy) is essential to obtain a definitive diagnosis and determine the histological subtype of the cancer. This will allow for accurate staging and tailored treatment planning.\\\\n* **Further Lab Tests:**  Consideration should be given to additional tests, such as serum tumor markers (e.g., CEA, CYFRA 21-1), depending on the imaging findings.\\\\n\\\\n\\\\n**Treatment Planning:**  Treatment options will depend heavily on the results of the imaging and biopsy, including the stage and histological subtype of the cancer.  Treatment may involve surgery, chemotherapy, radiation therapy, targeted therapy, or a combination thereof.  The patient\\'s comorbidities (T2DM and hypertension) need careful consideration in treatment selection and management to minimize potential complications.  Her current medications will need to be reviewed for potential interactions with anticancer agents.  A multidisciplinary team (MDT) approach involving oncologists, pulmonologists, radiologists, pathologists, and potentially other specialists (e.g., endocrinologist for diabetes management) is essential for optimal management.\\\\n\\\\n\\\\n**Limitations and Uncertainties:** The current information is limited.  A definitive diagnosis cannot be made without further investigations.  The severity of the patient\\'s comorbidities and their impact on treatment tolerance needs further assessment.\\\\n\\\\n\\\\n**Patient-Centered Care:**  The patient\\'s preferences and values should be central to all treatment decisions.  Open communication and shared decision-making are crucial to ensure that the treatment plan aligns with her goals and expectations.  Psychosocial support should be offered to address the emotional and psychological impact of her condition.\"\\n    }\\n  },\\n  \"imaging_context\": {\\n    \"summary\": \"**Imaging Analysis Report - Patient ID: MDT2024001**\",\\n    \"details\": {\\n      \"summary\": \"**Imaging Analysis Report - Patient ID: MDT2024001**\",\\n      \"disease_extent\": {\\n        \"primary_tumor\": \"** 3.8 x 3.2 cm (CT Chest)\",\\n        \"nodal_status\": \"** Multiple enlarged right hilar and mediastinal lymph nodes (CT Chest and PET-CT).  SUVmax of 8.2 in involved nodes (PET-CT).\",\\n        \"metastatic_status\": \"** Although the PET-CT was negative for distant metastases, a dedicated CT scan of the abdomen and pelvis could be considered for a more comprehensive assessment, particularly if there are clinical findings suggestive of distant disease.\"\\n      },\\n      \"staging\": {\\n        \"clinical_stage\": \"\",\\n        \"key_findings\": [\\n          \"* **Chest X-ray (2024-02-01):** Demonstrates a 3.5 cm mass in the right upper lobe with associated hilar lymphadenopathy.  The findings are highly suggestive of a primary lung malignancy.  The resolution is limited, preventing precise characterization of the mass.\",\\n          \"* **CT Chest (2024-02-05):**  Reveals a 3.8 x 3.2 cm spiculated mass in the right upper lobe, consistent with a malignant neoplasm.  Multiple enlarged right hilar and mediastinal lymph nodes are present.  No evidence of distant metastases is identified. Mild emphysematous changes are noted in the upper lobes.\",\\n          \"* **PET-CT (2024-02-12):** Confirms the presence of a right upper lobe mass with an SUVmax of 12.4, indicative of high metabolic activity consistent with malignancy.  FDG-avid right hilar and mediastinal lymph nodes are present, with an SUVmax of 8.2, suggesting metastatic involvement. No evidence of distant metastatic disease is seen.\",\\n          \"* **Primary Lesion:** 3.8 x 3.2 cm (CT Chest)\",\\n          \"The primary lesion is located in the right upper lobe, close to the hilum.  The involvement of hilar and mediastinal lymph nodes suggests spread within the regional lymphatic system.  The relationship of the tumor to major vessels and bronchi will be crucial for surgical planning, if surgery is considered.  The mild emphysema may influence surgical resectability and post-operative recovery.\"\\n        ]\\n      },\\n      \"treatment_implications\": []\\n    }\\n  }\\n}', 'task': \"Analyze the patient's pathological and molecular findings. Provide a structured interpretation including histological classification, molecular profile, biomarker status, and therapeutic implications.\"}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "human",
        "name": null,
        "id": null,
        "example": false
      }
    },
    {
      "type": "ai",
      "data": {
        "content": "{'summary': '**Pathology Analysis Agent Report - Patient ID: MDT2024001**', 'histology': '**  Complete review of H&E stained slides to determine the grade and subtype of the adenocarcinoma (e.g., acinar, papillary, lepidic, etc.). This will refine the prognostic assessment.', 'molecular_profile': {'key_mutations': '**4. Biomarker Status:**', 'immunotherapy_markers': '80%', 'other_markers': {}}, 'therapeutic_implications': ['The provided data does not include information regarding the grade and differentiation of the adenocarcinoma.  This information is crucial for prognosis and treatment planning.  Review of the hematoxylin and eosin (H&E) stained slides by a pathologist is necessary to determine the grade and differentiation.', 'The molecular testing reveals a *KRAS* G12C mutation.  This is a significant finding as it identifies a targetable oncogenic driver mutation.  The absence of EGFR, ALK, and ROS1 rearrangements excludes these as drivers in this case.', '* **PD-L1:**  The tumor shows 80% PD-L1 expression.  This high expression level strongly suggests that the patient may benefit from immunotherapy, specifically PD-1/PD-L1 inhibitors.', '* **KRAS G12C:** The presence of the *KRAS* G12C mutation indicates a specific targetable mutation.  Sotorasib and adagrasib are FDA-approved therapies specifically targeting this mutation.', '**5. Therapeutic Targets:**', 'Based on the current data, the key therapeutic targets are:', '* **KRAS G12C mutation:**  Treatment with a KRAS G12C inhibitor (sotorasib or adagrasib) should be strongly considered as a first-line treatment option.', \"* **High PD-L1 expression:**  Given the high PD-L1 expression (80%), immunotherapy with a PD-1/PD-L1 inhibitor may be considered as a first-line or subsequent treatment option, either as monotherapy or in combination with chemotherapy or a KRAS G12C inhibitor.  The optimal sequencing of these agents needs further discussion within the MDT considering the patient's overall condition and comorbidities.\", \"The patient is a candidate for targeted therapy with a KRAS G12C inhibitor (sotorasib or adagrasib) and/or immunotherapy with a PD-1/PD-L1 inhibitor. The optimal treatment strategy requires consideration of the patient's overall health status, performance status (ECOG score), and comorbidities.  A multidisciplinary team (MDT) discussion is crucial for personalized treatment planning.\", '2. **Staging Investigations:**  Thorough staging is essential before treatment.  This includes a detailed review of the existing imaging studies (CT Chest, PET-CT) to confirm the stage and extent of disease, specifically to assess for any distant metastasis not currently identified.  It is recommended to conduct a CT scan of the abdomen and pelvis to fully exclude distant metastasis.', '3. **Microsatellite Instability (MSI) and Tumor Mutational Burden (TMB) testing:**  These tests could provide additional information to guide treatment choices, particularly in relation to immunotherapy.', \"4. **Comprehensive Comorbidity Assessment:** A thorough assessment of the patient's comorbidities (T2DM, hypertension, osteoarthritis) and their impact on treatment tolerance is critical for safe and effective treatment.  A consultation with an endocrinologist or cardiologist may be warranted.\", '**Disclaimer:** This report is based on the information provided.  A complete and accurate diagnosis and treatment plan require a comprehensive clinical evaluation and integration of all available data within a multidisciplinary team setting.  This analysis should not be considered a substitute for professional medical advice.']}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "ai",
        "name": null,
        "id": null,
        "example": false,
        "tool_calls": [],
        "invalid_tool_calls": [],
        "usage_metadata": null
      }
    }
  ],
  "43bdffb8-6195-47c9-ac2d-d2dd3b1bc67c_PathologyAgent": [
    {
      "type": "human",
      "data": {
        "content": "{'context': '{\\n  \"patient_id\": \"MDT2024001\",\\n  \"demographics\": {\\n    \"age\": 62,\\n    \"gender\": \"F\",\\n    \"ethnicity\": \"Caucasian\",\\n    \"occupation\": \"Retired Teacher\",\\n    \"smoking_status\": \"Former smoker, quit 10 years ago\"\\n  },\\n  \"pathology_results\": {\\n    \"bronchoscopy_biopsy\": {\\n      \"date\": \"2024-02-15\",\\n      \"specimen\": \"Right upper lobe mass biopsy\",\\n      \"microscopic\": \"Malignant cells consistent with adenocarcinoma\",\\n      \"immunohistochemistry\": {\\n        \"TTF-1\": \"Positive\",\\n        \"CK7\": \"Positive\",\\n        \"CK20\": \"Negative\",\\n        \"PD-L1\": \"80% expression\"\\n      },\\n      \"molecular\": {\\n        \"EGFR\": \"Wild type\",\\n        \"ALK\": \"No rearrangement\",\\n        \"ROS1\": \"No rearrangement\",\\n        \"KRAS\": \"G12C mutation detected\"\\n      },\\n      \"diagnosis\": \"Lung adenocarcinoma, KRAS G12C mutated, PD-L1 80%\"\\n    }\\n  },\\n  \"current_condition\": {\\n    \"primary_complaint\": \"Persistent cough with occasional blood-tinged sputum\",\\n    \"onset\": \"2024-01-15\",\\n    \"severity\": \"Moderate to severe\",\\n    \"associated_symptoms\": [\\n      \"Unintentional weight loss (5kg in 3 months)\",\\n      \"Fatigue\",\\n      \"Decreased appetite\",\\n      \"Night sweats\"\\n    ],\\n    \"physical_exam\": {\\n      \"vital_signs\": {\\n        \"temperature\": \"37.2\\\\u00b0C\",\\n        \"blood_pressure\": \"132/82\",\\n        \"heart_rate\": \"88\",\\n        \"respiratory_rate\": \"20\",\\n        \"oxygen_saturation\": \"95% on room air\"\\n      },\\n      \"chest\": \"Decreased breath sounds in right upper lobe\",\\n      \"lymph_nodes\": \"Right supraclavicular lymphadenopathy\",\\n      \"weight\": \"68 kg\",\\n      \"height\": \"165 cm\"\\n    }\\n  },\\n  \"ehr_context\": {\\n    \"summary\": \"The diagnosis remains presumptive until confirmed by histopathological examination.  The extent of disease and the patient\\'s response to treatment are uncertain at this stage.  A comprehensive psychosocial assessment is required to address the patient\\'s emotional and functional needs.\",\\n    \"details\": {\\n      \"summary\": \"The diagnosis remains presumptive until confirmed by histopathological examination.  The extent of disease and the patient\\'s response to treatment are uncertain at this stage.  A comprehensive psychosocial assessment is required to address the patient\\'s emotional and functional needs.\",\\n      \"key_history_points\": [],\\n      \"current_presentation\": {\\n        \"main_symptoms\": [],\\n        \"performance_status\": \"**  The case requires immediate discussion within an MDT (including oncologists, pulmonologists, radiologists, and pathologists) to formulate a comprehensive and individualized treatment plan.  Treatment options will depend on the stage of the cancer, histological subtype, and the patient\\'s overall performance status and comorbidities.\",\\n        \"comorbidity_impact\": \"\"\\n      },\\n      \"risk_factors\": [],\\n      \"clinical_implications\": [],\\n      \"raw_output\": \"**EHR Analysis Agent Report: Patient ID MDT2024001**\\\\n\\\\n**1. Key History Points:**\\\\n\\\\n* **Chronological Progression of Symptoms:** The patient, a 62-year-old Caucasian female, presents with a persistent cough with occasional hemoptysis (blood-tinged sputum) starting on January 15th, 2024.  This is accompanied by significant unintentional weight loss (5kg in 3 months), fatigue, decreased appetite, and night sweats \\\\u2013 all suggestive of a serious underlying condition, potentially malignancy.\\\\n\\\\n* **Medical History:**  The patient has a history of well-controlled Type 2 Diabetes Mellitus (T2DM), well-controlled hypertension, and osteoarthritis.  These comorbidities will need careful consideration in treatment planning due to potential drug interactions and increased risk of complications.\\\\n\\\\n* **Social and Functional Factors:** The patient is a retired teacher, suggesting a previously active lifestyle, now potentially impacted by her current illness.  Her social support network is unknown and requires further assessment.\\\\n\\\\n**2. Current Clinical Status:**\\\\n\\\\n* **Symptoms:**  The primary complaint of a persistent cough with hemoptysis, coupled with significant weight loss, fatigue, decreased appetite, and night sweats, strongly points towards a concerning diagnosis, most likely lung cancer.  The presence of right supraclavicular lymphadenopathy further supports this suspicion.\\\\n\\\\n* **Physical Exam:** Decreased breath sounds in the right upper lobe and right supraclavicular lymphadenopathy are highly suggestive of a right-sided lung pathology.\\\\n\\\\n* **Investigations:**  Initial lab results show relatively normal complete blood count (CBC) and liver function tests (LFTs), which do not definitively rule out malignancy but do not indicate severe anemia or significant liver involvement at this stage.  Further investigations are crucial, including chest imaging (CT scan with contrast), sputum cytology, and potentially bronchoscopy with biopsy for definitive diagnosis and staging.\\\\n\\\\n**3. Relevant Risk Factors:**\\\\n\\\\n* **Age:** 62 years old \\\\u2013 placing her within a high-risk age group for lung cancer.\\\\n* **Smoking History:** Former smoker (quit 10 years ago) \\\\u2013 significantly increases the risk of lung cancer even after cessation.  The duration of smoking is not specified and would be a crucial piece of information.\\\\n* **Family History:**  Family history of lung cancer or other cancers is unknown and needs to be elicited.\\\\n\\\\n**4. Performance Status Assessment:**\\\\n\\\\nBased on the reported symptoms (significant weight loss, fatigue, decreased appetite), a preliminary assessment of performance status using the Eastern Cooperative Oncology Group (ECOG) scale would likely place the patient in either ECOG performance status 2 (requiring occasional assistance with daily activities) or possibly 3 (requiring significant assistance).  A more precise assessment requires a comprehensive physical examination and functional assessment.\\\\n\\\\n**5. Clinical Implications:**\\\\n\\\\nThe clinical presentation strongly suggests the possibility of lung cancer.  The presence of hemoptysis, weight loss, and supraclavicular lymphadenopathy raises concerns for advanced disease.  The patient\\'s comorbidities (T2DM and hypertension) will require careful management during any subsequent treatment.  The osteoarthritis may influence pain management and the choice of certain medications.\\\\n\\\\n\\\\n**Further Investigations and Management Plan:**\\\\n\\\\n* **Imaging:** High-resolution CT scan of the chest with contrast is urgently needed to evaluate the lung lesions and lymph nodes.\\\\n* **Bronchoscopy with Biopsy:**  This is crucial for obtaining tissue for histopathological examination and definitive diagnosis.\\\\n* **Sputum Cytology:**  Should be performed to screen for malignant cells.\\\\n* **PET Scan:**  May be considered for staging if lung cancer is confirmed.\\\\n* **Multidisciplinary Team (MDT) Discussion:**  The case requires immediate discussion within an MDT (including oncologists, pulmonologists, radiologists, and pathologists) to formulate a comprehensive and individualized treatment plan.  Treatment options will depend on the stage of the cancer, histological subtype, and the patient\\'s overall performance status and comorbidities.\\\\n\\\\n\\\\n**Limitations and Uncertainties:**\\\\n\\\\nThe diagnosis remains presumptive until confirmed by histopathological examination.  The extent of disease and the patient\\'s response to treatment are uncertain at this stage.  A comprehensive psychosocial assessment is required to address the patient\\'s emotional and functional needs.\\\\n\\\\n\\\\n**Conclusion:**\\\\n\\\\nThis patient requires urgent further investigation for suspected lung cancer.  A multidisciplinary approach is essential for optimal management.  The patient\\'s comorbidities need careful consideration in treatment planning.  Close monitoring of her clinical status and careful management of her diabetes and hypertension are crucial throughout the treatment process.\"\\n    }\\n  },\\n  \"imaging_context\": {\\n    \"summary\": \"**Imaging Analysis Report: Patient ID MDT2024001**\",\\n    \"details\": {\\n      \"summary\": \"**Imaging Analysis Report: Patient ID MDT2024001**\",\\n      \"disease_extent\": {\\n        \"primary_tumor\": \"** 3.8 x 3.2 cm (CT Chest).\",\\n        \"nodal_status\": \"**  If surgical resection is planned, EBUS or mediastinoscopy might be considered for more precise lymph node sampling and staging, potentially altering the surgical approach.  This would be decided upon in consultation with the thoracic surgeon.\",\\n        \"metastatic_status\": \"** Although the PET-CT did not reveal any distant metastases, a brain MRI might be considered to rule out brain metastases, especially if the patient demonstrates neurological symptoms.  This is not routinely required in this initial staging assessment but is an option depending on clinical presentation.\"\\n      },\\n      \"staging\": {\\n        \"clinical_stage\": \"\",\\n        \"key_findings\": [\\n          \"* **Chest X-ray (2024-02-01):** Demonstrates a 3.5 cm mass in the right upper lobe with associated hilar lymphadenopathy.  The findings are highly suggestive of a primary lung malignancy.  This initial imaging served as a screening tool and prompted further investigation.\",\\n          \"* **CT Chest (2024-02-05):**  Confirms a 3.8 x 3.2 cm spiculated mass in the right upper lobe, consistent with a primary lung cancer.  Multiple enlarged right hilar and mediastinal lymph nodes are identified. No evidence of distant metastases is observed. Mild emphysematous changes are present in the upper lobes.  The spiculated margins of the primary lesion are suggestive of malignancy.\",\\n          \"* **PET-CT (2024-02-12):**  Shows a right upper lobe mass with a maximum standardized uptake value (SUVmax) of 12.4, indicating high metabolic activity consistent with malignancy.  FDG-avid right hilar and mediastinal lymph nodes are present, with a maximum SUVmax of 8.2, confirming the presence of metastatic disease in regional lymph nodes.  No evidence of distant metastatic disease is seen.\",\\n          \"* **Primary Lesion:** 3.8 x 3.2 cm (CT Chest).\",\\n          \"The primary lesion is located in the right upper lobe, close to the hilum.  The involvement of hilar and mediastinal lymph nodes indicates locoregional spread.  The anatomical location necessitates careful consideration during surgical planning, potentially requiring lobectomy or pneumonectomy.  The proximity to major vessels and bronchi needs to be assessed pre-operatively with high-resolution imaging.\"\\n        ]\\n      },\\n      \"treatment_implications\": [\\n        \"The imaging strongly suggests a need for multidisciplinary management, including medical oncology, thoracic surgery, radiation oncology, and potentially other specialists.  Treatment options could include surgery (potentially lobectomy or pneumonectomy), chemotherapy, radiotherapy, or a combination thereof, depending on the pathological findings, patient\\'s performance status, and comorbidities.  This will be determined after a comprehensive MDT discussion.\"\\n      ]\\n    }\\n  }\\n}', 'task': \"Analyze the patient's pathological and molecular findings. Provide a structured interpretation including histological classification, molecular profile, biomarker status, and therapeutic implications.\"}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "human",
        "name": null,
        "id": null,
        "example": false
      }
    },
    {
      "type": "ai",
      "data": {
        "content": "{'summary': '**Pathology Analysis Agent Report: Patient ID MDT2024001**', 'histology': '**', 'molecular_profile': {'key_mutations': '**  While KRAS G12C is a primary driver mutation, additional molecular testing might be considered to detect additional mutations or alterations that could influence treatment choices or predict response.', 'immunotherapy_markers': '**10. Recommendations for Additional Testing:**', 'other_markers': {}}, 'therapeutic_implications': ['*6. Pathological Diagnosis:**']}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "ai",
        "name": null,
        "id": null,
        "example": false,
        "tool_calls": [],
        "invalid_tool_calls": [],
        "usage_metadata": null
      }
    }
  ],
  "bdaf8997-4cd7-4936-a7d7-b055d1f8234f_PathologyAgent": [
    {
      "type": "human",
      "data": {
        "content": "{'context': '{\\n  \"patient_id\": \"MDT2024001\",\\n  \"demographics\": {\\n    \"age\": 62,\\n    \"gender\": \"F\",\\n    \"ethnicity\": \"Caucasian\",\\n    \"occupation\": \"Retired Teacher\",\\n    \"smoking_status\": \"Former smoker, quit 10 years ago\"\\n  },\\n  \"pathology_results\": {\\n    \"bronchoscopy_biopsy\": {\\n      \"date\": \"2024-02-15\",\\n      \"specimen\": \"Right upper lobe mass biopsy\",\\n      \"microscopic\": \"Malignant cells consistent with adenocarcinoma\",\\n      \"immunohistochemistry\": {\\n        \"TTF-1\": \"Positive\",\\n        \"CK7\": \"Positive\",\\n        \"CK20\": \"Negative\",\\n        \"PD-L1\": \"80% expression\"\\n      },\\n      \"molecular\": {\\n        \"EGFR\": \"Wild type\",\\n        \"ALK\": \"No rearrangement\",\\n        \"ROS1\": \"No rearrangement\",\\n        \"KRAS\": \"G12C mutation detected\"\\n      },\\n      \"diagnosis\": \"Lung adenocarcinoma, KRAS G12C mutated, PD-L1 80%\"\\n    }\\n  },\\n  \"current_condition\": {\\n    \"primary_complaint\": \"Persistent cough with occasional blood-tinged sputum\",\\n    \"onset\": \"2024-01-15\",\\n    \"severity\": \"Moderate to severe\",\\n    \"associated_symptoms\": [\\n      \"Unintentional weight loss (5kg in 3 months)\",\\n      \"Fatigue\",\\n      \"Decreased appetite\",\\n      \"Night sweats\"\\n    ],\\n    \"physical_exam\": {\\n      \"vital_signs\": {\\n        \"temperature\": \"37.2\\\\u00b0C\",\\n        \"blood_pressure\": \"132/82\",\\n        \"heart_rate\": \"88\",\\n        \"respiratory_rate\": \"20\",\\n        \"oxygen_saturation\": \"95% on room air\"\\n      },\\n      \"chest\": \"Decreased breath sounds in right upper lobe\",\\n      \"lymph_nodes\": \"Right supraclavicular lymphadenopathy\",\\n      \"weight\": \"68 kg\",\\n      \"height\": \"165 cm\"\\n    }\\n  },\\n  \"ehr_context\": {\\n    \"summary\": \"Based on the information provided, a preliminary assessment suggests a Karnofsky Performance Status (KPS) score of 60-70%. This is an educated estimate based on the reported fatigue, weight loss, and the severity of the cough, which significantly impacts her daily activities. A more accurate assessment would require a more detailed functional assessment.  However, this suggests she may be able to tolerate some forms of treatment, but aggressive interventions might need careful consideration and monitoring.\",\\n    \"details\": {\\n      \"summary\": \"Based on the information provided, a preliminary assessment suggests a Karnofsky Performance Status (KPS) score of 60-70%. This is an educated estimate based on the reported fatigue, weight loss, and the severity of the cough, which significantly impacts her daily activities. A more accurate assessment would require a more detailed functional assessment.  However, this suggests she may be able to tolerate some forms of treatment, but aggressive interventions might need careful consideration and monitoring.\",\\n      \"key_history_points\": [],\\n      \"current_presentation\": {\\n        \"main_symptoms\": [],\\n        \"performance_status\": \"**  Treatment will depend on the histological diagnosis and staging of the cancer.  Options might include surgery, chemotherapy, radiotherapy, targeted therapy, or a combination thereof.  Careful consideration must be given to her comorbidities (T2DM, hypertension, osteoarthritis) to minimize potential drug interactions and adverse effects.  The patient\\'s performance status will also guide treatment intensity and choice.  A multidisciplinary team (MDT) approach involving oncologists, pulmonologists, radiologists, pathologists, and potentially other specialists, is essential for optimal management.\",\\n        \"comorbidity_impact\": \"**  The patient has well-controlled Type 2 Diabetes Mellitus (T2DM) managed with Metformin and well-controlled hypertension managed with Lisinopril.  She also has osteoarthritis affecting her knees and hands. These comorbidities will need careful consideration during treatment planning, particularly regarding potential drug interactions and the overall tolerance of aggressive therapies.\"\\n      },\\n      \"risk_factors\": [],\\n      \"clinical_implications\": [],\\n      \"raw_output\": \"**EHR Analysis Agent Report: Patient MDT2024001**\\\\n\\\\n**1. Key History Points:**\\\\n\\\\n* **Chronological Progression of Symptoms:** The patient, a 62-year-old Caucasian female, presents with a concerning 2-month history of persistent cough, initially dry but now producing occasional blood-tinged sputum.  This is accompanied by significant unintentional weight loss (5kg in 3 months), fatigue, decreased appetite, and night sweats \\\\u2013 all classic features suggestive of underlying malignancy.  The onset of symptoms is relatively recent, raising concerns about rapid disease progression.\\\\n\\\\n* **Comorbidities:**  The patient has well-controlled Type 2 Diabetes Mellitus (T2DM) managed with Metformin and well-controlled hypertension managed with Lisinopril.  She also has osteoarthritis affecting her knees and hands. These comorbidities will need careful consideration during treatment planning, particularly regarding potential drug interactions and the overall tolerance of aggressive therapies.\\\\n\\\\n* **Social and Functional Factors:** The patient is a retired teacher, suggesting a previously active lifestyle.  Her current symptoms significantly impact her functional status, given the fatigue, weight loss, and persistent cough.  This needs assessment to determine her ability to tolerate treatment and participate in rehabilitation.\\\\n\\\\n* **Risk Factors:**  Her history of smoking (former smoker, quit 10 years ago) increases her risk of lung cancer. Age (62) is also a significant risk factor.\\\\n\\\\n**2. Current Clinical Status:**\\\\n\\\\n* **Primary Complaint:** Persistent cough with hemoptysis.\\\\n* **Physical Exam:**  Significant findings include decreased breath sounds in the right upper lobe and right supraclavicular lymphadenopathy, highly suggestive of intrathoracic pathology, possibly malignancy.\\\\n* **Laboratory Results:**  The complete blood count (CBC) shows normal hemoglobin, white blood cell count, and platelets, which doesn\\'t exclude malignancy but doesn\\'t reveal significant anemia or infection.  Liver function tests (LFTs) are mildly elevated (AST 32 U/L, ALT 28 U/L), which warrants further investigation but could be related to the underlying condition or medications.  The albumin level is within the normal range.  Renal function, as assessed by creatinine, is normal.\\\\n\\\\n**3. Relevant Risk Factors:**\\\\n\\\\n* **Age:** 62 years\\\\n* **Smoking History:** Former smoker\\\\n* **Symptoms:**  Persistent cough with hemoptysis, weight loss, fatigue, night sweats, decreased appetite, and lymphadenopathy.  These are all strong indicators of potential malignancy.\\\\n\\\\n\\\\n**4. Performance Status Assessment:**\\\\n\\\\nBased on the information provided, a preliminary assessment suggests a Karnofsky Performance Status (KPS) score of 60-70%. This is an educated estimate based on the reported fatigue, weight loss, and the severity of the cough, which significantly impacts her daily activities. A more accurate assessment would require a more detailed functional assessment.  However, this suggests she may be able to tolerate some forms of treatment, but aggressive interventions might need careful consideration and monitoring.\\\\n\\\\n\\\\n**5. Clinical Implications:**\\\\n\\\\nThe clinical presentation strongly suggests the possibility of lung cancer.  The right supraclavicular lymphadenopathy points towards advanced disease.  The blood-tinged sputum further supports this suspicion.  The patient requires urgent further investigations, including:\\\\n\\\\n* **Chest X-ray:** To confirm the findings on physical examination.\\\\n* **CT Chest with contrast:** To accurately stage the disease and evaluate the extent of involvement.\\\\n* **Bronchoscopy with bronchoalveolar lavage (BAL) and biopsy:**  To obtain tissue for histopathological examination and cytology.  This is crucial for definitive diagnosis and subtyping of the malignancy.\\\\n* **PET-CT scan:**  To assess for distant metastases.\\\\n* **Further blood tests:** Consider tumor markers such as CEA and CYFRA 21-1, although these are not definitive for diagnosis.\\\\n\\\\n**Treatment Planning:**  Treatment will depend on the histological diagnosis and staging of the cancer.  Options might include surgery, chemotherapy, radiotherapy, targeted therapy, or a combination thereof.  Careful consideration must be given to her comorbidities (T2DM, hypertension, osteoarthritis) to minimize potential drug interactions and adverse effects.  The patient\\'s performance status will also guide treatment intensity and choice.  A multidisciplinary team (MDT) approach involving oncologists, pulmonologists, radiologists, pathologists, and potentially other specialists, is essential for optimal management.\\\\n\\\\n**Limitations and Uncertainties:**  This analysis is based on limited information.  A definitive diagnosis and treatment plan can only be established after completing the recommended investigations and discussions within the MDT.\\\\n\\\\n\\\\n**Conclusion:** This patient requires urgent specialist referral for further evaluation and management of suspected lung cancer.  The MDT approach is crucial for optimizing her care.\"\\n    }\\n  },\\n  \"imaging_context\": {\\n    \"summary\": \"**Imaging Analysis Report: Patient MDT2024001**\",\\n    \"details\": {\\n      \"summary\": \"**Imaging Analysis Report: Patient MDT2024001**\",\\n      \"disease_extent\": {\\n        \"primary_tumor\": \"**  The primary tumor (T) is larger than 3cm, suggesting a T2 classification or potentially a T3 if there is involvement of the main bronchus or visceral pleura (this requires further clarification from the CT report).\",\\n        \"nodal_status\": \"**  These procedures are crucial for definitive staging of mediastinal lymph nodes.  Imaging alone cannot definitively determine the presence of microscopic involvement.  Tissue sampling is necessary for accurate nodal staging.\",\\n        \"metastatic_status\": \"** No distant metastases (M0).\"\\n      },\\n      \"staging\": {\\n        \"clinical_stage\": \"\",\\n        \"key_findings\": [\\n          \"* **Chest X-ray (2024-02-01):** Demonstrates a 3.5 cm mass in the right upper lobe with associated hilar lymphadenopathy.  The impression of a highly suspicious primary lung malignancy is consistent with subsequent imaging.\",\\n          \"* **CT Chest (2024-02-05):** Confirms a 3.8 x 3.2 cm spiculated mass in the right upper lobe, characteristic of malignancy.  Multiple enlarged right hilar and mediastinal lymph nodes are present.  No evidence of distant metastases is identified.  Mild emphysematous changes are noted in the upper lobes.\",\\n          \"* **PET-CT (2024-02-12):** Shows a right upper lobe mass with a maximum standardized uptake value (SUVmax) of 12.4, indicating high metabolic activity consistent with malignancy.  FDG-avid right hilar and mediastinal lymph nodes are present, with a maximum SUVmax of 8.2, confirming their involvement.  No evidence of distant metastatic disease is observed.\",\\n          \"* **Primary lesion:** 3.8 x 3.2 cm (CT Chest)\",\\n          \"* **SUVmax of primary lesion:** 12.4 (PET-CT)\",\\n          \"The primary lesion is located in the right upper lobe, close to the hilum, with involvement of hilar and mediastinal lymph nodes. The proximity of the tumor to the mediastinum and the presence of mediastinal lymphadenopathy are crucial considerations for surgical resectability and treatment planning.  The mild emphysema might impact surgical feasibility.\"\\n        ]\\n      },\\n      \"treatment_implications\": []\\n    }\\n  }\\n}', 'task': \"Analyze the patient's pathological and molecular findings. Provide a structured interpretation including histological classification, molecular profile, biomarker status, and therapeutic implications.\"}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "human",
        "name": null,
        "id": null,
        "example": false
      }
    },
    {
      "type": "ai",
      "data": {
        "content": "{'summary': '**Pathology Analysis Agent Report: Patient MDT2024001**', 'histology': '**', 'molecular_profile': {'key_mutations': '**  If available, molecular testing should be performed on additional tissue samples to confirm the KRAS G12C mutation and to look for other potential driver mutations.', 'immunotherapy_markers': '**  A PD-1/PD-L1 inhibitor (pembrolizumab or nivolumab) should be strongly considered, potentially as a single agent or in combination with chemotherapy or targeted therapy.  The high PD-L1 expression makes this a strong option.', 'other_markers': {'KRAS': '**  A KRAS G12C inhibitor (sotorasib or adagrasib) is the preferred first-line targeted therapy.'}}, 'therapeutic_implications': ['**Stage of Disease:** The imaging suggests locally advanced disease (likely Stage IIIA or IIIB), but surgical resection may be considered if deemed feasible based on further assessment of resectability by thoracic surgery.  The proximity of the tumor to the mediastinum and the presence of mediastinal lymphadenopathy must be carefully evaluated for resectability.', '**Treatment Options:**  Options include:']}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "ai",
        "name": null,
        "id": null,
        "example": false,
        "tool_calls": [],
        "invalid_tool_calls": [],
        "usage_metadata": null
      }
    }
  ],
  "8b811dda-c3da-40ef-89fd-93fa506806ec_PathologyAgent": [
    {
      "type": "human",
      "data": {
        "content": "{'context': '{\\n  \"patient_id\": \"MDT2024001\",\\n  \"demographics\": {\\n    \"age\": 62,\\n    \"gender\": \"F\",\\n    \"ethnicity\": \"Caucasian\",\\n    \"occupation\": \"Retired Teacher\",\\n    \"smoking_status\": \"Former smoker, quit 10 years ago\"\\n  },\\n  \"pathology_results\": {\\n    \"bronchoscopy_biopsy\": {\\n      \"date\": \"2024-02-15\",\\n      \"specimen\": \"Right upper lobe mass biopsy\",\\n      \"microscopic\": \"Malignant cells consistent with adenocarcinoma\",\\n      \"immunohistochemistry\": {\\n        \"TTF-1\": \"Positive\",\\n        \"CK7\": \"Positive\",\\n        \"CK20\": \"Negative\",\\n        \"PD-L1\": \"80% expression\"\\n      },\\n      \"molecular\": {\\n        \"EGFR\": \"Wild type\",\\n        \"ALK\": \"No rearrangement\",\\n        \"ROS1\": \"No rearrangement\",\\n        \"KRAS\": \"G12C mutation detected\"\\n      },\\n      \"diagnosis\": \"Lung adenocarcinoma, KRAS G12C mutated, PD-L1 80%\"\\n    }\\n  },\\n  \"current_condition\": {\\n    \"primary_complaint\": \"Persistent cough with occasional blood-tinged sputum\",\\n    \"onset\": \"2024-01-15\",\\n    \"severity\": \"Moderate to severe\",\\n    \"associated_symptoms\": [\\n      \"Unintentional weight loss (5kg in 3 months)\",\\n      \"Fatigue\",\\n      \"Decreased appetite\",\\n      \"Night sweats\"\\n    ],\\n    \"physical_exam\": {\\n      \"vital_signs\": {\\n        \"temperature\": \"37.2\\\\u00b0C\",\\n        \"blood_pressure\": \"132/82\",\\n        \"heart_rate\": \"88\",\\n        \"respiratory_rate\": \"20\",\\n        \"oxygen_saturation\": \"95% on room air\"\\n      },\\n      \"chest\": \"Decreased breath sounds in right upper lobe\",\\n      \"lymph_nodes\": \"Right supraclavicular lymphadenopathy\",\\n      \"weight\": \"68 kg\",\\n      \"height\": \"165 cm\"\\n    }\\n  },\\n  \"ehr_context\": {\\n    \"summary\": \"Based on the reported symptoms and weight loss, the patient\\'s performance status is likely ECOG 2-3.  Further assessment using a validated tool like the ECOG performance status scale is needed for accurate staging and treatment planning.  The significant weight loss and fatigue indicate a decline in her functional capacity.\",\\n    \"details\": {\\n      \"summary\": \"Based on the reported symptoms and weight loss, the patient\\'s performance status is likely ECOG 2-3.  Further assessment using a validated tool like the ECOG performance status scale is needed for accurate staging and treatment planning.  The significant weight loss and fatigue indicate a decline in her functional capacity.\",\\n      \"key_history_points\": [],\\n      \"current_presentation\": {\\n        \"main_symptoms\": [],\\n        \"performance_status\": \"**  Treatment will depend entirely on the histological diagnosis, staging, and the patient\\'s performance status.  Options might range from surgery (if localized), chemotherapy, targeted therapy, radiation therapy, or palliative care.  Her comorbidities will need to be carefully considered when choosing treatment modalities and dosages to minimize potential drug interactions and adverse events.  A multidisciplinary team (MDT) approach involving oncologists, pulmonologists, radiologists, pathologists, and potentially other specialists, is crucial for optimal patient management.\",\\n        \"comorbidity_impact\": \"** The patient has well-controlled Type 2 Diabetes Mellitus (T2DM) and hypertension, managed with Metformin and Lisinopril respectively.  She also has osteoarthritis affecting her knees and hands. These comorbidities will impact treatment choices and require careful monitoring for potential drug interactions and adverse events.  Specifically, renal function needs monitoring due to the use of Metformin and Lisinopril.\"\\n      },\\n      \"risk_factors\": [],\\n      \"clinical_implications\": [],\\n      \"raw_output\": \"**EHR Analysis Agent Report - Patient ID: MDT2024001**\\\\n\\\\n**1. Key History Points:**\\\\n\\\\n* **Chronological Progression of Symptoms:** The patient, a 62-year-old Caucasian female, presents with a persistent cough (onset January 15th, 2024) initially characterized as moderate to severe, progressing to include blood-tinged sputum.  Concomitant symptoms include significant unintentional weight loss (5kg in 3 months), fatigue, decreased appetite, and night sweats.  This constellation of symptoms warrants serious concern, particularly given the age and presence of other comorbidities.\\\\n\\\\n* **Comorbidities:** The patient has well-controlled Type 2 Diabetes Mellitus (T2DM) and hypertension, managed with Metformin and Lisinopril respectively.  She also has osteoarthritis affecting her knees and hands. These comorbidities will impact treatment choices and require careful monitoring for potential drug interactions and adverse events.  Specifically, renal function needs monitoring due to the use of Metformin and Lisinopril.\\\\n\\\\n* **Social and Functional Factors:** The patient is a retired teacher, suggesting a potentially decreased level of physical activity compared to her previous occupation.  Her retirement status may also influence adherence to treatment regimens and access to support systems.\\\\n\\\\n**2. Current Clinical Status:**\\\\n\\\\n* **Primary Complaint:** Persistent cough with hemoptysis.\\\\n* **Physical Exam Findings:**  Significant findings include decreased breath sounds in the right upper lobe, suggestive of a possible lung lesion or consolidation, and right supraclavicular lymphadenopathy, which is highly suggestive of underlying malignancy.\\\\n* **Lab Results:**  Complete Blood Count (CBC) shows normal hemoglobin, white blood cell count, and platelets, ruling out overt anemia or significant infection.  Basic metabolic panel is largely unremarkable, suggesting normal renal and liver function.  However, further investigations are needed.\\\\n\\\\n**3. Relevant Risk Factors:**\\\\n\\\\n* **Age:**  62 years old places her within a higher risk group for several malignancies.\\\\n* **Smoking History:** Former smoker (quit 10 years ago) significantly increases the risk of lung cancer. Although she quit 10 years ago, the risk remains elevated compared to a never-smoker.\\\\n* **Symptoms:** The combination of cough (with hemoptysis), weight loss, fatigue, night sweats, and lymphadenopathy are highly suggestive of malignancy, most likely lung cancer.\\\\n\\\\n**4. Performance Status Assessment:**\\\\n\\\\nBased on the reported symptoms and weight loss, the patient\\'s performance status is likely ECOG 2-3.  Further assessment using a validated tool like the ECOG performance status scale is needed for accurate staging and treatment planning.  The significant weight loss and fatigue indicate a decline in her functional capacity.\\\\n\\\\n**5. Clinical Implications:**\\\\n\\\\nThe clinical presentation strongly suggests the possibility of lung cancer.  Further investigation is urgently required, including:\\\\n\\\\n* **Chest X-Ray/CT Scan:** To visualize the lung parenchyma and confirm the presence and extent of any lesions or adenopathy.\\\\n* **Bronchoscopy with Bronchoalveolar Lavage (BAL) and Biopsy:** To obtain tissue samples for definitive histological diagnosis and to rule out other causes of the symptoms.  This is the highest priority investigation.\\\\n* **PET-CT Scan:** To assess for distant metastases and stage the disease.\\\\n* **Further Blood Tests:**  Consider serum tumor markers (CEA, CYFRA 21-1) and possibly a more extensive metabolic panel to evaluate for paraneoplastic syndromes.\\\\n\\\\n**Differential Diagnosis:**  While lung cancer is the most likely diagnosis, other possibilities must be considered and ruled out, including:\\\\n\\\\n* **Tuberculosis:** Requires appropriate microbiological testing.\\\\n* **Lung Infection (Pneumonia, Lung Abscess):**  Requires further investigation with imaging and sputum analysis.\\\\n* **Sarcoidosis:** Less likely given the presentation but needs to be considered.\\\\n\\\\n**Treatment Planning:**  Treatment will depend entirely on the histological diagnosis, staging, and the patient\\'s performance status.  Options might range from surgery (if localized), chemotherapy, targeted therapy, radiation therapy, or palliative care.  Her comorbidities will need to be carefully considered when choosing treatment modalities and dosages to minimize potential drug interactions and adverse events.  A multidisciplinary team (MDT) approach involving oncologists, pulmonologists, radiologists, pathologists, and potentially other specialists, is crucial for optimal patient management.\\\\n\\\\n\\\\n**Limitations and Uncertainties:**  This analysis is based on the limited information provided.  A complete clinical evaluation, including detailed history taking, physical examination, and further investigations, is essential to confirm the diagnosis and formulate a definitive treatment plan.\\\\n\\\\n\\\\n**Next Steps:**  Immediate referral to a pulmonologist and oncologist for further evaluation and management is strongly recommended.  The patient should be informed about the possible diagnoses and the need for further investigations.  Patient education and shared decision-making are vital components of patient-centered care.\"\\n    }\\n  },\\n  \"imaging_context\": {\\n    \"summary\": \"**Imaging Analysis Report - Patient ID: MDT2024001**\",\\n    \"details\": {\\n      \"summary\": \"**Imaging Analysis Report - Patient ID: MDT2024001**\",\\n      \"disease_extent\": {\\n        \"primary_tumor\": \"** 3.8 x 3.2 cm (CT Chest).\",\\n        \"nodal_status\": \"** If invasive procedures are needed for tissue sampling of mediastinal lymph nodes.\",\\n        \"metastatic_status\": \"** M0 (no evidence of distant metastases).\"\\n      },\\n      \"staging\": {\\n        \"clinical_stage\": \"\",\\n        \"key_findings\": [\\n          \"* **Chest X-ray (2024-02-01):** Demonstrates a 3.5 cm mass in the right upper lobe with associated hilar lymphadenopathy.  The findings are highly suspicious for primary lung malignancy.  Limited spatial resolution prevents precise characterization.\",\\n          \"* **CT Chest (2024-02-05):** Confirms a 3.8 x 3.2 cm spiculated mass in the right upper lobe, consistent with a malignant neoplasm.  Multiple enlarged right hilar and mediastinal lymph nodes are present. No evidence of distant metastases is identified. Mild emphysematous changes are noted in the upper lobes.\",\\n          \"* **PET-CT (2024-02-12):**  The right upper lobe mass shows a maximum standardized uptake value (SUVmax) of 12.4, indicating significant FDG avidity consistent with malignancy.  FDG-avid right hilar and mediastinal lymph nodes are present, with a maximum SUVmax of 8.2. No evidence of distant metastatic disease is detected.\",\\n          \"* **Primary Lesion:** 3.8 x 3.2 cm (CT Chest).\",\\n          \"The primary lesion is located in the right upper lobe, close to the hilum, explaining the associated hilar lymphadenopathy.  The mediastinal lymph node involvement suggests locoregional spread.  The absence of distant metastases on PET-CT is reassuring, but this needs confirmation.  The mild emphysema may impact surgical resectability, though this should be assessed post-biopsy.\"\\n        ]\\n      },\\n      \"treatment_implications\": []\\n    }\\n  }\\n}', 'task': \"Analyze the patient's pathological and molecular findings. Provide a structured interpretation including histological classification, molecular profile, biomarker status, and therapeutic implications.\"}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "human",
        "name": null,
        "id": null,
        "example": false
      }
    },
    {
      "type": "ai",
      "data": {
        "content": "{'summary': '**Pathology Analysis Report - Patient ID: MDT2024001**', 'histology': '**', 'molecular_profile': {'key_mutations': '**  While KRAS G12C is the key driver mutation, additional molecular testing may be considered based on treatment response and disease progression, to identify any potential secondary mutations.', 'immunotherapy_markers': '** The high PD-L1 expression (80%) suggests a potential benefit from immunotherapy with PD-1 or PD-L1 inhibitors (e.g., pembrolizumab, nivolumab). This could be used as a monotherapy or in combination with chemotherapy or targeted therapy.', 'other_markers': {}}, 'therapeutic_implications': ['The provided data does not include information on the grade and differentiation of the adenocarcinoma.  Further pathological assessment of the biopsy specimen, including a detailed review by a pathologist experienced in lung cancer grading (e.g., using the WHO classification), is crucial to determine the grade and differentiation. This will significantly influence prognosis and treatment decisions.', '**5. Therapeutic Targets:**', 'Based on the available data, the following therapeutic targets are identified:', '* **KRAS G12C:**  The presence of a *KRAS* G12C mutation makes this patient a candidate for targeted therapy with a KRAS G12C inhibitor (e.g., sotorasib, adagrasib).  These are highly effective in patients with this specific mutation.', '* **PD-L1:** The high PD-L1 expression (80%) suggests a potential benefit from immunotherapy with PD-1 or PD-L1 inhibitors (e.g., pembrolizumab, nivolumab). This could be used as a monotherapy or in combination with chemotherapy or targeted therapy.', \"The patient is a candidate for targeted therapy with a KRAS G12C inhibitor and/or immunotherapy with a PD-1/PD-L1 inhibitor.  The choice of treatment will depend on several factors including the patient's overall health, performance status (ECOG), and the presence of any other comorbidities.  The treatment plan should be individualized and determined by a multidisciplinary team.\", '* **Further Molecular Testing:**  While KRAS G12C is the key driver mutation, additional molecular testing may be considered based on treatment response and disease progression, to identify any potential secondary mutations.', \"* **ECOG Performance Status:**  Formal assessment using the ECOG performance status scale is needed to accurately determine the patient's functional capacity and to guide treatment decisions.\", '**Disclaimer:** This report is based on the provided data.  A complete clinical evaluation, including detailed history taking, physical examination, and further investigations, is essential to confirm the diagnosis and formulate a definitive treatment plan.  This report should be considered as part of a larger multidisciplinary discussion and does not constitute a final treatment plan.']}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "ai",
        "name": null,
        "id": null,
        "example": false,
        "tool_calls": [],
        "invalid_tool_calls": [],
        "usage_metadata": null
      }
    }
  ],
  "17abfed3-0bbe-47f9-b550-eb661cdf5691_PathologyAgent": [
    {
      "type": "human",
      "data": {
        "content": "{'context': '{\\n  \"patient_id\": \"MDT2024001\",\\n  \"demographics\": {\\n    \"age\": 62,\\n    \"gender\": \"F\",\\n    \"ethnicity\": \"Caucasian\",\\n    \"occupation\": \"Retired Teacher\",\\n    \"smoking_status\": \"Former smoker, quit 10 years ago\"\\n  },\\n  \"pathology_results\": {\\n    \"bronchoscopy_biopsy\": {\\n      \"date\": \"2024-02-15\",\\n      \"specimen\": \"Right upper lobe mass biopsy\",\\n      \"microscopic\": \"Malignant cells consistent with adenocarcinoma\",\\n      \"immunohistochemistry\": {\\n        \"TTF-1\": \"Positive\",\\n        \"CK7\": \"Positive\",\\n        \"CK20\": \"Negative\",\\n        \"PD-L1\": \"80% expression\"\\n      },\\n      \"molecular\": {\\n        \"EGFR\": \"Wild type\",\\n        \"ALK\": \"No rearrangement\",\\n        \"ROS1\": \"No rearrangement\",\\n        \"KRAS\": \"G12C mutation detected\"\\n      },\\n      \"diagnosis\": \"Lung adenocarcinoma, KRAS G12C mutated, PD-L1 80%\"\\n    }\\n  },\\n  \"current_condition\": {\\n    \"primary_complaint\": \"Persistent cough with occasional blood-tinged sputum\",\\n    \"onset\": \"2024-01-15\",\\n    \"severity\": \"Moderate to severe\",\\n    \"associated_symptoms\": [\\n      \"Unintentional weight loss (5kg in 3 months)\",\\n      \"Fatigue\",\\n      \"Decreased appetite\",\\n      \"Night sweats\"\\n    ],\\n    \"physical_exam\": {\\n      \"vital_signs\": {\\n        \"temperature\": \"37.2\\\\u00b0C\",\\n        \"blood_pressure\": \"132/82\",\\n        \"heart_rate\": \"88\",\\n        \"respiratory_rate\": \"20\",\\n        \"oxygen_saturation\": \"95% on room air\"\\n      },\\n      \"chest\": \"Decreased breath sounds in right upper lobe\",\\n      \"lymph_nodes\": \"Right supraclavicular lymphadenopathy\",\\n      \"weight\": \"68 kg\",\\n      \"height\": \"165 cm\"\\n    }\\n  },\\n  \"ehr_context\": {\\n    \"summary\": \"Based on the reported symptoms (fatigue, weight loss, decreased appetite) and the severity of the cough, a preliminary assessment suggests a performance status of ECOG 2-3.  A more thorough assessment using validated tools like the ECOG Performance Status scale is necessary for accurate staging and treatment planning.  The presence of comorbidities (diabetes, hypertension, osteoarthritis) may further impact her functional capacity and tolerance to treatment.\",\\n    \"details\": {\\n      \"summary\": \"Based on the reported symptoms (fatigue, weight loss, decreased appetite) and the severity of the cough, a preliminary assessment suggests a performance status of ECOG 2-3.  A more thorough assessment using validated tools like the ECOG Performance Status scale is necessary for accurate staging and treatment planning.  The presence of comorbidities (diabetes, hypertension, osteoarthritis) may further impact her functional capacity and tolerance to treatment.\",\\n      \"key_history_points\": [],\\n      \"current_presentation\": {\\n        \"main_symptoms\": [],\\n        \"performance_status\": \"\",\\n        \"comorbidity_impact\": \"** The patient has well-controlled Type 2 Diabetes (on Metformin), well-controlled Hypertension (on Lisinopril), and Osteoarthritis affecting her knees and hands. These comorbidities will need careful consideration during treatment planning due to potential drug interactions and impact on overall tolerance.\"\\n      },\\n      \"risk_factors\": [],\\n      \"clinical_implications\": [],\\n      \"raw_output\": \"## EHR Analysis Agent Report: Patient MDT2024001\\\\n\\\\n**1. Key History Points:**\\\\n\\\\n* **Chronological Progression of Symptoms:** The patient, a 62-year-old Caucasian female, presents with a persistent cough (onset January 15th, 2024) initially characterized as moderate to severe, progressing to include blood-tinged sputum.  Significant weight loss (5kg in 3 months), fatigue, decreased appetite, and night sweats further indicate a concerning clinical picture.  The temporal relationship between these symptoms strongly suggests a serious underlying condition, possibly malignancy.\\\\n\\\\n* **Comorbidities:** The patient has well-controlled Type 2 Diabetes (on Metformin), well-controlled Hypertension (on Lisinopril), and Osteoarthritis affecting her knees and hands. These comorbidities will need careful consideration during treatment planning due to potential drug interactions and impact on overall tolerance.\\\\n\\\\n* **Social and Functional Factors:** The patient is a retired teacher, suggesting a potentially stable social support network but also potential limitations in physical activity and tolerance for intensive treatment based on her pre-existing osteoarthritis.\\\\n\\\\n* **Risk Factors:**  Former smoker (quit 10 years ago) is a significant risk factor for lung cancer.  Age (62) also places her in a higher risk category for various malignancies.\\\\n\\\\n**2. Current Clinical Status:**\\\\n\\\\n* **Primary Complaint:** Persistent cough with hemoptysis.\\\\n* **Physical Examination:**  Suggestive findings include decreased breath sounds in the right upper lobe and right supraclavicular lymphadenopathy, highly suspicious for lung malignancy.\\\\n* **Laboratory Results:**  The complete blood count is unremarkable, excluding overt anemia. Liver function tests (ALT and AST) are mildly elevated, which warrants further investigation but could be secondary to other factors such as medication or underlying inflammation. Albumin levels are within normal range. Creatinine is normal, suggesting no significant renal impairment.\\\\n\\\\n**3. Relevant Risk Factors:**\\\\n\\\\n* **Age:** 62 years\\\\n* **Smoking history:** Former smoker\\\\n* **Symptoms:** Cough with hemoptysis, weight loss, fatigue, night sweats, decreased appetite, lymphadenopathy\\\\n* **Physical Exam:** Decreased breath sounds, lymphadenopathy\\\\n\\\\n**4. Performance Status Assessment:**\\\\n\\\\nBased on the reported symptoms (fatigue, weight loss, decreased appetite) and the severity of the cough, a preliminary assessment suggests a performance status of ECOG 2-3.  A more thorough assessment using validated tools like the ECOG Performance Status scale is necessary for accurate staging and treatment planning.  The presence of comorbidities (diabetes, hypertension, osteoarthritis) may further impact her functional capacity and tolerance to treatment.\\\\n\\\\n\\\\n**5. Clinical Implications:**\\\\n\\\\nThe clinical presentation strongly suggests the possibility of lung cancer.  The combination of hemoptysis, weight loss, fatigue, night sweats, and lymphadenopathy warrants urgent further investigation.  The next steps should include:\\\\n\\\\n* **Imaging:**  High-resolution computed tomography (HRCT) of the chest is crucial to visualize the lung lesions, assess their extent, and evaluate for lymph node involvement.  Further imaging may be needed depending on the HRCT findings (e.g., PET-CT).\\\\n* **Bronchoscopy:**  This procedure is indicated for tissue sampling to confirm the diagnosis and determine the histological subtype of the tumor.  Bronchoalveolar lavage (BAL) may also be beneficial.\\\\n* **Biopsy:**  If bronchoscopy is non-diagnostic, a CT-guided biopsy or surgical biopsy may be necessary.\\\\n* **Staging:**  Once a diagnosis is confirmed, a comprehensive staging workup is necessary to determine the extent of the disease and guide treatment decisions. This may include additional imaging (e.g., brain MRI, bone scan) and blood tests (e.g., tumor markers).\\\\n\\\\n**Treatment Planning:**\\\\n\\\\nTreatment options will depend heavily on the histological subtype, stage of the cancer, and the patient\\'s overall performance status and comorbidities.  Potential treatment modalities include surgery, chemotherapy, radiation therapy, targeted therapy, or immunotherapy, either alone or in combination.  Careful consideration must be given to the potential interactions between cancer treatments and her existing medications for diabetes and hypertension.  Multidisciplinary team (MDT) discussion involving oncologists, pulmonologists, radiologists, pathologists, and potentially other specialists is essential for optimal patient care.\\\\n\\\\n**Limitations and Uncertainties:**\\\\n\\\\nThe analysis is based on the information provided.  Further investigations are crucial to confirm the diagnosis and determine the appropriate treatment strategy.  The patient\\'s performance status requires further evaluation.  The impact of comorbidities on treatment tolerance remains to be fully assessed.\\\\n\\\\n\\\\n**Conclusion:**\\\\n\\\\nThe patient presents with a high suspicion of lung cancer.  Urgent further investigations, including imaging and biopsy, are essential.  A multidisciplinary team approach is crucial for optimal diagnosis and management.  Close monitoring of her comorbidities and careful consideration of their impact on treatment choices are vital for patient-centered care.\"\\n    }\\n  },\\n  \"imaging_context\": {\\n    \"summary\": \"**Imaging Analysis Report: Patient MDT2024001**\",\\n    \"details\": {\\n      \"summary\": \"**Imaging Analysis Report: Patient MDT2024001**\",\\n      \"disease_extent\": {\\n        \"primary_tumor\": \"** 3.8 x 3.2 cm (CT Chest)\",\\n        \"nodal_status\": \"** Multiple enlarged right hilar and mediastinal lymph nodes (CT Chest and PET-CT).  Precise nodal size not specified but significant FDG avidity suggests substantial involvement.\",\\n        \"metastatic_status\": \"** A bone scan may be considered to exclude bone metastases, particularly if there are clinical findings suggestive of bone involvement (e.g., bone pain).\"\\n      },\\n      \"staging\": {\\n        \"clinical_stage\": \"\",\\n        \"key_findings\": [\\n          \"* **Chest X-ray (2024-02-01):** Demonstrates a 3.5 cm mass in the right upper lobe with associated hilar lymphadenopathy.  The finding is highly suggestive of a primary lung malignancy.  Resolution is limited, preventing precise characterization of the mass.\",\\n          \"* **CT Chest (2024-02-05):**  Confirms a 3.8 x 3.2 cm spiculated mass in the right upper lobe, consistent with malignancy.  Multiple enlarged right hilar and mediastinal lymph nodes are identified.  No evidence of distant metastases is seen. Mild emphysematous changes are noted in the upper lobes.\",\\n          \"* **PET-CT (2024-02-12):**  Shows an SUVmax of 12.4 in the right upper lobe mass, indicating high metabolic activity consistent with malignancy.  FDG-avid right hilar and mediastinal lymph nodes are present, with an SUVmax of 8.2, suggesting metastatic involvement.  No evidence of distant metastatic disease is found.\",\\n          \"* **Primary Lesion:** 3.8 x 3.2 cm (CT Chest)\",\\n          \"Based on the imaging findings, the patient presents with a large primary lung mass in the right upper lobe with significant regional lymph node involvement (N2). There is no evidence of distant metastasis (M0).  Therefore, a preliminary assessment based on imaging alone suggests a Stage IIIA (T2-3 N2 M0) non-small cell lung cancer (NSCLC).  This staging is provisional and requires confirmation with histopathological diagnosis and clinical staging.\"\\n        ]\\n      },\\n      \"treatment_implications\": []\\n    }\\n  }\\n}', 'task': \"Analyze the patient's pathological and molecular findings. Provide a structured interpretation including histological classification, molecular profile, biomarker status, and therapeutic implications.\"}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "human",
        "name": null,
        "id": null,
        "example": false
      }
    },
    {
      "type": "ai",
      "data": {
        "content": "{'summary': '**Pathology Analysis Report: Patient MDT2024001**', 'histology': '**', 'molecular_profile': {'key_mutations': '** While KRAS G12C is the main driver mutation identified, additional molecular profiling may be considered to identify other potential targetable alterations.', 'immunotherapy_markers': '80%.', 'other_markers': {}}, 'therapeutic_implications': ['The provided data does not specify the grade or differentiation of the adenocarcinoma.  Further pathological review of the biopsy specimen, including assessment of nuclear pleomorphism, mitotic rate, and architectural features, is necessary to determine the grade.  This information is crucial for prognosis and treatment planning.', 'PD-L1 expression is 80%, a high level indicating potential responsiveness to immunotherapy.  This finding is crucial for treatment consideration.', '**5. Therapeutic Targets:**', 'Based on the molecular and biomarker findings, the following therapeutic targets are identified:', '* **KRAS G12C:** The presence of this mutation makes the patient eligible for targeted therapy with KRAS G12C inhibitors (e.g., sotorasib, adagrasib).  These are highly effective in a subset of *KRAS* G12C-mutated lung adenocarcinomas.', '* **PD-L1:** The high PD-L1 expression (80%) suggests a strong likelihood of benefit from immunotherapy with a PD-1 or PD-L1 inhibitor (e.g., pembrolizumab, nivolumab).  Immunotherapy may be used as a first-line treatment or in combination with chemotherapy or targeted therapy.', \"The patient is a candidate for targeted therapy with a KRAS G12C inhibitor and/or immunotherapy with a PD-1/PD-L1 inhibitor.  The choice of treatment will depend on factors such as the patient's overall health, performance status (ECOG score needs to be formally assessed), comorbidities, and the results of staging investigations.  A multidisciplinary team discussion is essential to optimize treatment strategy.  Combination therapies should be considered.\", '* **Comprehensive staging:**  This is crucial to determine the extent of disease and guide treatment planning.  This should include a detailed assessment of the primary tumor (size, location, invasion), regional lymph node involvement (N stage), and distant metastases (M stage).  Imaging studies (CT chest, PET-CT, brain MRI, bone scan) are necessary.', '* **Further molecular testing:** While KRAS G12C is the main driver mutation identified, additional molecular profiling may be considered to identify other potential targetable alterations.', \"* **ECOG performance status assessment:**  A formal assessment of the patient's performance status using the ECOG Performance Status scale is essential for treatment planning and determining her suitability for various treatment regimens.\", \"The analysis is based on currently available data.  The grade and differentiation of the adenocarcinoma require further pathological assessment.  The definitive staging and prognosis depend on the results of the recommended additional investigations.  The optimal treatment strategy will be determined through a multidisciplinary team discussion, considering all clinical and pathological information, as well as the patient's preferences and comorbidities.\"]}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "ai",
        "name": null,
        "id": null,
        "example": false,
        "tool_calls": [],
        "invalid_tool_calls": [],
        "usage_metadata": null
      }
    }
  ],
  "767eda57-9a56-43d0-8bfb-22978cccd6b7_PathologyAgent": [
    {
      "type": "human",
      "data": {
        "content": "{'context': '{\\n  \"patient_id\": \"MDT2024001\",\\n  \"demographics\": {\\n    \"age\": 62,\\n    \"gender\": \"F\",\\n    \"ethnicity\": \"Caucasian\",\\n    \"occupation\": \"Retired Teacher\",\\n    \"smoking_status\": \"Former smoker, quit 10 years ago\"\\n  },\\n  \"pathology_results\": {\\n    \"bronchoscopy_biopsy\": {\\n      \"date\": \"2024-02-15\",\\n      \"specimen\": \"Right upper lobe mass biopsy\",\\n      \"microscopic\": \"Malignant cells consistent with adenocarcinoma\",\\n      \"immunohistochemistry\": {\\n        \"TTF-1\": \"Positive\",\\n        \"CK7\": \"Positive\",\\n        \"CK20\": \"Negative\",\\n        \"PD-L1\": \"80% expression\"\\n      },\\n      \"molecular\": {\\n        \"EGFR\": \"Wild type\",\\n        \"ALK\": \"No rearrangement\",\\n        \"ROS1\": \"No rearrangement\",\\n        \"KRAS\": \"G12C mutation detected\"\\n      },\\n      \"diagnosis\": \"Lung adenocarcinoma, KRAS G12C mutated, PD-L1 80%\"\\n    }\\n  },\\n  \"current_condition\": {\\n    \"primary_complaint\": \"Persistent cough with occasional blood-tinged sputum\",\\n    \"onset\": \"2024-01-15\",\\n    \"severity\": \"Moderate to severe\",\\n    \"associated_symptoms\": [\\n      \"Unintentional weight loss (5kg in 3 months)\",\\n      \"Fatigue\",\\n      \"Decreased appetite\",\\n      \"Night sweats\"\\n    ],\\n    \"physical_exam\": {\\n      \"vital_signs\": {\\n        \"temperature\": \"37.2\\\\u00b0C\",\\n        \"blood_pressure\": \"132/82\",\\n        \"heart_rate\": \"88\",\\n        \"respiratory_rate\": \"20\",\\n        \"oxygen_saturation\": \"95% on room air\"\\n      },\\n      \"chest\": \"Decreased breath sounds in right upper lobe\",\\n      \"lymph_nodes\": \"Right supraclavicular lymphadenopathy\",\\n      \"weight\": \"68 kg\",\\n      \"height\": \"165 cm\"\\n    }\\n  },\\n  \"ehr_context\": {\\n    \"summary\": \"Based on the presented information, a preliminary assessment suggests a Karnofsky Performance Status (KPS) score of 60-70%. This is an estimation based on the reported fatigue, weight loss, and the severity of her symptoms.  A more comprehensive assessment is needed including a detailed functional assessment to accurately determine her performance status.  This is crucial for determining treatment suitability and tolerance.\",\\n    \"details\": {\\n      \"summary\": \"Based on the presented information, a preliminary assessment suggests a Karnofsky Performance Status (KPS) score of 60-70%. This is an estimation based on the reported fatigue, weight loss, and the severity of her symptoms.  A more comprehensive assessment is needed including a detailed functional assessment to accurately determine her performance status.  This is crucial for determining treatment suitability and tolerance.\",\\n      \"key_history_points\": [],\\n      \"current_presentation\": {\\n        \"main_symptoms\": [],\\n        \"performance_status\": \"\",\\n        \"comorbidity_impact\": \"**  The patient\\'s comorbidities need to be carefully managed throughout the diagnostic and treatment process.  Close monitoring of blood glucose and blood pressure is essential.  The choice of treatment modalities needs to account for potential drug interactions and the overall health status of the patient.\"\\n      },\\n      \"risk_factors\": [],\\n      \"clinical_implications\": [],\\n      \"raw_output\": \"**EHR Analysis Agent Report - Patient ID: MDT2024001**\\\\n\\\\n**1. Key History Points:**\\\\n\\\\n* **Chronological Progression of Symptoms:** The patient, a 62-year-old Caucasian female, presents with a persistent cough (onset January 15, 2024) initially described as moderate to severe, progressing to include blood-tinged sputum.  This is accompanied by significant unintentional weight loss (5kg in 3 months), fatigue, decreased appetite, and night sweats \\\\u2013 all highly suggestive of a serious underlying condition, potentially malignancy.\\\\n\\\\n* **Comorbidities:** The patient has well-controlled Type 2 Diabetes (on Metformin), well-controlled Hypertension (on Lisinopril), and Osteoarthritis affecting her knees and hands.  These comorbidities will need careful consideration during treatment planning due to potential drug interactions and the added burden on overall health.\\\\n\\\\n* **Social and Functional Factors:** The patient is a retired teacher, suggesting a potentially stable social support system but also a potential impact on her ability to tolerate intensive treatment regimens.  Further social history is needed to fully assess her support network and functional capacity.\\\\n\\\\n* **Risk Factors:**  Former smoker (quit 10 years ago) \\\\u2013 a significant risk factor for lung cancer.  Age (62) also places her within a higher risk group for various malignancies. The combination of these factors significantly increases the likelihood of a serious underlying pathology.\\\\n\\\\n**2. Current Clinical Status:**\\\\n\\\\n* **Presenting Complaint:** Persistent cough with hemoptysis, weight loss, fatigue, decreased appetite, and night sweats.  These symptoms strongly suggest a possible malignancy, particularly lung cancer.\\\\n\\\\n* **Physical Examination:**  Decreased breath sounds in the right upper lobe and right supraclavicular lymphadenopathy strongly support the suspicion of lung cancer.  Vital signs are generally stable, although the slightly elevated blood pressure (132/82) warrants monitoring, especially given her existing hypertension.\\\\n\\\\n* **Laboratory Results:**  The complete blood count (CBC) shows normal hemoglobin, WBC, and platelets, which doesn\\'t rule out malignancy but doesn\\'t provide strong evidence for infection or significant anemia.  Liver function tests (ALT and AST) are mildly elevated, requiring further investigation to determine the cause.  Albumin is within the normal range.\\\\n\\\\n**3. Relevant Risk Factors:**\\\\n\\\\n* **Age:** 62 years\\\\n* **Smoking history:** Former smoker (10 years quit)\\\\n* **Symptoms:** Persistent cough with hemoptysis, weight loss, fatigue, anorexia, night sweats.\\\\n* **Physical Exam:** Decreased breath sounds in the right upper lobe, right supraclavicular lymphadenopathy.\\\\n\\\\n**4. Performance Status Assessment:**\\\\n\\\\nBased on the presented information, a preliminary assessment suggests a Karnofsky Performance Status (KPS) score of 60-70%. This is an estimation based on the reported fatigue, weight loss, and the severity of her symptoms.  A more comprehensive assessment is needed including a detailed functional assessment to accurately determine her performance status.  This is crucial for determining treatment suitability and tolerance.\\\\n\\\\n\\\\n**5. Clinical Implications:**\\\\n\\\\nThe clinical picture strongly suggests the need for further investigation to rule out lung cancer.  The next steps should include:\\\\n\\\\n* **Imaging:** A chest CT scan with contrast is crucial to evaluate the extent of any lung lesions and to assess for mediastinal lymphadenopathy.  Further imaging modalities (PET-CT) may be indicated depending on the CT findings.\\\\n\\\\n* **Bronchoscopy:**  Bronchoscopy with bronchoalveolar lavage (BAL) and biopsy would be essential for obtaining tissue samples for histopathological examination, confirming the diagnosis and determining the type and stage of cancer.\\\\n\\\\n* **Further Laboratory Investigations:**  Consideration of tumor markers (e.g., CEA, CYFRA 21-1) should be given, although these should not be solely relied upon for diagnosis.  Further investigation into the mildly elevated liver enzymes is also necessary.\\\\n\\\\n* **Multidisciplinary Team (MDT) Discussion:** This case requires immediate discussion within an MDT involving pulmonology, oncology, radiology, and potentially thoracic surgery to plan the optimal diagnostic and treatment strategy.\\\\n\\\\n* **Comorbidity Management:**  The patient\\'s comorbidities need to be carefully managed throughout the diagnostic and treatment process.  Close monitoring of blood glucose and blood pressure is essential.  The choice of treatment modalities needs to account for potential drug interactions and the overall health status of the patient.\\\\n\\\\n**Limitations and Uncertainties:**\\\\n\\\\nThis analysis is based on the limited information provided.  A complete clinical picture requires a thorough physical examination, detailed review of imaging studies, and histopathological confirmation of any suspected malignancy.  The KPS score is a preliminary estimate.\\\\n\\\\n\\\\n**Patient-Centered Care:**\\\\n\\\\nIt\\'s crucial to involve the patient in all decision-making processes, ensuring she understands the potential diagnoses, treatment options, and their associated risks and benefits.  Open communication and addressing her concerns are paramount throughout her journey.\"\\n    }\\n  },\\n  \"imaging_context\": {\\n    \"summary\": \"**Imaging Analysis Report - Patient ID: MDT2024001**\",\\n    \"details\": {\\n      \"summary\": \"**Imaging Analysis Report - Patient ID: MDT2024001**\",\\n      \"disease_extent\": {\\n        \"primary_tumor\": \"** HRCT can provide more detailed information about the primary tumor, its relationship to surrounding structures, and the extent of any pleural involvement, which could impact the T-stage.\",\\n        \"nodal_status\": \"** This procedure is essential for obtaining tissue samples for histopathological diagnosis, confirming the type of lung cancer (e.g., adenocarcinoma, squamous cell carcinoma, etc.) and determining the precise extent of lymph node involvement.  EBUS allows for targeted sampling of mediastinal nodes, improving diagnostic accuracy compared to conventional mediastinoscopy.\",\\n        \"metastatic_status\": \"\"\\n      },\\n      \"staging\": {\\n        \"clinical_stage\": \"\",\\n        \"key_findings\": [\\n          \"* **Chest X-ray (2024-02-01):** Demonstrates a 3.5 cm mass in the right upper lobe with associated hilar lymphadenopathy.  The finding is highly suspicious for a primary lung malignancy.  Resolution is limited, preventing precise characterization.\",\\n          \"* **CT Chest (2024-02-05):**  Confirms a 3.8 x 3.2 cm spiculated mass in the right upper lobe, consistent with malignancy.  Multiple enlarged right hilar and mediastinal lymph nodes are present.  No evidence of distant metastases is identified. Mild emphysematous changes are noted in the upper lobes.\",\\n          \"* **PET-CT (2024-02-12):**  Shows a right upper lobe mass with a maximum standardized uptake value (SUVmax) of 12.4, indicating high metabolic activity consistent with malignancy.  FDG-avid right hilar and mediastinal lymph nodes are present, with a maximum SUVmax of 8.2.  No evidence of distant metastatic disease is seen.\",\\n          \"* **Primary Lesion:** 3.8 x 3.2 cm (CT Chest)\",\\n          \"The primary lesion is located in the right upper lobe, close to the hilum.  The involvement of hilar and mediastinal lymph nodes suggests locoregional spread. The relationship of the tumor to major vessels and the extent of pleural involvement needs further clarification through higher-resolution imaging or bronchoscopy with endobronchial ultrasound (EBUS).\"\\n        ]\\n      },\\n      \"treatment_implications\": []\\n    }\\n  }\\n}', 'task': \"Analyze the patient's pathological and molecular findings. Provide a structured interpretation including histological classification, molecular profile, biomarker status, and therapeutic implications.\"}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "human",
        "name": null,
        "id": null,
        "example": false
      }
    },
    {
      "type": "ai",
      "data": {
        "content": "{'summary': '**Pathology Analysis Report - Patient ID: MDT2024001**', 'histology': '**', 'molecular_profile': {'key_mutations': \"** While the *KRAS* G12C mutation is a key finding, it's prudent to consider broader next-generation sequencing (NGS) panels to detect other potentially actionable mutations.\", 'immunotherapy_markers': '**Recommendations for Additional Testing:**', 'other_markers': {}}, 'therapeutic_implications': ['*Pathological Diagnosis:**']}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "ai",
        "name": null,
        "id": null,
        "example": false,
        "tool_calls": [],
        "invalid_tool_calls": [],
        "usage_metadata": null
      }
    }
  ],
  "5aa60ea2-2268-457a-81a2-b2fb5dca805e_PathologyAgent": [
    {
      "type": "human",
      "data": {
        "content": "{'context': '{\\n  \"patient_id\": \"MDT2024001\",\\n  \"demographics\": {\\n    \"age\": 62,\\n    \"gender\": \"F\",\\n    \"ethnicity\": \"Caucasian\",\\n    \"occupation\": \"Retired Teacher\",\\n    \"smoking_status\": \"Former smoker, quit 10 years ago\"\\n  },\\n  \"pathology_results\": {\\n    \"bronchoscopy_biopsy\": {\\n      \"date\": \"2024-02-15\",\\n      \"specimen\": \"Right upper lobe mass biopsy\",\\n      \"microscopic\": \"Malignant cells consistent with adenocarcinoma\",\\n      \"immunohistochemistry\": {\\n        \"TTF-1\": \"Positive\",\\n        \"CK7\": \"Positive\",\\n        \"CK20\": \"Negative\",\\n        \"PD-L1\": \"80% expression\"\\n      },\\n      \"molecular\": {\\n        \"EGFR\": \"Wild type\",\\n        \"ALK\": \"No rearrangement\",\\n        \"ROS1\": \"No rearrangement\",\\n        \"KRAS\": \"G12C mutation detected\"\\n      },\\n      \"diagnosis\": \"Lung adenocarcinoma, KRAS G12C mutated, PD-L1 80%\"\\n    }\\n  },\\n  \"current_condition\": {\\n    \"primary_complaint\": \"Persistent cough with occasional blood-tinged sputum\",\\n    \"onset\": \"2024-01-15\",\\n    \"severity\": \"Moderate to severe\",\\n    \"associated_symptoms\": [\\n      \"Unintentional weight loss (5kg in 3 months)\",\\n      \"Fatigue\",\\n      \"Decreased appetite\",\\n      \"Night sweats\"\\n    ],\\n    \"physical_exam\": {\\n      \"vital_signs\": {\\n        \"temperature\": \"37.2\\\\u00b0C\",\\n        \"blood_pressure\": \"132/82\",\\n        \"heart_rate\": \"88\",\\n        \"respiratory_rate\": \"20\",\\n        \"oxygen_saturation\": \"95% on room air\"\\n      },\\n      \"chest\": \"Decreased breath sounds in right upper lobe\",\\n      \"lymph_nodes\": \"Right supraclavicular lymphadenopathy\",\\n      \"weight\": \"68 kg\",\\n      \"height\": \"165 cm\"\\n    }\\n  },\\n  \"ehr_context\": {\\n    \"summary\": \"A full performance status assessment using a validated tool like the ECOG (Eastern Cooperative Oncology Group) performance status scale is needed.  Based on the presented information, a preliminary assessment suggests a performance status of 2 or possibly 3, given the reported fatigue, weight loss, and moderate to severe symptom burden.  A more thorough evaluation is crucial for appropriate treatment planning.\",\\n    \"details\": {\\n      \"summary\": \"A full performance status assessment using a validated tool like the ECOG (Eastern Cooperative Oncology Group) performance status scale is needed.  Based on the presented information, a preliminary assessment suggests a performance status of 2 or possibly 3, given the reported fatigue, weight loss, and moderate to severe symptom burden.  A more thorough evaluation is crucial for appropriate treatment planning.\",\\n      \"key_history_points\": [],\\n      \"current_presentation\": {\\n        \"main_symptoms\": [],\\n        \"performance_status\": \"\",\\n        \"comorbidity_impact\": \"**\"\\n      },\\n      \"risk_factors\": [],\\n      \"clinical_implications\": [],\\n      \"raw_output\": \"**EHR Analysis Agent Report: Patient MDT2024001**\\\\n\\\\n**1. Key History Points:**\\\\n\\\\n* **Chronological Progression of Symptoms:** The patient, a 62-year-old Caucasian female, presents with a persistent cough (onset 2024-01-15) progressing to include blood-tinged sputum, unintentional weight loss (5kg in 3 months), fatigue, decreased appetite, and night sweats. This constellation of symptoms warrants serious concern for malignancy, particularly lung cancer.\\\\n\\\\n* **Medical History:**  The patient has a history of well-controlled Type 2 Diabetes (Metformin 1000mg BID, HbA1c 6.8%), well-controlled Hypertension (Lisinopril 20mg daily, BP 128/78), and Osteoarthritis affecting her knees and hands.  These comorbidities will need consideration in treatment planning due to potential drug interactions and impact on overall tolerance.  Her history of smoking (former smoker, quit 10 years ago) is a significant risk factor for lung cancer.\\\\n\\\\n* **Social and Functional Factors:**  The patient is retired, suggesting a potentially decreased functional capacity compared to someone actively employed. This should be assessed further to determine her ability to tolerate potential treatment regimens.\\\\n\\\\n**2. Current Clinical Status:**\\\\n\\\\n* **Primary Complaint:** Persistent cough with hemoptysis.\\\\n* **Physical Exam:**  Significant findings include decreased breath sounds in the right upper lobe, suggestive of a space-occupying lesion, and right supraclavicular lymphadenopathy, highly suggestive of metastatic disease.\\\\n* **Laboratory Results:**  The complete blood count (CBC) shows normal hemoglobin, white blood cell count, and platelets, not providing definitive evidence of malignancy but not ruling it out.  Liver function tests (LFTs) are mildly elevated (ALT 28 U/L, AST 32 U/L), which could be due to various factors including medication or underlying disease and requires further investigation.\\\\n\\\\n**3. Relevant Risk Factors:**\\\\n\\\\n* **Age:** 62 years old (increased risk of malignancy).\\\\n* **Gender:** Female (lung cancer incidence is lower in females, but this doesn\\'t negate the possibility).\\\\n* **Smoking History:** Former smoker, though cessation 10 years prior still increases risk.\\\\n* **Symptoms:** Hemoptysis, weight loss, fatigue, night sweats \\\\u2013 classic symptoms suggestive of lung cancer.\\\\n* **Physical Exam Findings:** Decreased breath sounds and supraclavicular lymphadenopathy are highly concerning for malignancy.\\\\n\\\\n\\\\n**4. Performance Status Assessment:**\\\\n\\\\nA full performance status assessment using a validated tool like the ECOG (Eastern Cooperative Oncology Group) performance status scale is needed.  Based on the presented information, a preliminary assessment suggests a performance status of 2 or possibly 3, given the reported fatigue, weight loss, and moderate to severe symptom burden.  A more thorough evaluation is crucial for appropriate treatment planning.\\\\n\\\\n\\\\n**5. Clinical Implications:**\\\\n\\\\nThe clinical presentation strongly suggests the possibility of lung cancer.  The right supraclavicular lymphadenopathy indicates potential metastatic spread.  Further investigations are urgently required, including:\\\\n\\\\n* **Chest X-ray:** To further evaluate the right upper lobe findings.\\\\n* **Computed Tomography (CT) Scan of the Chest, Abdomen, and Pelvis:** To fully stage the disease and detect any metastatic spread.\\\\n* **Bronchoscopy with Bronchoalveolar Lavage (BAL) and Biopsy:** To obtain tissue for definitive diagnosis and histopathological analysis.  This is the most crucial step.\\\\n* **Positron Emission Tomography (PET) Scan:** To further assess the extent of disease and guide treatment planning.\\\\n\\\\n**Comorbidities and Treatment Implications:**\\\\n\\\\nThe patient\\'s comorbidities (diabetes, hypertension, osteoarthritis) will influence treatment choices.  Careful consideration is needed to select therapies that minimize adverse effects while effectively managing the cancer.  Renal function should be monitored closely due to the use of Metformin and potential nephrotoxicity from other medications.  The use of NSAIDs for osteoarthritis needs to be carefully considered in light of potential interactions with other medications and impact on bleeding risk.\\\\n\\\\n**Medication Interactions:**  Potential drug interactions between the current medications and any future cancer treatments (chemotherapy, targeted therapy, immunotherapy) must be carefully considered and managed by a pharmacist experienced in oncology.\\\\n\\\\n**Conclusion:**\\\\n\\\\nThis patient requires urgent specialist referral to a pulmonologist and oncologist for comprehensive evaluation and management.  The high suspicion for lung cancer necessitates prompt investigation and multidisciplinary discussion to develop a patient-centered treatment plan that considers her comorbidities and performance status.  The information provided is insufficient for definitive diagnosis or treatment recommendations; further investigations are crucial.  This analysis is for informational purposes only and does not constitute medical advice.\"\\n    }\\n  },\\n  \"imaging_context\": {\\n    \"summary\": \"**Imaging Analysis Agent Report: Patient MDT2024001**\",\\n    \"details\": {\\n      \"summary\": \"**Imaging Analysis Agent Report: Patient MDT2024001**\",\\n      \"disease_extent\": {\\n        \"primary_tumor\": \"** 3.8 x 3.2 cm (CT Chest)\",\\n        \"nodal_status\": \"**  Given the mediastinal lymphadenopathy, EBUS or mediastinoscopy with lymph node biopsy is strongly recommended for precise nodal staging. This will help to determine the extent of lymph node involvement and refine the N classification.\",\\n        \"metastatic_status\": \"**  While the PET-CT did not show evidence of brain metastasis, an MRI of the brain is often recommended in staging lung cancer to rule out occult CNS involvement.\"\\n      },\\n      \"staging\": {\\n        \"clinical_stage\": \"\",\\n        \"key_findings\": [\\n          \"* **Chest X-ray (2024-02-01):** Demonstrates a 3.5 cm mass in the right upper lobe with associated hilar lymphadenopathy.  The impression of a highly suspicious primary lung malignancy is consistent with subsequent imaging.\",\\n          \"* **CT Chest (2024-02-05):**  Confirms a 3.8 x 3.2 cm spiculated mass in the right upper lobe, characteristic of malignancy.  Multiple enlarged right hilar and mediastinal lymph nodes are present. No evidence of distant metastases is identified. Mild emphysematous changes are noted in the upper lobes.\",\\n          \"* **PET-CT (2024-02-12):**  The right upper lobe mass shows an SUVmax of 12.4, indicating high metabolic activity consistent with malignancy. FDG-avid right hilar and mediastinal lymph nodes are present with an SUVmax of 8.2, confirming their involvement.  No evidence of distant metastatic disease is observed.\",\\n          \"* **Primary Lesion:** 3.8 x 3.2 cm (CT Chest)\",\\n          \"Based on the available imaging, the patient presents with a large primary lung mass in the right upper lobe, with involvement of regional lymph nodes (hilar and mediastinal).  There is no evidence of distant metastases.  This strongly suggests a Stage IIIA Non-Small Cell Lung Cancer (NSCLC) according to the current TNM staging system (8th edition).  However, this is a preliminary assessment based on imaging alone.  Further information, including tissue biopsy and pathological analysis, is required for definitive staging.  The precise T, N, and M classifications require further investigation.  The size of the primary tumor suggests a T2 or possibly a T3 classification, and N2 classification is likely given the mediastinal lymph node involvement.  The absence of distant metastases suggests an M0 classification.\",\\n          \"The primary lesion is located in the right upper lobe, close to the hilum and major vascular structures.  The involvement of hilar and mediastinal lymph nodes indicates significant regional spread.  The location of the tumor will influence surgical options and potential complications. The mild emphysema may impact surgical feasibility and post-operative respiratory function.  The presence of right supraclavicular lymphadenopathy (noted in the physical exam) raises concern for potential N3 disease. This finding requires further investigation with additional imaging or biopsy.\"\\n        ]\\n      },\\n      \"treatment_implications\": []\\n    }\\n  }\\n}', 'task': \"Analyze the patient's pathological and molecular findings. Provide a structured interpretation including histological classification, molecular profile, biomarker status, and therapeutic implications.\"}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "human",
        "name": null,
        "id": null,
        "example": false
      }
    },
    {
      "type": "ai",
      "data": {
        "content": "{'summary': '**Pathology Analysis Agent Report: Patient MDT2024001**', 'histology': '**', 'molecular_profile': {'key_mutations': '**4. Biomarker Status:**', 'immunotherapy_markers': '**  Could identify another potential biomarker for immunotherapy response.', 'other_markers': {}}, 'therapeutic_implications': ['The provided data does not specify the grade or differentiation of the adenocarcinoma.  Further histopathological review of the biopsy specimen, including assessment of nuclear atypia, mitotic rate, and architectural features, is necessary to determine the grade (e.g., well-differentiated, moderately differentiated, poorly differentiated) and assign a specific differentiation subtype (e.g., acinar, papillary, lepidic, solid). This information is crucial for prognostication and treatment planning.', 'Molecular testing reveals a *KRAS* G12C mutation.  *EGFR*, *ALK*, and *ROS1* are wild-type/negative for rearrangement.  The presence of the *KRAS* G12C mutation is significant, as it identifies a specific targetable driver mutation.', 'PD-L1 expression is 80%.  This high level of expression suggests that the patient may benefit from immunotherapy, specifically PD-1/PD-L1 inhibitors.  However, the clinical benefit of immunotherapy in KRAS-mutated lung adenocarcinoma is generally less robust compared to other subtypes, and response rates can be variable.', '**5. Therapeutic Targets:**', 'The *KRAS* G12C mutation is a key therapeutic target.  Sotorasib and adagrasib are FDA-approved targeted therapies specifically designed to inhibit KRAS G12C.  These should be considered as first-line treatment options, given the high PD-L1 expression, combination therapy with immunotherapy (e.g., pembrolizumab or atezolizumab) could also be explored.  However, the efficacy of this combination needs to be carefully weighed against potential toxicity.', '* **Targeted Therapy:** Sotorasib or adagrasib are primary treatment considerations due to the *KRAS* G12C mutation.', '* **Immunotherapy:**  Given the high PD-L1 expression, the addition of immunotherapy (e.g., pembrolizumab or atezolizumab) should be evaluated, potentially in combination with targeted therapy.  However, this requires careful consideration of potential increased toxicity and the overall benefit-risk profile.', '* **Chemotherapy:**  While less likely to be first-line in this case given the availability of targeted therapy, chemotherapy may be considered as an alternative or in combination if targeted therapy fails or is poorly tolerated.', '* **Close Monitoring:**  Careful monitoring of response to therapy and potential adverse events is essential.', '1. **Complete histopathological review:**  To determine the grade and subtype of the adenocarcinoma. This will refine prognostication and treatment selection.', '2. **Comprehensive genomic profiling:**  While KRAS G12C is identified, broader genomic testing may reveal additional mutations or alterations that could influence treatment decisions or predict response to therapy.  This is particularly important given the relatively lower response rates of immunotherapy in KRAS-mutated lung adenocarcinoma.', '3. **Assessment of tumor mutational burden (TMB):**  Could be useful in selecting patients who might benefit from immunotherapy.', '4. **Microsatellite instability (MSI) testing:**  Could identify another potential biomarker for immunotherapy response.', '5. **Further staging investigations:**  As indicated in the EHR and imaging reports, EBUS/mediastinoscopy with lymph node biopsy, and brain MRI are crucial to definitively stage the disease. This will influence treatment decisions and prognosis.', 'The current analysis is based on the information provided.  Further investigations and multidisciplinary discussion are required to develop a comprehensive and personalized treatment plan. The absence of detailed information regarding performance status, comorbidities, and treatment preferences limits the scope of this analysis.  The efficacy of any treatment modality remains dependent on individual patient factors and response.']}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "ai",
        "name": null,
        "id": null,
        "example": false,
        "tool_calls": [],
        "invalid_tool_calls": [],
        "usage_metadata": null
      }
    }
  ],
  "e353a1be-3ac3-42f1-a660-bad66a2e58e2_PathologyAgent": [
    {
      "type": "human",
      "data": {
        "content": "{'context': '{\\n  \"patient_id\": \"MDT2024001\",\\n  \"demographics\": {\\n    \"age\": 62,\\n    \"gender\": \"F\",\\n    \"ethnicity\": \"Caucasian\",\\n    \"occupation\": \"Retired Teacher\",\\n    \"smoking_status\": \"Former smoker, quit 10 years ago\"\\n  },\\n  \"pathology_results\": {\\n    \"bronchoscopy_biopsy\": {\\n      \"date\": \"2024-02-15\",\\n      \"specimen\": \"Right upper lobe mass biopsy\",\\n      \"microscopic\": \"Malignant cells consistent with adenocarcinoma\",\\n      \"immunohistochemistry\": {\\n        \"TTF-1\": \"Positive\",\\n        \"CK7\": \"Positive\",\\n        \"CK20\": \"Negative\",\\n        \"PD-L1\": \"80% expression\"\\n      },\\n      \"molecular\": {\\n        \"EGFR\": \"Wild type\",\\n        \"ALK\": \"No rearrangement\",\\n        \"ROS1\": \"No rearrangement\",\\n        \"KRAS\": \"G12C mutation detected\"\\n      },\\n      \"diagnosis\": \"Lung adenocarcinoma, KRAS G12C mutated, PD-L1 80%\"\\n    }\\n  },\\n  \"current_condition\": {\\n    \"primary_complaint\": \"Persistent cough with occasional blood-tinged sputum\",\\n    \"onset\": \"2024-01-15\",\\n    \"severity\": \"Moderate to severe\",\\n    \"associated_symptoms\": [\\n      \"Unintentional weight loss (5kg in 3 months)\",\\n      \"Fatigue\",\\n      \"Decreased appetite\",\\n      \"Night sweats\"\\n    ],\\n    \"physical_exam\": {\\n      \"vital_signs\": {\\n        \"temperature\": \"37.2\\\\u00b0C\",\\n        \"blood_pressure\": \"132/82\",\\n        \"heart_rate\": \"88\",\\n        \"respiratory_rate\": \"20\",\\n        \"oxygen_saturation\": \"95% on room air\"\\n      },\\n      \"chest\": \"Decreased breath sounds in right upper lobe\",\\n      \"lymph_nodes\": \"Right supraclavicular lymphadenopathy\",\\n      \"weight\": \"68 kg\",\\n      \"height\": \"165 cm\"\\n    }\\n  },\\n  \"ehr_context\": {\\n    \"summary\": \"This analysis provides a preliminary assessment based on the available information. Further investigations are essential for definitive diagnosis and treatment planning.  Regular monitoring and adjustments to the treatment plan will be necessary based on the patient\\'s response.\",\\n    \"details\": {\\n      \"summary\": \"This analysis provides a preliminary assessment based on the available information. Further investigations are essential for definitive diagnosis and treatment planning.  Regular monitoring and adjustments to the treatment plan will be necessary based on the patient\\'s response.\",\\n      \"key_history_points\": [],\\n      \"current_presentation\": {\\n        \"main_symptoms\": [],\\n        \"performance_status\": \"\",\\n        \"comorbidity_impact\": \"**  The patient\\'s comorbidities will need careful consideration during treatment planning.  The potential for drug interactions between cancer therapies and her current medications (Metformin, Lisinopril, and PRN NSAIDs) must be assessed.  Close monitoring of blood glucose and blood pressure will be crucial during and after any cancer treatment.\"\\n      },\\n      \"risk_factors\": [],\\n      \"clinical_implications\": [],\\n      \"raw_output\": \"**EHR Analysis Agent Report: Patient ID MDT2024001**\\\\n\\\\n**1. Key History Points:**\\\\n\\\\n* **Chronological Progression of Symptoms:** The patient, a 62-year-old Caucasian female, presents with a persistent cough, initially noted on 2024-01-15, progressing to include blood-tinged sputum.  This is accompanied by significant unintentional weight loss (5kg in 3 months), fatigue, decreased appetite, and night sweats \\\\u2013 all highly suggestive of a serious underlying condition, possibly malignancy.\\\\n\\\\n* **Comorbidities:** The patient has well-controlled Type 2 Diabetes Mellitus (T2DM) and hypertension, managed with Metformin and Lisinopril respectively.  She also has osteoarthritis affecting her knees and hands, managed with PRN NSAIDs. These comorbidities will need careful consideration during treatment planning, as they may influence treatment tolerability and potential drug interactions.\\\\n\\\\n* **Social and Functional Factors:** The patient is a retired teacher, suggesting a previously active lifestyle.  Her current symptoms, however, significantly impair her functional status.  Further assessment of her daily living activities and social support network is necessary.\\\\n\\\\n* **Risk Factors:**  Her history of smoking (former smoker, quit 10 years ago) increases her risk for various respiratory malignancies.  Age and gender are also relevant risk factors for lung cancer.\\\\n\\\\n**2. Current Clinical Status:**\\\\n\\\\n* **Primary Complaint:** Persistent cough with occasional hemoptysis.\\\\n* **Physical Examination:**  Significant findings include decreased breath sounds in the right upper lobe and right supraclavicular lymphadenopathy \\\\u2013 strongly suggestive of lung pathology, potentially malignancy.\\\\n* **Laboratory Results:**  The complete blood count (CBC) shows normal hemoglobin, WBC, and platelets, although this does not rule out malignancy.  Liver function tests (LFTs) are mildly elevated (ALT 28 U/L, AST 32 U/L), which warrants further investigation.  Albumin is within the normal range. Renal function is normal.\\\\n\\\\n**3. Relevant Risk Factors:**\\\\n\\\\n* **Age:** 62 years (increased risk for lung cancer)\\\\n* **Gender:** Female (lung cancer risk is lower than in males but still significant)\\\\n* **Smoking History:** Former smoker (significant risk factor)\\\\n* **Symptoms:**  Cough with hemoptysis, weight loss, fatigue, anorexia, night sweats (highly suggestive of malignancy)\\\\n* **Physical Exam:** Decreased breath sounds, lymphadenopathy (highly suggestive of malignancy)\\\\n\\\\n**4. Performance Status Assessment:**\\\\n\\\\nBased on the presented information, a preliminary assessment suggests a performance status (PS) somewhere between ECOG 2-3.  The patient\\'s significant weight loss, fatigue, and symptomatic cough significantly impair her daily activities. A more formal assessment using the ECOG performance status scale is crucial for accurate staging and treatment planning.\\\\n\\\\n**5. Clinical Implications:**\\\\n\\\\nThe clinical presentation strongly suggests a possible lung malignancy.  The right supraclavicular lymphadenopathy is a particularly concerning finding, suggesting advanced disease.  Further investigations are urgently required, including:\\\\n\\\\n* **Chest X-ray/CT Scan:** To confirm the suspected lung pathology and assess the extent of the disease.\\\\n* **Bronchoscopy with Bronchoalveolar Lavage (BAL) and Biopsy:**  To obtain tissue for histopathological examination and cytological analysis for definitive diagnosis and staging.\\\\n* **PET-CT Scan:**  To evaluate for distant metastases and guide treatment planning.\\\\n* **Thoracic Surgery Consultation:** If indicated based on imaging and biopsy results.\\\\n* **Oncology Consultation:** For management and treatment planning.\\\\n\\\\n**Comorbidity Management:**  The patient\\'s comorbidities will need careful consideration during treatment planning.  The potential for drug interactions between cancer therapies and her current medications (Metformin, Lisinopril, and PRN NSAIDs) must be assessed.  Close monitoring of blood glucose and blood pressure will be crucial during and after any cancer treatment.\\\\n\\\\n**Limitations and Uncertainties:**  The diagnosis remains presumptive until confirmed by histopathological examination.  The severity of the underlying condition and its responsiveness to treatment are currently unknown.\\\\n\\\\n**Patient-Centered Care:**  A comprehensive discussion with the patient regarding the potential diagnosis, investigations, and treatment options is paramount.  Shared decision-making will be essential throughout the process, ensuring that the patient\\'s preferences and values are respected.  Psychological support should also be offered to address the emotional impact of the suspected diagnosis.\\\\n\\\\n\\\\nThis analysis provides a preliminary assessment based on the available information. Further investigations are essential for definitive diagnosis and treatment planning.  Regular monitoring and adjustments to the treatment plan will be necessary based on the patient\\'s response.\"\\n    }\\n  },\\n  \"imaging_context\": {\\n    \"summary\": \"**Imaging Analysis Agent Report: Patient ID MDT2024001**\",\\n    \"details\": {\\n      \"summary\": \"**Imaging Analysis Agent Report: Patient ID MDT2024001**\",\\n      \"disease_extent\": {\\n        \"primary_tumor\": \"** 3.8 x 3.2 cm (CT Chest)\",\\n        \"nodal_status\": \"**  Potentially feasible depending on the resectability of the tumor and the extent of lymph node involvement as confirmed by biopsy.  Surgical feasibility will be significantly influenced by the precise extent of nodal involvement and the proximity of the tumor to critical structures.\",\\n        \"metastatic_status\": \"\"\\n      },\\n      \"staging\": {\\n        \"clinical_stage\": \"\",\\n        \"key_findings\": [\\n          \"* **Chest X-ray (2024-02-01):** Demonstrates a 3.5 cm mass in the right upper lobe with associated hilar lymphadenopathy.  The findings are highly suspicious for a primary lung malignancy.  The resolution is limited, preventing precise characterization of the mass.\",\\n          \"* **CT Chest (2024-02-05):** Confirms a 3.8 x 3.2 cm spiculated mass in the right upper lobe, consistent with malignancy.  Multiple enlarged right hilar and mediastinal lymph nodes are present, suggesting nodal involvement.  No evidence of distant metastases is identified. Mild emphysematous changes are noted in the upper lobes.\",\\n          \"* **PET-CT (2024-02-12):**  Shows a right upper lobe mass with a maximum standardized uptake value (SUVmax) of 12.4, indicating high metabolic activity characteristic of malignancy.  FDG-avid right hilar and mediastinal lymph nodes are present, with an SUVmax of 8.2, confirming nodal involvement. No evidence of distant metastatic disease is seen.\",\\n          \"* **Primary lesion:** 3.8 x 3.2 cm (CT Chest)\",\\n          \"Based on the imaging findings, the patient presents with a large primary lung mass in the right upper lobe with significant regional lymph node involvement (N2).  There is no evidence of distant metastases (M0).  Therefore, a preliminary imaging-based staging assessment suggests **Stage IIIA** non-small cell lung cancer (NSCLC) according to the TNM staging system (T3N2M0).  This is a provisional staging; confirmation requires histopathological examination of the tumor tissue.\"\\n        ]\\n      },\\n      \"treatment_implications\": []\\n    }\\n  }\\n}', 'task': \"Analyze the patient's pathological and molecular findings. Provide a structured interpretation including histological classification, molecular profile, biomarker status, and therapeutic implications.\"}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "human",
        "name": null,
        "id": null,
        "example": false
      }
    },
    {
      "type": "ai",
      "data": {
        "content": "{'summary': '**Pathology Analysis Agent Report: Patient ID MDT2024001**', 'histology': '**', 'molecular_profile': {'key_mutations': '** Although the KRAS G12C mutation is a key driver mutation, additional molecular testing may be considered depending on treatment response and the development of resistance.', 'immunotherapy_markers': '** While targeted therapy and immunotherapy are preferred in this setting, chemotherapy regimens may be considered either as initial treatment or in combination with other modalities if the targeted therapies are ineffective or poorly tolerated.', 'other_markers': {}}, 'therapeutic_implications': ['The provided data does not specify the grade or differentiation of the adenocarcinoma.  Further pathological review of the biopsy specimen, including assessment of nuclear pleomorphism, mitotic rate, and the presence of necrosis, is necessary to determine the grade.  This information is crucial for prognosis and treatment planning.', 'Molecular testing reveals a *KRAS* G12C mutation.  *EGFR*, *ALK*, and *ROS1* are all wild-type (no rearrangement detected).  The presence of a *KRAS* G12C mutation is a significant finding, as it identifies a specific therapeutic target.', 'PD-L1 expression is 80%, indicating a high level of expression. This is highly significant as it suggests potential responsiveness to immunotherapy.', '**5. Therapeutic Targets:**', \"The patient's molecular profile and biomarker status suggest several potential therapeutic targets:\", '* **KRAS G12C Inhibition:** The presence of the *KRAS* G12C mutation makes her a candidate for treatment with a KRAS G12C inhibitor, such as sotorasib or adagrasib. These are targeted therapies specifically designed to inhibit the activity of the mutated KRAS protein.', '* **Immunotherapy:** The high PD-L1 expression (80%) strongly suggests that she may benefit from immunotherapy, either as a single agent or in combination with chemotherapy or targeted therapy.  Pembrolizumab or other PD-1/PD-L1 inhibitors are potential options.', '* **Chemotherapy:** While targeted therapy and immunotherapy are preferred in this setting, chemotherapy regimens may be considered either as initial treatment or in combination with other modalities if the targeted therapies are ineffective or poorly tolerated.', \"The patient is a strong candidate for treatment with a KRAS G12C inhibitor and/or immunotherapy.  The choice of specific agents and treatment strategy should be determined by a multidisciplinary team (MDT) considering the patient's overall health, performance status, and comorbidities.  Close monitoring of treatment response and potential side effects is crucial.\", '* **Complete pathological assessment of the biopsy:**  This is essential to determine the grade and differentiation of the adenocarcinoma.  This will refine prognostication and treatment planning.', '* **Further molecular testing:** Although the KRAS G12C mutation is a key driver mutation, additional molecular testing may be considered depending on treatment response and the development of resistance.', '* **Assessment of other biomarkers:**  Consideration of other biomarkers, such as tumor mutational burden (TMB) and microsatellite instability (MSI) status, could further guide treatment decisions, particularly in the context of immunotherapy.', \"* **Comprehensive Geriatric Assessment:** Given the patient's age and comorbidities, a comprehensive geriatric assessment should be performed to optimize treatment planning and minimize potential toxicities.\", '**Disclaimer:** This report is based on the information provided.  A definitive diagnosis and treatment plan require a comprehensive multidisciplinary evaluation.  This analysis should be considered a preliminary assessment to inform further investigations and discussions within the MDT.']}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "ai",
        "name": null,
        "id": null,
        "example": false,
        "tool_calls": [],
        "invalid_tool_calls": [],
        "usage_metadata": null
      }
    }
  ],
  "8106dfd8-6bd9-49a3-b9bd-51a1e7623fb3_PathologyAgent": [
    {
      "type": "human",
      "data": {
        "content": "{'context': '{\\n  \"patient_id\": \"MDT2024001\",\\n  \"demographics\": {\\n    \"age\": 62,\\n    \"gender\": \"F\",\\n    \"ethnicity\": \"Caucasian\",\\n    \"occupation\": \"Retired Teacher\",\\n    \"smoking_status\": \"Former smoker, quit 10 years ago\"\\n  },\\n  \"pathology_results\": {\\n    \"bronchoscopy_biopsy\": {\\n      \"date\": \"2024-02-15\",\\n      \"specimen\": \"Right upper lobe mass biopsy\",\\n      \"microscopic\": \"Malignant cells consistent with adenocarcinoma\",\\n      \"immunohistochemistry\": {\\n        \"TTF-1\": \"Positive\",\\n        \"CK7\": \"Positive\",\\n        \"CK20\": \"Negative\",\\n        \"PD-L1\": \"80% expression\"\\n      },\\n      \"molecular\": {\\n        \"EGFR\": \"Wild type\",\\n        \"ALK\": \"No rearrangement\",\\n        \"ROS1\": \"No rearrangement\",\\n        \"KRAS\": \"G12C mutation detected\"\\n      },\\n      \"diagnosis\": \"Lung adenocarcinoma, KRAS G12C mutated, PD-L1 80%\"\\n    }\\n  },\\n  \"current_condition\": {\\n    \"primary_complaint\": \"Persistent cough with occasional blood-tinged sputum\",\\n    \"onset\": \"2024-01-15\",\\n    \"severity\": \"Moderate to severe\",\\n    \"associated_symptoms\": [\\n      \"Unintentional weight loss (5kg in 3 months)\",\\n      \"Fatigue\",\\n      \"Decreased appetite\",\\n      \"Night sweats\"\\n    ],\\n    \"physical_exam\": {\\n      \"vital_signs\": {\\n        \"temperature\": \"37.2\\\\u00b0C\",\\n        \"blood_pressure\": \"132/82\",\\n        \"heart_rate\": \"88\",\\n        \"respiratory_rate\": \"20\",\\n        \"oxygen_saturation\": \"95% on room air\"\\n      },\\n      \"chest\": \"Decreased breath sounds in right upper lobe\",\\n      \"lymph_nodes\": \"Right supraclavicular lymphadenopathy\",\\n      \"weight\": \"68 kg\",\\n      \"height\": \"165 cm\"\\n    }\\n  },\\n  \"ehr_context\": {\\n    \"summary\": \"Based on the presented information, a preliminary assessment suggests a performance status (PS) of ECOG 2-3. The patient is experiencing significant symptoms (fatigue, weight loss, cough) impacting her daily activities.  A more precise assessment would require a detailed functional assessment.\",\\n    \"details\": {\\n      \"summary\": \"Based on the presented information, a preliminary assessment suggests a performance status (PS) of ECOG 2-3. The patient is experiencing significant symptoms (fatigue, weight loss, cough) impacting her daily activities.  A more precise assessment would require a detailed functional assessment.\",\\n      \"key_history_points\": [],\\n      \"current_presentation\": {\\n        \"main_symptoms\": [],\\n        \"performance_status\": \"\",\\n        \"comorbidity_impact\": \"**\"\\n      },\\n      \"risk_factors\": [],\\n      \"clinical_implications\": [],\\n      \"raw_output\": \"**EHR Analysis Agent Report: Patient MDT2024001**\\\\n\\\\n**1. Key History Points:**\\\\n\\\\n* **Chronological Progression of Symptoms:** The patient, a 62-year-old Caucasian female, presents with a persistent cough (onset January 15th, 2024) initially described as moderate to severe, progressing to include blood-tinged sputum.  Concomitant symptoms of unintentional weight loss (5kg in 3 months), fatigue, decreased appetite, and night sweats suggest a significant underlying pathology.  The temporal relationship between these symptoms strongly points towards a concerning systemic illness.\\\\n\\\\n* **Medical History:**  The patient has a history of well-controlled Type 2 Diabetes (since 2015) managed with Metformin, well-controlled Hypertension (since 2016) managed with Lisinopril, and Osteoarthritis (since 2018) managed with PRN NSAIDs.  These comorbidities will need careful consideration during treatment planning.\\\\n\\\\n* **Social and Functional Factors:** The patient is a retired teacher, suggesting a potential for reduced social interaction and physical activity compared to her previous employment. This factor could influence her tolerance of treatment and rehabilitation.\\\\n\\\\n**2. Current Clinical Status:**\\\\n\\\\n* **Primary Complaint:** Persistent cough with hemoptysis.\\\\n* **Physical Examination:**  Significant findings include decreased breath sounds in the right upper lobe, suggestive of a possible consolidation or mass, and right supraclavicular lymphadenopathy, raising strong suspicion for malignancy.\\\\n* **Laboratory Results:**  The complete blood count (CBC) shows normal hemoglobin, white blood cell count, and platelet count, which is not entirely reassuring given the clinical presentation; further investigation is required.  Liver function tests (LFTs) are mildly elevated (AST 32, ALT 28), which warrants further investigation and could indicate liver metastasis or other systemic effects. Albumin is within normal limits. Creatinine is normal.\\\\n\\\\n**3. Relevant Risk Factors:**\\\\n\\\\n* **Age:** 62 years old \\\\u2013 increased risk for various malignancies.\\\\n* **Smoking History:** Former smoker (quit 10 years ago) \\\\u2013 significant risk factor for lung cancer and other respiratory malignancies. The duration since quitting is relevant, as the risk remains elevated even after cessation.\\\\n* **Weight Loss:**  Significant unintentional weight loss (5kg in 3 months) strongly suggests a serious underlying medical condition, potentially malignancy.\\\\n* **Symptoms:** The constellation of symptoms (cough with hemoptysis, weight loss, fatigue, night sweats) is highly suggestive of lung cancer.\\\\n\\\\n**4. Performance Status Assessment:**\\\\n\\\\nBased on the presented information, a preliminary assessment suggests a performance status (PS) of ECOG 2-3. The patient is experiencing significant symptoms (fatigue, weight loss, cough) impacting her daily activities.  A more precise assessment would require a detailed functional assessment.\\\\n\\\\n**5. Clinical Implications:**\\\\n\\\\nThe clinical picture strongly suggests a possible malignancy, most likely lung cancer.  The right upper lobe findings, supraclavicular lymphadenopathy, and systemic symptoms necessitate urgent further investigation.\\\\n\\\\n**Further Investigations:**\\\\n\\\\n* **Imaging:** High-resolution computed tomography (HRCT) of the chest is crucial to evaluate the extent of lung involvement, assess for mediastinal lymphadenopathy, and identify potential metastatic disease.\\\\n* **Biopsy:**  Bronchoscopy with endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) or other appropriate biopsy techniques to obtain tissue for histopathological examination and molecular testing is essential for diagnosis and staging.  This is the highest priority.\\\\n* **Further Lab Investigations:**  Consider serum tumor markers (CEA, CYFRA 21-1, NSE), depending on the imaging results.\\\\n\\\\n\\\\n**Comorbidity Impact on Treatment:**\\\\n\\\\nThe patient\\'s comorbidities (diabetes, hypertension, osteoarthritis) need careful consideration when planning treatment.  The presence of diabetes and hypertension may influence the choice of chemotherapy regimens and require close monitoring for potential adverse effects. Osteoarthritis may impact the patient\\'s ability to tolerate certain treatments and will require appropriate pain management.\\\\n\\\\n**Treatment Planning:**\\\\n\\\\nTreatment planning will depend on the definitive diagnosis, stage of disease, and the patient\\'s performance status.  Options could include surgery, chemotherapy, radiation therapy, targeted therapy, or immunotherapy, potentially in combination.  A multidisciplinary team (MDT) approach involving oncologists, pulmonologists, radiologists, pathologists, and other specialists is crucial for optimal management.\\\\n\\\\n**Limitations and Uncertainties:**\\\\n\\\\nThis analysis is based on limited information.  The absence of detailed imaging and pathology results prevents a definitive diagnosis and precise staging.  A complete MDT discussion is necessary to formulate a comprehensive treatment plan.\\\\n\\\\n**Conclusion:**\\\\n\\\\nThis patient requires urgent further investigation to confirm the suspicion of lung cancer.  A multidisciplinary approach is crucial for optimal patient care, considering the patient\\'s comorbidities and performance status.  Patient-centered care should guide all treatment decisions.\"\\n    }\\n  },\\n  \"imaging_context\": {\\n    \"summary\": \"**Imaging Analysis Report: Patient MDT2024001**\",\\n    \"details\": {\\n      \"summary\": \"**Imaging Analysis Report: Patient MDT2024001**\",\\n      \"disease_extent\": {\\n        \"primary_tumor\": \"** 3.8 x 3.2 cm (CT Chest); SUVmax 12.4 (PET-CT)\",\\n        \"nodal_status\": \"** N2 (ipsilateral mediastinal lymph node involvement) given the involvement of hilar and mediastinal lymph nodes.\",\\n        \"metastatic_status\": \"If there is clinical suspicion of other metastases not detected by the initial PET-CT, further CT imaging of the abdomen and pelvis may be considered.\"\\n      },\\n      \"staging\": {\\n        \"clinical_stage\": \"\",\\n        \"key_findings\": [\\n          \"* **Chest X-ray (2024-02-01):** Demonstrates a 3.5 cm mass in the right upper lobe with associated hilar lymphadenopathy.  The finding is highly suggestive of a primary lung malignancy.  Limited in its ability to fully characterize the extent of disease.\",\\n          \"* **CT Chest (2024-02-05):**  Confirms a 3.8 x 3.2 cm spiculated mass in the right upper lobe, consistent with a primary lung cancer.  Multiple enlarged right hilar and mediastinal lymph nodes are present.  No evidence of distant metastases is identified. Mild emphysematous changes are noted in the upper lobes. This is a more detailed assessment than the chest x-ray, but still lacks the metabolic information provided by PET-CT.\",\\n          \"* **PET-CT (2024-02-12):**  Shows a right upper lobe mass with a maximum standardized uptake value (SUVmax) of 12.4, indicative of high metabolic activity characteristic of malignancy.  FDG-avid right hilar and mediastinal lymph nodes are present, with a maximum SUVmax of 8.2, confirming their malignant nature. No evidence of distant metastatic disease is found. This study provides crucial functional information confirming the malignancy and extent of nodal involvement.\",\\n          \"* **Primary lesion:** 3.8 x 3.2 cm (CT Chest); SUVmax 12.4 (PET-CT)\",\\n          \"The primary lesion is located in the right upper lobe, close to the hilum.  The involvement of hilar and mediastinal lymph nodes suggests locoregional spread. The lack of distant metastases on PET-CT is reassuring.  The mild emphysema might influence surgical planning.  The right supraclavicular lymphadenopathy noted on physical exam needs correlation with imaging findings (it may be a result of lymphatic drainage from the primary tumor, or may represent a separate finding requiring further assessment).\"\\n        ]\\n      },\\n      \"treatment_implications\": []\\n    }\\n  }\\n}', 'task': \"Analyze the patient's pathological and molecular findings. Provide a structured interpretation including histological classification, molecular profile, biomarker status, and therapeutic implications.\"}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "human",
        "name": null,
        "id": null,
        "example": false
      }
    },
    {
      "type": "ai",
      "data": {
        "content": "{'summary': '**Pathology Analysis Agent Report: Patient MDT2024001**', 'histology': '**', 'molecular_profile': {'key_mutations': 'Key mutations not specified', 'immunotherapy_markers': '**  While PD-L1 is informative, additional biomarker testing might be considered depending on the treatment approach, potentially including microsatellite instability (MSI) status.  This information can inform treatment choices and predict response to therapy.', 'other_markers': {}}, 'therapeutic_implications': ['*Recommendations for Additional Testing:**', '**Complete histopathological review:**  To determine the grade and differentiation of the adenocarcinoma.  This will improve prognostication and guide treatment decisions.', '**Comprehensive staging workup:**  Including a detailed assessment of the extent of disease using imaging (CT chest, abdomen, pelvis; PET-CT), and potentially other investigations such as brain MRI, bone scan, depending on initial imaging results.  This is crucial for accurate staging and treatment planning.']}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "ai",
        "name": null,
        "id": null,
        "example": false,
        "tool_calls": [],
        "invalid_tool_calls": [],
        "usage_metadata": null
      }
    }
  ],
  "b5654b5a-e88a-4c1c-89e6-0567ad3163ae_PathologyAgent": [
    {
      "type": "human",
      "data": {
        "content": "{'context': '{\\n  \"patient_id\": \"MDT2024001\",\\n  \"demographics\": {\\n    \"age\": 62,\\n    \"gender\": \"F\",\\n    \"ethnicity\": \"Caucasian\",\\n    \"occupation\": \"Retired Teacher\",\\n    \"smoking_status\": \"Former smoker, quit 10 years ago\"\\n  },\\n  \"pathology_results\": {\\n    \"bronchoscopy_biopsy\": {\\n      \"date\": \"2024-02-15\",\\n      \"specimen\": \"Right upper lobe mass biopsy\",\\n      \"microscopic\": \"Malignant cells consistent with adenocarcinoma\",\\n      \"immunohistochemistry\": {\\n        \"TTF-1\": \"Positive\",\\n        \"CK7\": \"Positive\",\\n        \"CK20\": \"Negative\",\\n        \"PD-L1\": \"80% expression\"\\n      },\\n      \"molecular\": {\\n        \"EGFR\": \"Wild type\",\\n        \"ALK\": \"No rearrangement\",\\n        \"ROS1\": \"No rearrangement\",\\n        \"KRAS\": \"G12C mutation detected\"\\n      },\\n      \"diagnosis\": \"Lung adenocarcinoma, KRAS G12C mutated, PD-L1 80%\"\\n    }\\n  },\\n  \"current_condition\": {\\n    \"primary_complaint\": \"Persistent cough with occasional blood-tinged sputum\",\\n    \"onset\": \"2024-01-15\",\\n    \"severity\": \"Moderate to severe\",\\n    \"associated_symptoms\": [\\n      \"Unintentional weight loss (5kg in 3 months)\",\\n      \"Fatigue\",\\n      \"Decreased appetite\",\\n      \"Night sweats\"\\n    ],\\n    \"physical_exam\": {\\n      \"vital_signs\": {\\n        \"temperature\": \"37.2\\\\u00b0C\",\\n        \"blood_pressure\": \"132/82\",\\n        \"heart_rate\": \"88\",\\n        \"respiratory_rate\": \"20\",\\n        \"oxygen_saturation\": \"95% on room air\"\\n      },\\n      \"chest\": \"Decreased breath sounds in right upper lobe\",\\n      \"lymph_nodes\": \"Right supraclavicular lymphadenopathy\",\\n      \"weight\": \"68 kg\",\\n      \"height\": \"165 cm\"\\n    }\\n  },\\n  \"ehr_context\": {\\n    \"summary\": \"The diagnosis remains presumptive until confirmed by histopathological examination.  The severity of the patient\\'s comorbidities and their impact on treatment tolerance requires further assessment.  The patient\\'s functional status needs to be fully evaluated to determine her ability to tolerate potentially intensive treatment regimens.\",\\n    \"details\": {\\n      \"summary\": \"The diagnosis remains presumptive until confirmed by histopathological examination.  The severity of the patient\\'s comorbidities and their impact on treatment tolerance requires further assessment.  The patient\\'s functional status needs to be fully evaluated to determine her ability to tolerate potentially intensive treatment regimens.\",\\n      \"key_history_points\": [],\\n      \"current_presentation\": {\\n        \"main_symptoms\": [],\\n        \"performance_status\": \"\",\\n        \"comorbidity_impact\": \"** The patient has well-controlled Type 2 Diabetes Mellitus (T2DM) and Hypertension, managed with Metformin and Lisinopril respectively.  She also has Osteoarthritis affecting her knees and hands, managed with PRN NSAIDs.  These comorbidities will need careful consideration during treatment planning due to potential drug interactions and increased risk of complications.\"\\n      },\\n      \"risk_factors\": [],\\n      \"clinical_implications\": [],\\n      \"raw_output\": \"**EHR Analysis Agent Report - Patient ID: MDT2024001**\\\\n\\\\n**1. Key History Points:**\\\\n\\\\n* **Chronological Progression of Symptoms:** The patient, a 62-year-old Caucasian female, presents with a persistent cough (onset January 15th, 2024) initially described as moderate to severe, now complicated by occasional blood-tinged sputum.  This is accompanied by significant weight loss (5kg in 3 months), fatigue, decreased appetite, and night sweats \\\\u2013 all highly suggestive of a serious underlying pathology, potentially malignancy.\\\\n\\\\n* **Comorbidities:** The patient has well-controlled Type 2 Diabetes Mellitus (T2DM) and Hypertension, managed with Metformin and Lisinopril respectively.  She also has Osteoarthritis affecting her knees and hands, managed with PRN NSAIDs.  These comorbidities will need careful consideration during treatment planning due to potential drug interactions and increased risk of complications.\\\\n\\\\n* **Social and Functional Factors:** The patient is a retired teacher, suggesting a previously active lifestyle, now potentially impacted by her current illness.  Her functional status needs further assessment.\\\\n\\\\n* **Risk Factors:**  Former smoker (quit 10 years ago) increases the risk of respiratory malignancy.  Age (62) also places her in a higher risk category for various cancers.  The combination of weight loss, cough, hemoptysis, and lymphadenopathy raises significant concern for lung cancer.\\\\n\\\\n**2. Current Clinical Status:**\\\\n\\\\n* **Symptoms:**  Persistent cough with hemoptysis, unintentional weight loss, fatigue, decreased appetite, and night sweats are highly suggestive of malignancy, particularly lung cancer.\\\\n\\\\n* **Physical Exam:** Decreased breath sounds in the right upper lobe and right supraclavicular lymphadenopathy strongly support the suspicion of lung cancer.  Vital signs are relatively stable, although the slightly elevated blood pressure (132/82) requires monitoring.\\\\n\\\\n* **Laboratory Results:**  The complete blood count (CBC) shows normal hemoglobin, WBC, and platelet counts, which doesn\\'t definitively rule out malignancy but does not reveal overt cytopenias.  The basic metabolic panel (BMP) is largely unremarkable, showing normal creatinine, slightly elevated AST (32 U/L) and ALT (28 U/L) which could be related to the underlying condition or medications.  Albumin is within the normal range.  Further investigations are needed.\\\\n\\\\n**3. Relevant Risk Factors:**\\\\n\\\\n* **Age:** 62 years\\\\n* **Gender:** Female (lung cancer is more common in males, but this doesn\\'t preclude the diagnosis)\\\\n* **Smoking history:** Former smoker\\\\n* **Symptoms:**  Highly suggestive of lung cancer (cough, hemoptysis, weight loss, fatigue, night sweats, lymphadenopathy)\\\\n\\\\n**4. Performance Status Assessment:**\\\\n\\\\nA more detailed assessment is needed using tools like the Eastern Cooperative Oncology Group (ECOG) performance status scale or the Karnofsky Performance Status scale.  Based on the presented information, a preliminary assessment suggests a performance status of 2-3 (moderate to severe limitations in activity).  Further evaluation is crucial for accurate staging and treatment planning.\\\\n\\\\n**5. Clinical Implications:**\\\\n\\\\nThe clinical picture strongly suggests the need for urgent further investigation to determine the cause of the patient\\'s symptoms.  This should include:\\\\n\\\\n* **Chest X-ray:** To confirm the physical exam findings.\\\\n* **CT scan of the chest and abdomen/pelvis:**  To stage the potential lung cancer and identify any metastases.\\\\n* **Bronchoscopy with bronchoalveolar lavage (BAL) and biopsy:** To obtain tissue samples for histopathological examination and cytology.  This is crucial for definitive diagnosis.\\\\n* **PET scan:** To assess for distant metastases.\\\\n* **Further blood tests:**  Tumor markers (e.g., CEA, CYFRA 21-1) should be considered.\\\\n\\\\n**Treatment planning will depend heavily on the results of these investigations.**  The presence of comorbidities (T2DM and hypertension) needs to be carefully managed to minimize treatment-related adverse effects.  The impact of the patient\\'s performance status on treatment tolerance will also be a key factor.  A multidisciplinary team (MDT) meeting involving oncologists, radiologists, pathologists, and potentially pulmonologists is essential for optimal treatment planning.  This MDT approach will ensure patient-centered care, balancing the potential benefits and risks of various treatment options while considering the patient\\'s overall health and preferences.\\\\n\\\\n\\\\n**Limitations and Uncertainties:**\\\\n\\\\nThe diagnosis remains presumptive until confirmed by histopathological examination.  The severity of the patient\\'s comorbidities and their impact on treatment tolerance requires further assessment.  The patient\\'s functional status needs to be fully evaluated to determine her ability to tolerate potentially intensive treatment regimens.\"\\n    }\\n  },\\n  \"imaging_context\": {\\n    \"summary\": \"**Imaging Analysis Report - Patient ID: MDT2024001**\",\\n    \"details\": {\\n      \"summary\": \"**Imaging Analysis Report - Patient ID: MDT2024001**\",\\n      \"disease_extent\": {\\n        \"primary_tumor\": \"** 3.8 x 3.2 cm (CT Chest).\",\\n        \"nodal_status\": \"** To obtain tissue samples for histopathological diagnosis and to directly assess mediastinal lymph node involvement. This is crucial for definitive staging and treatment planning.\",\\n        \"metastatic_status\": \"** Although the PET-CT did not show bony metastases, this could be considered if bone pain or elevated alkaline phosphatase is present.\"\\n      },\\n      \"staging\": {\\n        \"clinical_stage\": \"\",\\n        \"key_findings\": [\\n          \"* **Chest X-ray (2024-02-01):** Demonstrates a 3.5 cm mass in the right upper lobe with associated hilar lymphadenopathy.  The finding is highly suggestive of a primary lung malignancy.  Limited in its ability to fully characterize the lesion or assess for distant metastases.\",\\n          \"* **CT Chest (2024-02-05):**  Reveals a 3.8 x 3.2 cm spiculated mass in the right upper lobe, consistent with malignancy.  Multiple enlarged right hilar and mediastinal lymph nodes are present. No evidence of distant metastases is identified. Mild emphysematous changes are noted in the upper lobes.\",\\n          \"* **PET-CT (2024-02-12):** Confirms the presence of a highly FDG-avid right upper lobe mass (SUVmax 12.4), indicating high metabolic activity characteristic of malignancy.  FDG-avid right hilar and mediastinal lymph nodes (SUVmax 8.2) are also present, confirming lymph node involvement. No evidence of distant metastatic disease is detected.\",\\n          \"* **Primary Lesion:** 3.8 x 3.2 cm (CT Chest).\",\\n          \"Based on the imaging findings, the patient presents with a large primary lung mass in the right upper lobe with involvement of regional lymph nodes (hilar and mediastinal).  There is no evidence of distant metastases based on the available imaging.  This strongly suggests a Stage IIIA Non-Small Cell Lung Cancer (NSCLC) according to the 8th edition TNM staging system.  However, this is a presumptive staging based on imaging alone and requires confirmation by histopathological examination of tissue obtained via biopsy.  The exact T, N, and M classifications need confirmation through tissue diagnosis and potentially further staging investigations.\",\\n          \"The primary lesion is located in the right upper lobe, close to the hilum.  The involvement of hilar and mediastinal lymph nodes suggests locoregional spread.  The relationship of the tumor to major vessels and the trachea requires further assessment, potentially via bronchoscopy and endobronchial ultrasound (EBUS) or mediastinoscopy.  The mild emphysema may influence surgical planning.\",\\n          \"* **Further CT evaluation:** A high resolution CT scan might help to further define the extent of the lesion and the relationship with adjacent structures.\"\\n        ]\\n      },\\n      \"treatment_implications\": []\\n    }\\n  }\\n}', 'task': \"Analyze the patient's pathological and molecular findings. Provide a structured interpretation including histological classification, molecular profile, biomarker status, and therapeutic implications.\"}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "human",
        "name": null,
        "id": null,
        "example": false
      }
    },
    {
      "type": "ai",
      "data": {
        "content": "{'summary': '**Pathology Analysis Agent Report - Patient ID: MDT2024001**', 'histology': '**  A detailed review of the microscopic slides to determine the precise histological subtype and grade of the adenocarcinoma. This will refine the prognosis and inform treatment decisions.', 'molecular_profile': {'key_mutations': 'Key mutations not specified', 'immunotherapy_markers': '**  Given the high PD-L1 expression, immunotherapy with a PD-1 or PD-L1 inhibitor (e.g., pembrolizumab, nivolumab, atezolizumab) should be strongly considered, potentially in combination with chemotherapy or a KRAS G12C inhibitor.  The optimal combination strategy would require discussion within the MDT.', 'other_markers': {'EGFR': '** Wild type – This excludes the use of EGFR tyrosine kinase inhibitors (TKIs) as a first-line treatment option.', 'ALK': '** No rearrangement – This excludes ALK TKIs.', 'ROS1': '** No rearrangement – This excludes ROS1 TKIs.', 'KRAS': '**  Sotorasib or adagrasib are strong candidates for first-line treatment.  Response rates to these agents are not 100%, and careful monitoring for toxicity and response is essential.'}}, 'therapeutic_implications': ['The provided data does not include information on the grade and differentiation of the adenocarcinoma.  This information is crucial for prognosis and treatment planning and should be obtained from the microscopic examination of the biopsy.  The presence of a KRAS mutation suggests a potentially more aggressive phenotype, but this needs to be correlated with histological grading.', '* **EGFR:** Wild type – This excludes the use of EGFR tyrosine kinase inhibitors (TKIs) as a first-line treatment option.', '* **KRAS:** G12C mutation detected – This is a significant finding.  The presence of a KRAS G12C mutation identifies a specific therapeutic target.  Sotorasib and adagrasib are FDA-approved therapies targeting this mutation.', '* **PD-L1:** 80% expression – This high PD-L1 expression suggests the patient may benefit from immunotherapy, either as a monotherapy or in combination with chemotherapy or targeted therapy.  The exact threshold for immunotherapy eligibility can vary depending on the specific assay used and treatment guidelines.', '**5. Therapeutic Targets:**', 'Based on the molecular and biomarker data, the primary therapeutic targets are the KRAS G12C mutation and the high PD-L1 expression.', '* **KRAS G12C-targeted therapy:**  Sotorasib or adagrasib are strong candidates for first-line treatment.  Response rates to these agents are not 100%, and careful monitoring for toxicity and response is essential.', '* **Immunotherapy:**  Given the high PD-L1 expression, immunotherapy with a PD-1 or PD-L1 inhibitor (e.g., pembrolizumab, nivolumab, atezolizumab) should be strongly considered, potentially in combination with chemotherapy or a KRAS G12C inhibitor.  The optimal combination strategy would require discussion within the MDT.', \"* **Chemotherapy:**  Depending on the patient's overall health, performance status, and response to targeted therapy, chemotherapy might be considered as a component of combination therapy.  However, given the availability of targeted therapy for the KRAS mutation, chemotherapy might not be the first-line choice in this case.\", '1. **Histological review:**  A detailed review of the microscopic slides to determine the precise histological subtype and grade of the adenocarcinoma. This will refine the prognosis and inform treatment decisions.', '2. **Comprehensive genomic profiling:**  While KRAS G12C has been identified, broader genomic profiling might reveal additional targetable mutations or alterations that could influence treatment choices.  This is particularly relevant given the presence of other negative molecular markers.  This testing could reveal other genomic alterations that may be actionable', \"3. **Assessment of performance status:** A formal assessment using the ECOG or Karnofsky performance scale is necessary to evaluate the patient's fitness for various treatment regimens.\", '4. **Further staging investigations:**  While imaging suggests a Stage IIIA, the exact TNM staging requires confirmation through histopathological examination of lymph nodes (obtained via mediastinoscopy or EBUS) and assessment of distant metastasis.  This is critical for accurate staging and treatment planning.  Further imaging (e.g., high resolution CT) may also be beneficial in refining the extent of local disease.', \"The current analysis is based on limited data. The absence of detailed histological information and the need for further staging investigations represent significant limitations.  Treatment decisions must be made within the context of a comprehensive MDT discussion, considering the patient's overall health, comorbidities, and preferences.  The response to therapy will require close monitoring.\"]}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "ai",
        "name": null,
        "id": null,
        "example": false,
        "tool_calls": [],
        "invalid_tool_calls": [],
        "usage_metadata": null
      }
    }
  ]
}